CN114195806A

CN114195806A - Carbonyl heterocyclic compound and application thereof

Info

Publication number: CN114195806A
Application number: CN202111101565.5A
Authority: CN
Inventors: 张朝欣; 夏广新; 向志军; 柯樱; 楼江松; 赵蒙浩; 郝利军
Original assignee: Shanghai Pharmaceuticals Holding Co Ltd
Current assignee: Shanghai Pharmaceuticals Holding Co Ltd
Priority date: 2020-09-18
Filing date: 2021-09-18
Publication date: 2022-03-18
Also published as: WO2022057932A1

Abstract

The invention discloses a carbonyl heterocyclic compound and application thereof. The invention provides a carbonyl heterocyclic compound shown as a formula II or pharmaceutically acceptable salt thereof; it can be used as a compound having a targeting lanthionine synthase C-like protein 2 pathway; the compounds may be used to treat a variety of conditions, including infectious diseases, autoimmune diseases, diabetes, and chronic inflammatory diseases.

Description

Carbonyl heterocyclic compound and application thereof

Technical Field

The invention relates to a carbonyl heterocyclic compound and application thereof.

Background

The activation of the LANCL2 pathway increases insulin sensitivity and reduces inflammation associated with various autoimmune, inflammatory and metabolic conditions the results of in vivo and in vitro tests in mice show that the use of compounds targeting this pathway reduces glucose levels in the glucose tolerance test by a factor of 2 and provides a reduction in glucose levels compared to the control group

(GlaxoSmithKline plc, Brenford, England) of Bronstedford, England) is an effective treatment but has significant side effects. Targeting the LANCL2 pathway also reduced intestinal inflammation by 90% and the number of lesions correspondingly reduced by 4-fold. The results of this testing and other verifications of the path have been mentioned in a number of articles.

Within the category of autoimmune-related inflammation, there is currently a global pandemic of autoimmune disorders, such as Inflammatory Bowel Disease (IBD), systemic lupus, rheumatoid arthritis, type 1 diabetes, psoriasis, multiple sclerosis. There is also a pandemic of chronic metabolic inflammatory diseases including metabolic syndrome, obesity, prediabetes, cardiovascular disease and type 2 diabetes. Current treatments are moderately effective, but are expensive and have serious side effects. The route of administration of the most effective treatment for autoimmune diseases (e.g., anti-TNF antibodies) is via IV or subcutaneous injection, thus requiring visits to the clinic/surgery and frequent monitoring. The unique mode of action of LANCL2 provides an orally administered therapeutic agent that is as effective as an anti-TNF antibody, but without side effects and high cost. Given the overall prevalence of inflammatory and autoimmune diseases, the LANCL2 pathway has the potential to significantly affect millions of patients.

Abscisic acid ("ABA") is a natural compound found in the original screening process that binds to LANCL 2.

A large number of compounds are described in the field of synthetic organic chemistry. Various compounds are provided by the following references: w01997/036866 to Diana et al, WO 2006/053109 to Sun et al, WO 2006/080821 to Kim et al, WO 2007/019417 to Nunes et al, WO 2009/067600 and WO 2009/067621 to Singh et al, WO2008/079277 to Adams et al, JP 2008/056615 to Urasoe et al, WO 2011/066898 to Stoessel et al, US 2013/0142825 to Basaganya-Riera et al, and U.S. Pat. No. 7,741,367 to Basaganya-Riera et al. International patent application WO2016064445 discloses a compound targeting the C-like protein 2 pathway of lanthionine synthase that can be used to treat a variety of conditions including infectious diseases, autoimmune diseases, diabetes and chronic inflammatory diseases. Some of the compounds described in these references are known to activate the LANCL2 pathway, while others do not. There is a need to develop novel ligands for the LANCL2 pathway to allow treatment to be specifically tailored to individual diseases and potentially maximize its efficacy.

Disclosure of Invention

The technical problem to be solved by the invention is to overcome the problem of the lack of the therapeutic agent based on the lanthionine synthase C-like 2 in the prior art; and provides a carbonyl heterocyclic compound and application thereof. The carbonyl heterocyclic compound provided by the invention is a compound with a targeting lanthionine synthase C-like protein 2 path; the compounds can bind to the LANCL2 protein and achieve beneficial responses in a variety of disease conditions, which can be used to treat a variety of conditions, including metabolic and infectious diseases, autoimmune diseases, diabetes, and chronic inflammatory diseases.

The present invention solves the above-mentioned problems by the following technical means.

The invention provides a carbonyl heterocyclic compound shown as a formula II or pharmaceutically acceptable salt thereof;

wherein A is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond or-NH-;

q is

or-NH-;

L¹-Z¹and Z²-L²Independently is

(i.e., L)¹And L²Independently a connecting bond) or

(B-terminal represents a bond to a carbonyl group or B') and is not simultaneously

Ring Q²Is a 5-7 membered cycloalkyl or a 5-7 membered monocyclic heterocycloalkyl; 5-7 membered monocyclic heterocycloalkyl containing 1 to 3N atoms;

b' is a connecting bond,

-C (═ O) - (5-7 membered cycloalkyl) - (right side is attached to a '), -C (═ O) - (6-10 membered fused heterocycloalkyl) - (right side is attached to a '), -C (═ O) - (oxo 5-7 membered heterocycloalkenyl) - (right side is attached to a '), -C (═ O) - (oxo),

or-C (═ O) - (7-10 membered fused heteroaryl) - (to the right is attached to a'); the 6-to 10-membered fused heterocycloalkyl group contains 1 to 3N atoms; c (═ O) - (oxo 5-7 membered heterocycloalkenyl) -contains 1 to 3N atoms; the-C (═ O) - (7-10 membered fused heteroaryl) -group contains 1 to 3N atoms;

Z³-L³、Z^3a-L^3ais a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

Y^3aand Y^4aIndependently CH or N;

R³is C_1-6Alkyl groups of (a);

a' is

NO₂、-O-C_1-6Alkyl of (C)_1-6Alkyl group of (A) or (B),

Or H;

Y⁵is CH or N;

the band ". about" carbon atom represents, when chiral, S configuration, R configuration or a mixture thereof;

when Q is

A is

When A and A' are different.

In certain preferred embodiments of the present invention, certain groups of the carbonyl heterocyclic compound represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, or a salt of a solvate thereof are defined as follows (the groups not mentioned are as described in any embodiment of the present application), and are referred to hereinafter in certain preferred embodiments of the present invention.

In certain preferred embodiments of the invention, when R is¹And R²Independently is C_6-18Aryl of (2), said C_6-14Aryl of (a) is phenyl, naphthyl, phenanthryl or anthracyl, for example phenyl.

In certain preferred embodiments of the present invention,

is composed of

For example

Also for example

(end a indicates the position of connection with A)

In certain preferred embodiments of the present invention, when T is-NH-,

is composed of

In certain preferred embodiments of the present invention,

(when T isWhen connecting a key) are

For example

Also for example

(end a indicates the position of connection with A)

In certain preferred embodiments of the invention, Q²In, Z¹And Z²At the ortho, meta or para position.

In certain preferred embodiments of the invention, when Q²When the alkyl is 5-7 membered cycloalkyl, the 5-7 membered cycloalkyl is cyclopentyl, cyclohexyl or cycloheptyl; e.g. cyclohexyl, and

in certain preferred embodiments of the invention, when Q²When the heterocyclic group is a 5-7 membered monocyclic heterocyclic alkyl group, the 5-7 membered monocyclic heterocyclic alkyl group is an N-heterocyclic pentyl group or an N-heterocyclic hexyl group; for example

(b-terminal represents a bond to the carbonyl group)

In certain preferred embodiments of the present invention, when B' is

When the temperature of the water is higher than the set temperature,

(may be)

for example

(the a 'end indicates attachment to A').

In certain preferred embodiments of the present invention, when B' is-C (═ O) - (5-7 membered cycloalkyl) -said 5-7 membered cycloalkyl is cyclopentyl, cyclohexyl or cycloheptyl; for example cyclohexyl, and or-C (═ O) -is located in the ortho, meta or para position, for example the meta position, of a'; and for example-C (═ O) - (5-7 membered cycloalkyl) -is

In certain preferred embodiments of the present invention, when B' is-C (═ O) - (6-10 membered fused heterocycloalkyl) -said 6-10 membered fused heterocycloalkyl is an 8-10 membered fused heterocycloalkyl wherein N atoms are 1 or 2 and one N atom is attached to-C (═ O) -; for example-C (═ O) - (6-to 10-membered fused heterocycloalkyl) -is

In certain preferred embodiments of the invention, when B' is-C (═ O) - (oxo 5-7 membered heterocycloalkenyl), said 5-7 membered heterocycloalkenyl is heterocyclohexenyl, containing 2N atoms, e.g.

In certain preferred embodiments of the present invention, when B' is-C (═ O) - (oxo 5-7 membered heterocycloalkenyl), said C (═ O) - (oxo 5-7 membered heterocycloalkenyl) is

In certain preferred embodiments of the present invention, when B' is-C (═ O) - (7-10 membered fused heteroaryl) -it is 6-membered heteroarylacene or 5-membered heteroarylacene, and may also be quinolinyl (e.g., quinolinyl)

) Or indolyl (e.g. as

)。

In certain preferred embodiments of the invention, when R is³Is C_1-6When there is an alkyl group, said C_1-6Alkyl of (a) is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl.

In certain preferred embodiments of the invention, Z^3a-L^3aIs a connecting bond, -C (═ O) -or-C (═ O) -NH-; such as-C (═ O) -.

In certain preferred embodiments of the present invention, when B' is

When the temperature of the water is higher than the set temperature,

(may be)

for example

Also for example

In certain preferred embodiments of the present invention, when A' is

When the temperature of the water is higher than the set temperature,

is composed of

In certain preferred embodiments of the invention, A is

In certain preferred embodiments of the invention, A is

In certain preferred embodiments of the invention, A is

In certain preferred embodiments of the invention, A is-NR¹R²。

In certain preferred embodiments of the invention, A is the same as A'; and/or the presence of a gas in the gas,

same as B'.

In certain preferred embodiments of the present invention,

(when T is a bond) is as follows:

can also be enclosed as

In certain preferred embodiments of the invention, Q is

Q²Is a 5-7 membered cycloalkyl group, L¹-Z¹And Z²-L²Independently is

For example

Is composed of

In certain preferred embodiments of the present invention,

q is

When Q is²In the case of 5-to 7-membered monocyclic heterocycloalkyl, L¹-Z¹And Z²-L²One of them is

The other is

For example

Is composed of

(b-terminal indicates attachment to the carbonyl group).

In certain preferred embodiments of the invention, Q is

or-NH-.

In certain preferred embodiments of the invention, B 'is a bond and A' is

In certain preferred embodiments of the present invention, B' is

A' is

NO₂、-O-C_1-6Alkyl of (C)_1-6Alkyl group of (A) or (B),

Or H, can also be

Or NO₂。

In certain preferred embodiments of the invention, B 'is-C (═ O) - (5-7 membered cycloalkyl) -, and a' is

In certain preferred embodiments of the invention, B 'is-C (═ O) - (6-to 10-membered fused heterocycloalkyl) -, and a' is

In certain preferred embodiments of the invention, B 'is-C (═ O) - (oxo 5-7 membered heterocycloalkenyl) -, and a' is H.

In certain preferred embodiments of the present invention, B' is

A' is

In certain preferred embodiments of the present invention, B' is

A' is H.

In certain preferred embodiments of the invention, B 'is-C (═ O) - (7-10 membered fused heteroaryl) -, and a' is H.

In certain preferred embodiments of the invention, B '-A' is of the structure:

in certain preferred embodiments of the present invention,

wherein A is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond or-NH-;

q is

or-NH-;

L¹-Z¹and Z²-L²Independently is

And not simultaneously being

Ring Q²Is 5-7 membered monocyclic heterocycloalkyl; 5-7 membered monocyclic heterocycloalkyl containing 1 to 3N atoms;

b' is

-C (═ O) - (oxo 5-7 membered heterocycloalkenyl) -, -O,

or-C (═ O) - (7-10 membered fused heteroaryl) -;

Z³-L³、Z^3a-L^3ais a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

Y^3aand Y^4aIndependently CH or N;

R³is C_1-6Alkyl groups of (a);

a' is

-O-C_1-6Alkyl of (C)_1-6Alkyl group of (A) or (B),

Or H;

Y⁵is CH or N;

when Q is

A is

When A and A' are different.

In certain preferred embodiments of the present invention,

wherein A is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond or-NH-;

q is

or-NH-;

L¹-Z¹and Z²-L²Independently is

And not simultaneously being

b' is a connecting bond,

-C (═ O) - (5-7 membered cycloalkyl) -or-C (═ O) - (6-10 membered fused heterocycloalkyl) -;

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

a' is

NO₂or-O-C_1-6Alkyl groups of (a);

Y⁵is CH or N;

the band "-" carbon atom means, when a chiral carbon atom, an S configuration, an R configuration, or a mixture thereof.

In certain preferred embodiments of the present invention,

wherein A is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond or-NH-;

q is

or-NH-;

L¹-Z¹and Z²-L²Independently is

And not simultaneously being

b' is a connecting bond,

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

a' is

NO₂or-O-C_1-6Alkyl groups of (a);

Y⁵is CH or N;

In certain preferred embodiments of the present invention,

wherein A is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond;

q is

B' is a connecting bond,

-C (═ O) - (oxo 5-7 membered heterocycloalkenyl) -, -O,

or-C (═ O) - (7-10 membered fused heteroaryl) -;

Z³-L³、Z^3a-L^3ais a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

Y^3aand Y^4aIndependently CH or N;

R³is C_1-6Alkyl groups of (a);

a' is

C_1-6Alkyl group of (A) or (B),

Or H;

Y⁵is CH or N;

when Q is

A is

When A and A' are different.

In certain preferred embodiments of the present invention,

wherein A is

Y¹And Y²Independently CH or N;

t is a connecting bond;

q is

B '-A' is the following structure:

when A is

When A and A' are different.

In certain preferred embodiments of the present invention,

wherein A is

T is a connecting bond;

q is

B '-A' is the following structure:

in certain preferred embodiments of the present invention,

a is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond;

q is

L¹-Z¹And Z²-L²Independently is

And not simultaneously being

Ring Q²Is 5-7 membered monocyclic heterocycloalkyl;

b' is a connecting bond,

-C (═ O) - (5-7 membered cycloalkyl) -or-C (═ O) - (6-10 membered fused cyclicHeterocycloalkyl) -;

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N.

A' is

NO₂、

or-O-C_1-6Alkyl groups of (a);

Y⁵is CH or N;

In certain preferred embodiments of the present invention,

a is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond;

q is

L¹-Z¹And Z²-L²Independently is

And not simultaneously being

Ring Q²Is 5-7 membered monocyclic heterocycloalkyl;

b' is

or-C (═ O) - (5-7 membered cycloalkyl) -;

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N.

A' is

or-O-C_1-6Alkyl groups of (a);

Y⁵is CH or N;

In certain preferred embodiments of the present invention,

a is

For example

Y¹And Y²Independently CH or N;

q is

B' is

Z³-L³is-C (═ O) -;

Y³and Y⁴Independently CH or N;

a' is

For example

It is preferable thatThe ground is a mixture of a plurality of ground,

is composed of

And/or B' is

More preferably, A is the same as A';

and/or the presence of a gas in the gas,

same as B'.

In certain preferred embodiments of the present invention, the carbonyl heterocyclic compound of formula II is a carbonyl heterocyclic compound of formula II-a:

wherein A is

Y¹And Y²Independently CH or N;

q is

L¹-Z¹And Z²-L²Independently is

(i.e., L)¹And L²Independently a connecting bond) or

(b-terminal indicates the linkage to the carbonyl group) and does not simultaneously represent

b' is a connecting bond,

-C (═ O) - (5-7 membered cycloalkyl) -or-C (═ O) - (6-10 membered fused heterocycloalkyl) - (right side attached to a'); the 6-to 10-membered fused heterocycloalkyl group contains 1 to 3N atoms;

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

a' is

Or NO₂；

Y⁵Is CH or N;

In certain preferred embodiments of the present invention,

the structure is as follows:

in certain preferred embodiments of the present invention, B' is

A' is

Or NO₂。

In certain preferred embodiments of the invention, B '-A' is of the structure:

in certain preferred embodiments of the invention, A is

Y¹And Y²Independently CH or N;

q is

L¹-Z¹And Z²-L²Independently is

(i.e., L)¹And L²Independently a connecting bond) or

Q²Is a 5-7 membered cycloalkyl or a 5-7 membered monocyclic heterocycloalkyl; 5-7 membered monocyclic heterocycloalkyl containing 1 to 3N atoms; for example by Z¹And Z²The other ring atoms are all carbon;

b' is a connecting bond,

-C (═ O) - (5-7 membered cycloalkyl) -or-C (═ O) - (6-10 membered fused heterocycloalkyl)) - (right side linked to a'); the 6-to 10-membered fused heterocycloalkyl group contains 1 to 3N atoms; for example, the ring atoms other than the N atom attached to the carbonyl group or A' are all carbon;

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

a' is

Or NO₂；

Y⁵Is CH or N.

In certain preferred embodiments of the present invention,

a is

Is composed of

Q is

B' is a connecting bond,

A' is

Or NO₂；

Y⁵Is CH or N.

In certain preferred embodiments of the present invention, the carbonyl heterocyclic compound represented by formula II is of any one of the following structures:

in the invention, the carbonyl heterocyclic compound shown as the formula II or the pharmaceutically acceptable salt thereof has one or more chiral carbon atoms, so that optical purity isomers, such as pure enantiomers, racemes or mixed isomers, can be obtained by separation. Pure single isomers can be obtained by separation methods in the art, such as chiral crystallization to form salts, or by chiral preparative column separation.

In the invention, if stereoisomers exist in the carbonyl heterocyclic compound shown in the formula II or pharmaceutically acceptable salts thereof, the carbonyl heterocyclic compound can exist in the form of a single stereoisomer or a mixture (such as racemate) of the stereoisomer. The term "stereoisomer" refers to either a cis-trans isomer or an optical isomer. The stereoisomers can be separated, purified and enriched by an asymmetric synthesis method or a chiral separation method (including but not limited to thin layer chromatography, rotary chromatography, column chromatography, gas chromatography, high pressure liquid chromatography and the like), and can also be obtained by chiral resolution in a mode of forming bonds (chemical bonding and the like) or salifying (physical bonding and the like) with other chiral compounds and the like. The term "single stereoisomer" means that the mass content of one stereoisomer of the compound according to the invention is not less than 95% relative to all stereoisomers of the compound.

The carbonyl heterocyclic compound shown in the formula II or the pharmaceutically acceptable salt thereof can be synthesized by a method similar to a method known in the chemical field, and the steps and the conditions can be synthesized by referring to the steps and the conditions of similar reactions in the field, particularly according to the description in the text. The starting materials are generally from commercial sources, such as Aldrich or can be readily prepared using methods well known to those skilled in the art (obtained via SciFinder, Reaxys online databases).

The necessary starting materials or reagents for the preparation of carbonyl heterocycles as shown in formula II or pharmaceutically acceptable salts thereof are commercially available or prepared by synthetic methods known in the art. The compounds of the invention can be prepared as free bases or as salts with acids by the methods described in the experimental section below. The term pharmaceutically acceptable salt refers to a pharmaceutically acceptable salt as defined herein and has all the effects of the parent compound. Pharmaceutically acceptable salts can be prepared by treating according to conventional methods with the corresponding acid in a suitable organic solvent which is an organic base.

Examples of salt formation include: for base addition salts, it is possible to prepare salts of alkali metals (such as sodium, potassium or lithium) or alkaline earth metals (such as aluminum, magnesium, calcium, zinc or bismuth) by treating the compounds of the invention having suitably acidic protons in an aqueous medium with alkali metal or alkaline earth metal hydroxides or alkoxides (such as ethoxide or methoxide) or with suitably basic organic amines (such as diethanolamine, choline or meglumine).

Alternatively, for acid addition salts, salts with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; and organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, oxalic acid, pyruvic acid, malonic acid, mandelic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, citric acid, cinnamic acid, p-toluenesulfonic acid, or trimethylacetic acid.

In the invention, the carbonyl heterocyclic compound shown in the formula II or the pharmaceutically acceptable salt thereof can also be prepared by peripherally modifying the prepared carbonyl heterocyclic compound shown in the formula II or the pharmaceutically acceptable salt thereof by adopting a conventional method in the field to obtain other carbonyl heterocyclic compounds shown in the formula II or the pharmaceutically acceptable salt thereof.

In general, the compounds of the present invention may be prepared by the methods described herein, wherein the substituents are as defined in formula II, unless otherwise specified.

The invention also provides a pharmaceutical composition, which comprises the carbonyl heterocyclic compound shown as the formula II or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers. In the pharmaceutical composition, the carbonyl heterocyclic compound shown in formula II or a pharmaceutically acceptable salt thereof may be used in an amount of therapeutically effective amount.

The pharmaceutically acceptable carrier (pharmaceutic adjuvant) can be those widely used in the field of pharmaceutical production. The excipients are used primarily to provide a safe, stable and functional pharmaceutical composition and may also provide methods for dissolving the active ingredient at a desired rate or for promoting the effective absorption of the active ingredient after administration of the composition by a subject. The pharmaceutical excipients may be inert fillers or provide a function such as stabilizing the overall pH of the composition or preventing degradation of the active ingredients of the composition. The pharmaceutical excipients may include one or more of the following excipients: binders, suspending agents, emulsifiers, diluents, fillers, granulating agents, adhesives, disintegrating agents, lubricants, antiadherents, glidants, wetting agents, gelling agents, absorption delaying agents, dissolution inhibitors, reinforcing agents, adsorbents, buffering agents, chelating agents, preservatives, colorants, flavoring agents and sweeteners.

The pharmaceutical compositions of the present invention may be prepared according to the disclosure using any method known to those skilled in the art. For example, conventional mixing, dissolving, granulating, emulsifying, levigating, encapsulating, entrapping or lyophilizing processes.

The pharmaceutical compositions of the present invention may be administered in any form, including injection (intravenous), mucosal, oral (solid and liquid formulations), inhalation, ocular, rectal, topical or parenteral (infusion, injection, implant, subcutaneous, intravenous, intraarterial, intramuscular) administration. The pharmaceutical compositions of the present invention may also be in a controlled release or delayed release dosage form (e.g., liposomes or microspheres). Examples of solid oral formulations include, but are not limited to, powders, capsules, caplets, soft capsules, and tablets. Examples of liquid formulations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs and solutions. Examples of topical formulations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops or serum formulations. Examples of formulations for parenteral administration include, but are not limited to, solutions for injection, dry preparations which can be dissolved or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection. Examples of other suitable formulations of the pharmaceutical composition include, but are not limited to, eye drops and other ophthalmic formulations; aerosol: such as nasal sprays or inhalants; liquid dosage forms suitable for parenteral administration; suppositories and lozenges.

The invention also provides application of the carbonyl heterocyclic compound shown as the formula II or pharmaceutically acceptable salt thereof in preparing a lanthionine C-like protein 2(LANCL2) agonist. In said use, said activator of lanthionine C-like protein 2(LANCL2) can be used in a mammalian organism; also useful in vitro, primarily for experimental purposes, for example: provide comparison as a standard sample or a control sample, or prepare a kit according to the conventional method in the field, and provide a rapid detection for the activation effect of the lanthionine C-like protein 2(LANCL 2).

The invention also provides an application of the carbonyl heterocyclic compound shown as the formula II or pharmaceutically acceptable salt thereof in preparing medicaments; the medicament can be a medicament for preventing and/or treating diseases related to the lanthionine C-like protein 2(LANCL 2). The disease associated with lanthionine C-like protein 2(LANCL2) can be one or more of an autoimmune, chronic inflammatory, chronic metabolic, and infectious disease.

The invention also provides an application of the carbonyl heterocyclic compound shown as the formula II, pharmaceutically acceptable salt thereof or the composition in preparing medicines; the medicament may be a medicament for the prevention and/or treatment of autoimmune, chronic inflammatory, chronic metabolic or infectious diseases.

Another aspect of the present invention relates to a method for preventing and/or treating a disease associated with lanthionine C-like protein 2(LANCL2), comprising administering to a patient a therapeutically effective amount of said carbonyl heterocycle according to formula II, a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same as described above.

Another aspect of the present invention relates to a method for the treatment, prevention and/or treatment of autoimmune, chronic inflammatory, chronic metabolic or infectious diseases, comprising administering to a patient a therapeutically effective amount of said carbonyl heterocyclic compound of formula II, a pharmaceutically acceptable salt thereof or a composition thereof.

Another aspect of the present invention relates to a medicament for lanthionine C-like protein 2(LANCL2), comprising said carbonyl heterocycle according to formula II, a pharmaceutically acceptable salt thereof, or a combination thereof.

The autoimmune disorder as described above can be Inflammatory Bowel Disease (IBD) including ulcerative colitis and/or Crohn's disease, systemic lupus, rheumatoid arthritis, type 1 diabetes, psoriasis, multiple sclerosis.

The chronic metabolic disease as described above may be metabolic syndrome, obesity, prediabetes, cardiovascular disease and type 2 diabetes.

The infectious disease as described above may be a viral disease, such as an influenza infection.

The invention also provides methods of treating a condition in an animal with any one or more of the compounds described herein. The methods comprise administering to the animal an effective amount of one or more of the compounds described herein. The condition may be selected from the group consisting of: infectious diseases, autoimmune diseases, diabetes, and chronic inflammatory diseases. In some methods, the infectious disease comprises a viral disease, such as influenza infection. In some methods, the autoimmune disease comprises an autoimmune inflammatory disease, such as inflammatory bowel disease, including ulcerative colitis and/or Crohn's disease. In some methods, the diabetes is selected from the group consisting of type 1 diabetes and type 2 diabetes. In some methods, the chronic inflammatory disease comprises metabolic syndrome. In some methods, the methods comprise administering an amount of a compound effective to increase LANCL2 activity, reduce inflammation, and/or increase anti-inflammatory effects.

The invention also provides compounds for treating a condition in an animal with any one or more of the compounds described herein. Compounds for such use include any of the compounds described herein. Use may comprise administering to the animal an effective amount of one or more of the compounds described herein, wherein the condition is selected from the group consisting of: infectious diseases, autoimmune diseases, diabetes, and chronic inflammatory diseases. In some versions, the infectious disease comprises a viral disease, such as an influenza infection. In some versions, the autoimmune disease comprises an autoimmune inflammatory disease, such as inflammatory bowel disease, including ulcerative colitis and/or crohn's disease. In some versions, diabetes is selected from the group consisting of type 1 diabetes and type 2 diabetes. In some versions, the chronic inflammatory disease comprises metabolic syndrome. In some versions, the compounds are effective to increase LANCL2 activity, reduce inflammation, and/or increase anti-inflammatory effects.

The term "pharmaceutically acceptable" means that the salts, solvents, excipients, etc., are generally non-toxic, safe, and suitable for use by the patient. The "patient" is preferably a mammal, more preferably a human.

The term "pharmaceutically acceptable salts" refers to salts prepared from the compounds of the present invention with relatively non-toxic, pharmaceutically acceptable acids.

By "treatment" is meant any treatment of a disease in a mammal, including: (1) preventing disease, i.e., the symptoms that cause clinical disease do not develop; (2) inhibiting disease, i.e., arresting the development of clinical symptoms; (3) alleviating the disease, i.e., causing regression of clinical symptoms.

By "effective amount" is meant an amount of a compound, when administered to a patient in need of treatment, that is sufficient to (i) treat the associated disease, (ii) attenuate, ameliorate, or eliminate one or more symptoms of a particular disease or condition, or (iii) delay the onset of one or more symptoms of a particular disease or condition described herein. The amount of said carbonyl heterocyclic compound of formula II or a pharmaceutically acceptable salt thereof or a pharmaceutical composition as described above that corresponds to this amount will vary depending on factors such as the particular compound, the disease condition and its severity, the characteristics of the patient in need of treatment (e.g. body weight), etc., but may nevertheless be routinely determined by one skilled in the art.

"prevention" as used herein refers to a reduction in the risk of acquiring or developing a disease or disorder.

"pharmaceutical composition" as used herein, refers to a formulation of one or more compounds of the present invention or salts thereof with a carrier generally accepted in the art for delivery of biologically active compounds to an organism (e.g., a human). The purpose of the pharmaceutical composition is to facilitate delivery of the drug to an organism.

The term "pharmaceutically acceptable carrier" refers to a substance that is co-administered with, and facilitates the administration of, an active ingredient, including, but not limited to, any glidant, sweetener, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersant, disintegrant, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier that is acceptable for use in humans or animals (e.g., livestock) as permitted by the national food and drug administration. Examples include, but are not limited to, calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

The pharmaceutical composition can be prepared into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powder, granules, paste, emulsions, suspensions, solutions, suppositories, injections, inhalants, gels, microspheres, aerosols and the like.

The pharmaceutical compositions of the present invention may be manufactured by methods well known in the art, such as conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, lyophilizing, and the like.

The route of administration of the compounds of the present invention or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof includes, but is not limited to, oral, rectal, transmucosal, enteral, or topical, transdermal, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, intravenous administration. The preferred route of administration is oral.

For oral administration, the pharmaceutical compositions may be formulated by mixing the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, slurries, suspensions and the like, for oral administration to a patient. For example, for pharmaceutical compositions intended for oral administration, tablets may be obtained in the following manner: the active ingredient is combined with one or more solid carriers, the resulting mixture is granulated if necessary, and processed into a mixture or granules, if necessary with the addition of small amounts of excipients, to form tablets or tablet cores. The core may be combined with an optional enteric coating material and processed into a coated dosage form more readily absorbed by an organism (e.g., a human).

The following definitions as used herein should be applied unless otherwise indicated. For the purposes of the present invention, the chemical elements are in accordance with the CAS version of the periodic Table of the elements, and the handbook of chemistry and Physics, 75 th edition, 1994. In addition, general principles of Organic Chemistry can be referred to as described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausaltito: 1999, and "March's Advanced Organic Chemistry" by Michael B.Smith and Jerry March, John Wiley & Sons, New York:2007, the entire contents of which are incorporated herein by reference.

In the present specification, groups and substituents thereof may be selected by one skilled in the art to provide stable moieties and compounds. When a substituent is described by a general formula written from left to right, the substituent also includes chemically equivalent substituents obtained when the formula is written from right to left.

Certain chemical groups defined herein are preceded by a shorthand notation to indicate the total number of carbon atoms present in the group. E.g. C₁-C₆Alkyl refers to an alkyl group as defined below having a total of 1,2, 3,4, 5, or 6 carbon atoms. The total number of carbon atoms in the shorthand notation excludes carbons that may be present in a substituent of the group.

Numerical ranges defined in the substituents herein, such as 0 to 4, 1-4, 1 to 3, etc., indicate integers within the range, such as 1-6 being 1,2, 3,4, 5, 6.

In addition to the foregoing, the following terms, when used in the specification and claims of this application, have the meanings indicated below, unless otherwise specifically indicated.

The term "comprising" is open-ended, i.e. comprising what is specified in the invention, but does not exclude other aspects.

The term "substituted" means that any one or more hydrogen atoms on a particular atom is replaced with a substituent, including deuterium and hydrogen variants, so long as the valency of the particular atom is normal and the substituted compound is stable.

In general, the term "substituted" means that one or more hydrogen atoms in a given structure are replaced with a particular substituent. Further, when the group is substituted with 1 or more of the substituents, the substituents are independent of each other, that is, the 1 or more substituents may be different from each other or the same. Unless otherwise indicated, a substituent group may be substituted at each substitutable position of the substituted group. When more than one position in a given formula can be substituted with one or more substituents selected from a particular group, the substituents may be substituted at each position, identically or differently.

The term "one or more" or "one or more" means 1,2, 3,4, 5,6, 7, 8, 9 or more; such as 1,2, 3,4 or 5.

In this application, as a group or part of another group, unless otherwise specified, the term "cycloalkyl" means a saturated monocyclic, polycyclic or bridged carbocyclic substituent consisting only of carbon and hydrogen atoms, and which may be attached to the remainder of the molecule by a single bond via any suitable carbon atom; when polycyclic, it may be a spiro ring system or bridged ring system with a fused or spiro ring linkage (i.e., two geminal hydrogens on a carbon atom are replaced with an alkylene group).

In this application, the term "heterocycloalkyl" as a group or part of another group means a stable 3-to 16-membered saturated cyclic group consisting of 2 to 11 carbon atoms and 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur. Unless otherwise specifically indicated in the specification, a heterocycloalkyl group can be either monocyclic ("monocyclic heterocycloalkyl"), or a bicyclic, tricyclic, or higher ring system, which can include fused (fused), bridged (bridged), or spiro (spiro) ring systems (e.g., bicyclic ring systems ("bicyclic heterocycloalkyl"). the heterocycloalkyl bicyclic ring system can include one or more heteroatoms in one or both rings, and is saturated.

The terms "moiety," "structural moiety," "chemical moiety," "group," "chemical group" as used herein refer to a specific fragment or functional group in a molecule. Chemical moieties are generally considered to be chemical entities that are embedded in or attached to a molecule.

When no atom is indicated in the listed substituents for connecting to a compound included in the general chemical structure but not specifically mentioned, such substituent may be bonded through any atom thereof. Combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.

When no substituent is specifically indicated in the listed group, such group is simply referred to as unsubstituted. For example when "C₁～C₄When an alkyl group is "without the limitation of" substituted or unsubstituted ", it means only" C₁～C₄Alkyl "by itself or unsubstituted C₁～C₄Alkyl groups ".

In each of the parts of the invention, linking substituents are described. Where the structure clearly requires a linking group, the markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the markush group definition for the variable recites "alkyl" or "aryl," it is understood that the "alkyl" or "aryl" represents an attached alkylene group or arylene group, respectively.

In some specific structures, when an alkyl group is expressly indicated as a linking group, then the alkyl group represents a linked alkylene group, e.g., the group "halo-C₁-C₆C in alkyl₁-C₆Alkyl is understood to mean C₁-C₆An alkylene group.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is standard in the art to which the claimed subject matter belongs. In case there are multiple definitions for a term, the definitions herein control.

It should be understood that as used herein, singular forms, such as "a", "an", include plural references unless the context clearly dictates otherwise. Furthermore, the term "comprising" is open-ended, i.e. including what is specified in the invention, but not excluding other aspects.

The present invention employs conventional methods of mass spectrometry, elemental analysis, and the various steps and conditions can be referred to those conventional in the art unless otherwise indicated.

Unless otherwise indicated, the present invention employs standard nomenclature for analytical chemistry, organic synthetic chemistry, and optics, and standard laboratory procedures and techniques. In some cases, standard techniques are used for chemical synthesis, chemical analysis, light emitting device performance detection.

In addition, it should be noted that, unless otherwise explicitly indicated, the description of "… independently" as used herein is to be understood in a broad sense to mean that each individual entity so described is independent of the other and may be independently the same or different specific groups. In more detail, the description "… is independently" can mean that the specific options expressed between the same symbols do not affect each other in different groups; it can also be said that in the same group, the specific options expressed between the same symbols do not affect each other.

It will be understood by those skilled in the art that, in accordance with the convention used in the art, the structural formulae used in the radicals described herein

Means that the corresponding group is linked to other fragments, groups in the compound through this site.

The above preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention without departing from the common general knowledge in the art.

The reagents and starting materials used in the present invention are commercially available.

The positive progress effects of the invention are as follows: the carbonyl heterocyclic compound provided by the invention is a compound with a targeting lanthionine synthase C-like protein 2 path; the compounds may be used to treat a variety of conditions, including infectious diseases, autoimmune diseases, diabetes, and chronic inflammatory diseases.

Drawings

FIG. 1 is a binding curve of compound L7-LANCL2

FIG. 2 is a binding curve of compound L8-LANCL2

FIG. 3 is a binding curve of compound L12-LANCL2

FIG. 4 is a binding curve of compound L17-LANCL2

FIG. 5 is a binding curve of compound L22-LANCL2

FIG. 6 is a binding curve of compound L28-LANCL2

FIG. 7 is a binding curve of compound L29-LANCL2

FIG. 8 is a binding curve of compound L30-LANCL2

FIG. 9 is a binding curve of compound L32-LANCL2

FIG. 10 is a binding curve of compound L37-LANCL2

FIG. 11 is a binding curve of compound L44-LANCL2

FIG. 12 is a binding curve of compound L56-LANCL2

FIG. 13 shows the weight change and DAI scores (Compound L30, Compound L56, and control) for mice, wherein A) is a weight change data curve, and B) is DAI score data

FIG. 14 shows the change in the ratio of colon weight to length in mice (Compound L30, Compound L56, and control group), where A) is the ratio of colon weight to length, B) is the length of the colon, C) is the weight of the colon

FIG. 15 shows the intestinal morphology (Compound L30, Compound L56 and control)

FIG. 16 shows the body weight change and DAI scores of mice (Compound L11, Compound L25, Compound L84, Compound L77, Compound L101, Compound L10, Compound L23, and control group), wherein A) is a body weight change data curve, and B) is DAI score data

FIG. 17 shows the mouse diarrhea and hematochezia scores (Compound L11, Compound L25, Compound L84, Compound L77, Compound L101, Compound L10, Compound L23, and control group), wherein A) the mice have a change in diarrhea and B) the change in hematochezia status

FIG. 18 shows the change in the ratio of colon weight to length in mice (Compound L11, Compound L25, Compound L10, and control group), wherein A) colon length, B) colon weight, C) colon weight to length ratio

FIG. 19 shows the intestinal morphology (Compound L11, Compound L10 and control)

Detailed Description

The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.

Example 1: 6- (1H-benzo [ d ] imidazol-2-yl) -N- (3- (3- (3- (imidazoyl [1,2-a ] pyridin-2-yl) benzoyl) -3-azabicyclo [3.1.0] hex-6-yl) picolinamide (L-1)

Synthesis of methyl mono, 3- (imidazo [1,2-a ] pyridin-2-yl) benzoate

2-aminopyridine (1.6g,17mmol), methyl 3-acetylcarboxylate (2.3g,14mmol) and cuprous iodide (0.5g,2.8mmol) were dissolved in 50mL of 1, 4-dioxane at room temperature, the reaction was heated to reflux overnight and monitored by LC-MS to the end of the reaction. After concentration under reduced pressure, 50mL of water was added, and extraction was performed with ethyl acetate (50mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a residue, which was separated and purified by column chromatography (eluent: petroleum ether/ethyl acetate: 5/1) to obtain a white solid (1.8g,7.4mmol), with a yield of 52%. LC-MS: [ M + 1]]⁺:253.09

Synthesis of di, 3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid

Methyl 3- (imidazo [1,2-a ] pyridin-2-yl) benzoate (1.8g,7.4mmol) and lithium hydroxide (0.88g,37mmol) were dissolved in 20mL of ethanol and water (v/v ═ 10:1) at room temperature, heated to reflux, and the reaction was monitored by LC-MS to completion. The reaction mixture was concentrated under reduced pressure, and silica gel column chromatography of the concentrated solution was carried out to obtain a white solid (1.6g,0.67mmol), yield 90%. LC-MS: 238.07.

synthesis of tri, N' - (1, 2-aniline) bis (3- (imidazo [1,2-a ] pyridin-2-yl) benzamide

3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid (0.12g,0.5mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.1g,0.52mmol), 1-hydroxybenzotriazole (0.07g,0.52mmol) and N, N-diisopropylethylamine (0.14g,1.13mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-cooling, and after stirring for 0.5h, o-phenylenediamine (0.024g,0.228mmol) was added, and after stirring for 0.5h, the reaction was returned to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (15mg,2.7 μmol) with a yield of 5.4%. LC-MS, M/z (M + H) + -549.

¹H NMR(400MHz,Chloroform-d)δ9.42(s,2H),8.54(t,J＝1.8Hz,2H),8.27(m,2H),8.04(m,4H),7.93–7.87(m,2H),7.66–7.56(m,6H),7.20–7.08(m,4H),6.73(m,2H).

Example 26- (1H-benzo [ d ] imidazol-2-yl) -N- (3- (3- (3- (imidazoyl [1,2-a ] pyridin-2-yl) benzoyl) -3-azabicyclo [3.1.0] hex-6-yl) picolinamide (L-2)

3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid (0.12g,0.5mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.1g,0.52mmol), 1-hydroxybenzotriazole (0.07g,0.52mmol) and N, N-diisopropylethylamine (0.14g,1.13mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-cooling, and after stirring for 0.5H 6- (1H-benzo [ d ] imidazol-2-yl) -N- (3-azabicyclo [3.1.0] hex-6-yl) picolinamide (0.16g,0.5mmol) was added and stirring was continued for 0.5H and then allowed to return to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases combined, dried over anhydrous sodium sulfate and concentrated by silica gel column chromatography under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (20mg,37 μmol) in 7.4% yield. LC-MS M/z (M + H) + (540).

¹H NMR(400MHz,Chloroform-d)δ14.50(s,1H),8.91(s,1H),8.60(dd,J＝7.9,1.1Hz,1H),8.25(d,J＝6.8Hz,1H),8.19(dd,J＝7.7,1.0Hz,1H),8.09–7.98(m,3H),7.91(q,J＝8.0Hz,2H),7.59(d,J＝9.1Hz,1H),7.50(t,J＝7.7Hz,1H),7.42–7.36(m,1H),7.26–7.12(m,4H),6.88(m,1H),3.98(d,J＝12.3Hz,1H),3.39(d,J＝11.6Hz,2H),3.19(d,J＝12.8Hz,1H),1.79(s,1H),1.33(s,1H),1.06(s,1H).

Example 3(9- (3- (1 h-benzo [ d ] imidazol-2-yl) benzoyl) -3, 9-diazaspiro [5.5] undecan-3-yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone (L-3)

3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid (0.12g,0.5mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.1g,0.52mmol), 1-hydroxybenzotriazole (0.07g,0.52mmol) and N, N-diisopropylethylamine (0.14g,1.13mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-cooling, and after stirring for 0.5H 6- (1H-benzo [ d ] imidazol-2-yl) -N- (3-azabicyclo [3.1.0] hex-6-yl) picolinamide (0.18g,0.5mmol) was added and stirring was continued for 0.5H and then allowed to return to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (30mg,50 μmol) in 10% yield. LC-MS M/z (M + H) + (596).

¹H NMR(400MHz,Chloroform-d)δ10.53(s,1H),8.49(dd,J＝7.9,1.1Hz,1H),8.15(m,1H),8.06–7.94(m,3H),7.89(d,J＝14.0Hz,2H),7.65(d,J＝9.1Hz,1H),7.60(m,1H),7.51(m,2H),7.35(m,3H),7.21(m,1H),6.82(m,1H),3.84(s,4H),3.52(s,4H),1.74(s,4H),1.58(s,4H).

Example 4(1S, 4S) -5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyl) -2, 5-diazabicyclo [2.2.1] heptan-2-yl) (3- (imidazoyl [1,2-a ] pyridin-2-yl) phenyl) methanone (L-4)

3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid (0.12g,0.5mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.1g,0.52mmol), 1-hydroxybenzotriazole (0.07g,0.52mmol) and N, N-diisopropylethylamine (0.14g,1.13mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-cooling, and after stirring for 0.5H, (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (1S, 4S) -2, 5-diazabicyclo [2.2.1] hept-2-yl) methanone (0.18g,0.5mmol) was added, and after stirring for 0.5H, the reaction was allowed to return to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases combined, dried over anhydrous sodium sulfate and concentrated by silica gel column chromatography under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (25mg,46 μmol) in 9% yield. LC-MS M/z (M + H) + (540).

¹H NMR(400MHz,Chloroform-d)δ10.80(d,J＝23.5Hz,1H),8.57(d,J＝7.3Hz,1H),8.21–8.09(m,2H),8.02(m,3H),7.91(d,J＝10.4Hz,2H),7.73–7.62(m,2H),7.56(m,3H),7.37(s,1H),7.16(s,1H),6.85–6.75(m,1H),4.85–4.61(m,2H),4.08–3.74(m,4H),2.03(s,2H).

EXAMPLE 5N- (1- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) piperidin-4-yl) -3- (imidazo [1,2-a ] pyridin-2-yl) benzamide (L-5)

Synthesis of mono-tert-butyl (1- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinynyl) piperidin-4-yl) carbamate

6- (1H-benzo [ d ] imidazol-2-yl) picolinic acid (1g,4.2mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.96g,5mmol), 1-hydroxybenzotriazole (0.66g,5mmol) and N, N-diisopropylethylamine (1.19g,9.2mmol) were dissolved in 20mL of N, N-dimethylformamide under ice-bath, stirred for 0.5H, tert-butylpiperidin-4-ylcarbamate (0.92g,4.6mmol) was added, and after stirring for 0.5H, the reaction was returned to room temperature overnight. The reaction was poured into 80mL of water and extracted with ethyl acetate (80mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (PE: EA ═ 5:1) to give an off-white solid (1.3g,3mmol) with a yield of 73%. LC-MS M/z (M + H) + (421).

Synthesis of di, 6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (4-aminopiperidin-1-yl) methanone

Tert-butyl (1- (6- (1H-benzo [ d ]) under ice bath]Imidazol-2-yl) pyridinyloxy) piperidin-4-yl) carbamate (1.3g,3mmol) was dissolved in 20mL of dichloromethane, saturated 1, 4-dioxane hydrochloric acid solution (2mL,8mmol) was added, stirring was continued for 0.5 hours and then the reaction was returned to room temperature overnight. The reaction solution was concentrated under reduced pressure, and the obtained solid was directly used in the next reaction. Yield of>90％。LC-MS：321[M+1]⁺

Synthesis of N- (1- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) piperidin-4-yl) -3- (imidazo [1,2-a ] pyridin-2-yl) benzamide

Third, 3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid (0.12g,0.5mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.1g,0.52mmol), 1-hydroxybenzotriazole (0.07g,0.52mmol) and N, N-diisopropylethylamine (0.14g,1.13mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-bath, and after stirring for 0.5H, (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (4-aminopiperidin-1-yl) methanone (0.18g,0.5mmol) was added, and after stirring for 0.5H, the reaction was allowed to return to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (15mg,27 μmol) with a yield of 5.5%. LC-MS M/z (M + H) + (542).

¹H NMR(400MHz,Chloroform-d)δ11.87(s,1H),8.56(dd,J＝7.9,1.1Hz,1H),8.40(t,J＝1.7Hz,1H),8.21(m,1H),8.07–7.94(m,3H),7.90–7.80(m,2H),7.69(d,J＝9.1Hz,1H),7.61(dd,J＝7.7,1.1Hz,1H),7.48(m,2H),7.28–7.17(m,3H),6.87(m,1H),6.25(d,J＝7.9Hz,1H),4.68(d,J＝13.7Hz,1H),4.25(dd,J＝7.7,3.9Hz,1H),3.85(d,J＝13.9Hz,1H),3.19(t,J＝12.6Hz,1H),3.02–2.91(m,1H),2.12(s,1H),1.92(d,J＝12.8Hz,2H),1.61(m,1H).

Example 66- (1H-benzo [ d ] imidazol-2-yl) -N- (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) pyrrolidin-3-yl) picolinamide (L-6)

3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid (0.12g,0.5mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.1g,0.52mmol), 1-hydroxybenzotriazole (0.07g,0.52mmol) and N, N-diisopropylethylamine (0.14g,1.13mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-cooling, and after stirring for 0.5H 6- (1H-benzo [ d ] imidazol-2-yl) -N- (pyrrolidin-3-yl) picolinamide (0.14g,0.5mmol) was added and after stirring for 0.5H the reaction was allowed to return to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (18mg,34 μmol) with a yield of 5.5%.

LC-MS m/z:(M+H)+＝528，¹H NMR(400MHz,Chloroform-d)δ8.64–8.44(m,2H),8.08(d,J＝6.9Hz,1H),8.02–7.67(m,7H),7.62–7.44(m,3H),7.28–7.11(m,4H),6.83(t,J＝6.6Hz,1H),5.40–5.34(m,1H),4.92(d,J＝17.1Hz,1H),4.69–4.61(m,1H),4.09(m,1H),4.02–3.72(m,3H).

Example 7N, N' - (1, 2-phenylene) bis (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoline amide) (L-7)

Synthesis of 6- (1H-benzo [ d ] imidazol-2-yl) picolinic acid

Pyridine 2, 6-dicarboxylic acid (5g, 21.919mmol) was added to a solution of o-phenylenediamine (3.5g, 32mmol) in propylene glycol (100mL), and the resulting mixture was heated under reflux for 24h and then cooled to room temperature. Ice water (50mL) was added to the reaction mixture, and a brown solid was precipitated by stirring, and the precipitate was collected and dissolved in hot methanol, and the solution was filtered with activated carbon. The resulting filtrate was slowly evaporated to remove the solvent to give 6- (1H-benzimidazole-2-) pyridinecarboxylic acid. The yield thereof was found to be 52%. LC-MS: [ M + 1]]⁺:240.1

Synthesis of di, N' - (1, 2-phenylene) bis (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoline amide)

6- (1H-benzimidazole-2-) pyridine carboxylic acid (0.12g,0.5mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.1g,0.52mmol), 1-hydroxybenzotriazole (0.07g,0.52mmol) and N, N-diisopropylethylamine (0.14g,1.13mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-bath, stirred for 0.5H, added with o-phenylenediamine (0.024g,0.228mmol), allowed to stir for 0.5H and then returned to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (30mg,5.4 μmol) in 11% yield. LC-MS M/z (M + H) + (550.98),¹H NMR(400MHz,DMSO)δ12.58(s,2H),11.01(s,2H),8.20(d,J＝7.3Hz,2H),8.07–7.80(m,6H),7.67–7.53(m,2H),7.43(dd,J＝5.7,3.6Hz,2H),7.25–7.09(m,4H),7.03(d,J＝5.5Hz,2H).

example 8N, N' - (cyclohexane-1, 2-diyl) bis (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoline amide) (L-8)

N, N' - (cyclohexane-1, 2-diyl) bis (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoline amide)

The operation is the same as that of L-7, cyclohexane-1, 2-diamine purchased from Chinese medicine

LC-MS:m/z:(M+H)+＝557.26,¹H NMR(400MHz,CDCl₃)δ8.83(s,2H),8.42(d,J＝7.8Hz,2H),8.03(d,J＝7.7Hz,2H),7.79(t,J＝7.8Hz,6H),7.32(dd,J＝5.8,3.1Hz,2H),4.13(d,J＝16.6Hz,2H),2.35(d,J＝11.4Hz,2H),1.94–1.37(m,6H).

Example 9(3, 9-diazaspiro [5.5] undecane-3, 9-diyl) bis ((6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone) (L-9)

Synthesis of tert-butyl mono, 9- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinynyl) -3, 9-diazaspiro [5.5] undecane-3-carboxylate

6- (1H-benzimidazole-2-) pyridinecarboxylic acid (1g,4.2mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.96g,5mmol), 1-hydroxybenzotriazole (0.66g,5mmol) and N, N-diisopropylethylamine (1.19g,9.2mmol) were dissolved in 20mL of N, N-dimethylformamide under ice-bath, stirred for 0.5H, tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate (0.92g,4.6mmol) was added, and after stirring for 0.5H, the reaction was returned to room temperature overnight. The reaction was poured into 80mL of water and extracted with ethyl acetate (80mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (PE: EA ═ 5:1) to give an off-white solid (1.3g,3mmol) with a yield of 73%. LC-MS M/z (M + H) + (476).

Synthesis of di- (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (3, 9-diazaspiro [5.5] undecan-3-yl) methanone

9- (6-(1H-benzo [ d ]]Imidazol-2-yl) pyridinyloxy) -3, 9-diazaspiro [5.5]Tert-butyl undecane-3-carboxylate (1.3g,3mmol) was dissolved in 20mL of dichloromethane, saturated 1, 4-dioxane hydrochloric acid solution (2mL,8mmol) was added, stirring was continued for 0.5h and the reaction was allowed to return to room temperature overnight. The reaction solution was concentrated under reduced pressure, and the obtained solid was directly used in the next reaction. Yield of>90％。LC-MS：376[M+1]⁺。

Synthesis of tris, (3, 9-diazaspiro [5.5] undecane-3, 9-diyl) bis ((6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone)

6- (1H-Benzimidazol-2-) pyridinecarboxylic acid (0.14g,0.27mmol) and N, N-diisopropylethylamine (0.12g,1.0mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-bath, and after stirring for 0.5H, (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (3, 9-diazaspiro [5.5] undecan-3-yl) methanone (0.089g,0.27mmol) was added and after stirring for 0.5H the reaction was allowed to return to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (20mg,38 μmol), yield 14.3%.

LC-MS:m/z:(M+H)+＝598.1,¹H NMR(400MHz,CDCl₃)δ10.70(s,2H),8.49(d,J＝7.9Hz,2H),7.93(dd,J＝25.5,17.6Hz,4H),7.56(t,J＝8.1Hz,5H),7.38–7.30(m,5H),3.84(s,3H),3.51(s,5H),1.65(d,J＝67.9Hz,8H).

Example 10 (Tetrahydropyrrolo [3,4-c ] pyrrole-2, 5(1H, 3H) -diyl) bis ((6- (1H-benzo [ d ] imidazol-2-yl ] pyridin-2-yl) methanone) (L-10)

Synthesis of 5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) tert-hydropyrrolo [3,4-c ] pyrrole-2 (1H) -carboxylic acid tert-butyl ester

6- (1H-benzimidazole-2-) pyridinecarboxylic acid (1g,4.2mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.96g,5mmol), 1-hydroxybenzotriazole (0.66g,5mmol) and N, N-diisopropylethylamine (1.19g,9.2mmol) were dissolved in 20mL of N, N-dimethylformamide under ice-bath, stirred for 0.5H, tert-butylhexahydropyrrolo [3,4-c ] pyrrole-2 (1H) -carboxylate (0.92g,4.6mmol) was added, and after stirring for 0.5H, the reaction was returned to room temperature overnight. The reaction was poured into 80mL of water and extracted with ethyl acetate (80mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (PE: EA ═ 5:1) to give an off-white solid (1.3g,3mmol) with a yield of 73%. LC-MS M/z (M + H) + (434).

Synthesis of di (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone

Tert-butyl 5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) tert-hydropyrrolo [3,4-c ] pyrrole-2 (1H) -carboxylate (1.3g,3mmol) was dissolved in dichloromethane 20mL under ice-bath, saturated 1, 4-dioxane hydrochloric acid solution (2mL,8mmol) was added, stirring was continued for 0.5H and then returned to room temperature overnight. The reaction solution was concentrated under reduced pressure, and the obtained solid was directly used in the next reaction. The yield is more than 90%. LC-MS M/z (M + H) + 334.

Synthesis of tris (tetrahydropyrrolo [3,4-c ] pyrrole-2, 5(1H, 3H) -diyl) bis ((6- (1H-benzo [ d ] imidazol-2-yl ] pyridin-2-yl) methanone)

The operation is the same as L-9

(Tetrahydropyrrolo [3,4-c ] pyrrole-2, 5(1H, 3H) -diyl) bis ((6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone)

LC-MS:m/z:(M+H)+＝555.61,¹H NMR(400MHz,MeOD)δ8.49–8.29(m,3H),8.23–8.04(m,3H),8.03–7.93(m,1H),7.86(dd,J＝7.0,5.6Hz,1H),7.71(dd,J＝6.0,3.1Hz,1H),7.64–7.54(m,2H),7.50(dd,J＝8.1,5.7Hz,2H),7.41–7.28(m,2H),7.26–7.17(m,1H),7.01–6.87(m,1H),4.23–3.55(m,8H),3.27–3.04(m,2H).

Example 11N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hex-6-yl) -6- (1H-benzo [ d ] imidazol-2-yl) picolinic acid amide (L-11)

Synthesis of mono-tert-butyl (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridininyl) -3-azabicyclo [3.1.0] hexyl-6-yl) carbamate

6- (1H-benzimidazole-2-) pyridinecarboxylic acid (1g,4.2mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.96g,5mmol), 1-hydroxybenzotriazole (0.66g,5mmol) and N, N-diisopropylethylamine (1.19g,9.2mmol) were dissolved in 20mL of N, N-dimethylformamide under ice-bath, stirred for 0.5H, tert-butyl (3-azabicyclo [3.1.0] hex-6-yl) carbamate (0.92g,4.6mmol) was added, and stirring was continued for 0.5H and then allowed to return to room temperature overnight. The reaction was poured into 80mL of water and extracted with ethyl acetate (80mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (PE: EA ═ 5:1) to give an off-white solid (1.3g,3mmol) with a yield of 73%. LC-MS M/z (M + H) + (421).

Synthesis of di (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (6-amino-3-azabicyclo [3.1.0] hex-3-yl) methanone

Tert-butyl (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) carbamate (1.3g,3mmol) was dissolved in 20mL of dichloromethane in ice bath, saturated 1, 4-dioxane hydrochloric acid solution (2mL,8mmol) was added, stirring was continued for 0.5H and then returned to room temperature overnight. The reaction solution was concentrated under reduced pressure, and the obtained solid was directly used in the next reaction. The yield is more than 90%. LC-MS M/z (M + H) + (321).

Synthesis of tris, N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hex-6-yl) -6- (1H-benzo [ d ] imidazol-2-yl) picolinic acid amide

The operation is the same as L-9

LC-MS:m/z:(M+H)+＝541.20,¹H NMR(400MHz,CDCl₃)δ13.25(s,1H),12.09(s,1H),8.68(s,1H),8.48(d,J＝7.6Hz,1H),8.26(d,J＝7.6Hz,1H),8.01(d,J＝7.5Hz,1H),7.81(t,J＝7.8Hz,4H),7.50(dt,J＝20.7,5.8Hz,3H),7.38–7.30(m,4H),4.58(d,J＝11.3Hz,1H),4.45–4.22(m,2H),3.64–3.43(m,3H),2.63(s,1H),2.00(s,9H),1.60(s,2H).

Example 12(2, 5-diazabicyclo [2.2.1] heptane-2, 5-diyl) bis ((6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone) (L-12)

(2, 5-diazabicyclo [2.2.1] heptane-2, 5-diyl) bis ((6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone)

The operation is the same as L-7

LC-MS:m/z:(M+H)+＝541.59,¹H NMR(400MHz,CDCl₃)δ12.67(s,1H),8.13–7.82(m,4H),7.54–7.33(m,4H),7.26(d,J＝7.6Hz,2H),4.54(d,J＝11.9Hz,3H),4.04(t,J＝15.9Hz,3H),1.85(s,1H),1.77(s,1H).

Example 13N, N' - (1, 2-phenylene) bis (2-morpholinylpyrimidine-4-carboxamide) (L-13)

Synthesis of mono, 2-morpholinopyrimidine-4-carboxylic acid

2-Chloropyrimidine-4-carboxylic acid (500mg,3.15mmol) was dissolved in 15ml of tetrahydrofuran and 15ml of dioxane, 2ml of morpholine was added, and the reaction mixture was stirred at 70 ℃ for 18 hours. The reaction solution was cooled to room temperature and filtered. The solid was dissolved in 20mL of water, acidified to pH 1 with 1N hydrochloric acid and the solution extracted with dichloromethane/methanol 10:1(20mL × 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to give 580mg of a white solid with a yield of 87.9%. LC-MS M/z (M + H)⁺＝210.0。

1H NMR(400MHz,CD3OD)δ8.57(d,J＝4.8Hz,1H),7.20(d,J＝4.8Hz,1H),3.93–3.83(m,4H),3.76(m,4H).

Synthesis of di, N' - (1, 2-phenylene) bis (2-morpholinylpyrimidine-4-carboxamide)

2-Morpholinopyrimidine-4-carboxylic acid (100mg, 0.48mmol) (a compound represented by formula 3) was suspended in 2ml of N, N-dimethylformamide, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (137mg, 0.72mmol), 1-hydroxybenzotriazole (97mg, 0.72mmol) and N, N-diisopropylethylamine (185mg,1.4340mmol) were added. After the reaction mixture was stirred for 20 minutes, o-phenylenediamine (25.8mg, 0.24mmol) was added, and the reaction mixture was stirred at 15 ℃ for 16 hours. To the reaction solution was added 10mL of water, and extracted with ethyl acetate (10mL × 2). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product. The crude product was purified by thin layer chromatography (dichloromethane: methanol 10:1), and the obtained product was slurried with a mixed solution of dimethylsulfoxide (3mL) and methanol (2mL), filtered, and the solid was washed with methanol and dried to obtain 23mg of the desired product as a white solid with a yield of 9.81%.

LC-MS:m/z:(M+H)+＝491.0,¹H NMR(400MHz,DMSO-d6)δ10.46(s,2H),8.70(d,J＝4.8Hz,2H),7.78(dd,J＝6.0,3.6Hz,2H),7.36(dd,J＝6.0,3.6Hz,2H),7.26(d,J＝4.8Hz,2H),3.90–3.69(m,4H),3.60(d,J＝4.4Hz,4H).

Example 14N- (3- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) -2-morpholinopyrimidine-4-carboxamide (L-14)

N- (3- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) -2-morpholinopyrimidine-4-carboxamide

2-Morpholinopyrimidine-4-carboxylic acid (100mg, 0.48mmol) (a compound represented by formula 3) was suspended in 2ml of N, N-dimethylformamide, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (137mg, 0.72mmol), 1-hydroxybenzotriazole (97mg, 0.72mmol) and N, N-diisopropylethylamine (185mg,1.4340mmol) were added. After the reaction mixture was stirred for 20 minutes, (6-amino-3-azabicyclo [3.1.0] hex-3-yl) - [6- (1H-benzimidazol-2-yl) -2-pyridyl ] methanone (76mg, 0.24mmol) was added and the reaction mixture was stirred at 15 ℃ for 16 hours. To the reaction solution was added 10mL of water, and extracted with ethyl acetate (10mL × 2). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product. The crude product was purified by thin layer chromatography (dichloromethane: methanol 10:1) to yield 38mg of the desired product as a white solid in 31.14% yield.

LC-MS:m/z:(M+H)+＝511.0,¹H NMR(400MHz,DMSO-d6)δ8.75(s,1H),8.61(d,J＝7.8Hz,1H),8.35(d,J＝4.8Hz,1H),8.22(t,J＝13.6Hz,1H),7.99(t,J＝7.8Hz,1H),7.63(s,2H),7.31(dd,J＝6.6,3.5Hz,1H),6.78(d,J＝4.8Hz,1H),4.33(d,J＝12.5Hz,1H),4.20–4.10(m,2H),3.98(dd,J＝11.8,4.4Hz,1H),3.72(dd,J＝12.9,4.8Hz,9H),2.56(d,J＝2.1Hz,1H),2.12(d,J＝2.5Hz,1H),2.04(d,J＝4.7Hz,1H).

Example 159- (6- (1-H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3, 9-diazaspiro [5.5] undecan-3-yl) (2-morpholinopyrimidin-4-yl) methanone (L-15)

(9- (6- (1-H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3, 9-diazaspiro [5.5] undecan-3-yl) (2-morpholinopyrimidin-4-yl) methanone

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝567.0,¹H NMR(400MHz,CD₃OD)δ8.53(d,J＝7.8Hz,1H),8.44(d,J＝4.8Hz,1H),7.97(t,J＝7.8Hz,1H),7.73(s,2H),7.59(dd,J＝7.7,0.9Hz,1H),7.39–7.31(m,2H),6.70(d,J＝4.8Hz,1H),3.90-3.76(m,12H),3.51(d,J＝6.9Hz,4H),1.75-1.69(m,4H),1.59-1.57(m,4H).

Example 16(5- (6- (1- (1-H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2-morpholinopyrimidin-4-yl) methanone (L-16)

(5- (6- (1- (1-H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2-morpholinopyrimidin-but-4-yl) methanone

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝525.0,¹H NMR(400MHz,CDCl₃)δ8.60–8.37(m,2H),8.00(dd,J＝17.8,9.9Hz,1H),7.81(ddd,J＝14.2,8.7,2.6Hz,2H),7.65(d,J＝4.6Hz,1H),7.33(dd,J＝6.0,3.1Hz,2H),6.97(dd,J＝10.5,4.8Hz,1H),4.25–3.56(m,16H),3.21–2.81(m,2H).

Example 17N, N' - (cyclohexane-1, 2-diyl) bis (2-morpholinylpyrimidine-4-carboxamide) (L-17)

N, N' - (cyclohexane-1, 2-diyl) bis (2-morpholinylpyrimidine-4-carboxamide)

The operation is the same as L-7

LC-MS:m/z:(M+H)+＝497.0,¹H NMR(400MHz,CD₃OD)δ8.48(d,J＝4.8Hz,2H),8.14–7.99(m,2H),7.18(d,J＝4.8Hz,2H),3.96(s,2H),3.82–3.80(m,16H),2.24(d,J＝6.8Hz,2H),1.85(s,2H),1.45(d,J＝5.2Hz,4H).

Example 18(5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -2, 5-diazabicyclo [2.2.1] hept-2-yl) (2-morpholinopyrimidin-4-yl) methanone (L-18)

(5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -2, 5-diazabicyclo [2.2.1] hept-2-yl) (2-morpholinopyrimidin-4-yl) methanone

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝511.0,¹H NMR(400MHz,CDCl3)δ8.67–8.41(m,2H),8.06–7.87(m,4H),7.38–7.35(m,2H),7.19–6.98(m,1H),5.33–5.00(m,2H),4.20–3.41(m,12H),2.11–1.98(m,2H).

Example 19(N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy ] piperidin-4-yl) -2- (phenylamino) pyrimidine-4-carboxamide (L-19)

Mono, 2- (phenylamino) pyrimidine-4-carboxylic acid

2-Chloropyrimidine-4-carboxylic acid (500mg,3.15mmol) was dissolved in 15ml of dioxane, aniline (881mg,9.46mmol) was added, and the reaction solution was stirred at 70 ℃ for 18 hours. The reaction was cooled to room temperature, 20ml of water and 10ml of 1N sodium hydroxide were added, and the reaction was extracted twice with ethyl acetate (20 ml. times.2). The aqueous phase was acidified with 1N hydrochloric acid to pH 3 and the solid was filtered and dried to give 500mg of a white solid in 73.67% yield. LC-MS M/z (M + H) + (216.0).

Synthesis of di-tert-butyl (1- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) piperidin-4-yl) carbamate

6- (1H-benzimidazole-2-) pyridinecarboxylic acid (1g,4.2mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.96g,5mmol), 1-hydroxybenzotriazole (0.66g,5mmol) and N, N-diisopropylethylamine (1.19g,9.2mmol) were dissolved in 20mL of N, N-dimethylformamide under ice-bath, stirred for 0.5H, tert-butyl piperidin-4-ylcarbamate (0.92g,4.6mmol) was added, and after stirring for 0.5H, the reaction was returned to room temperature overnight. The reaction was poured into 80mL of water and extracted with ethyl acetate (80mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (PE: EA ═ 5:1) to give an off-white solid (1.3g,3mmol) with a yield of 73%. LC-MS M/z (M + H) + (421).

Synthesis of tris (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (4-aminopiperidin-1-yl) methanone

Tert-butyl (1- (6- (1H-benzo [ d ]) under ice bath]Imidazol-2-yl) pyridinyloxy) piperidin-4-yl) carbamate (1.3g,3mmol) was dissolved in 20mL of dichloromethane, saturated 1, 4-dioxane hydrochloric acid solution (2mL,8mmol) was added, stirring was continued for 0.5 hours and then the reaction was returned to room temperature overnight. The reaction solution was concentrated under reduced pressure, and the obtained solid was directly used in the next reaction. Yield of>90％。LC-MS：321[M+1]⁺。

Tetra, (N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperidin-4-yl) -2- (phenylamino) pyrimidine-4-carboxamide the same procedure as for L-14

LC-MS:m/z:(M+H)+＝519.0,1H NMR(400MHz,CD3OD)δ8.64(d,J＝4.9Hz,1H),8.40(dd,J＝8.0,1.0Hz,1H),8.13(t,J＝7.9Hz,1H),7.76–7.58(m,5H),7.40–7.26(m,5H),7.08–6.99(m,1H),4.64(d,J＝13.6Hz,1H),4.27–4.15(m,1H),3.85(d,J＝14.1Hz,1H),3.43(dd,J＝18.3,7.0Hz,1H),3.31–3.20(m,1H),2.19(d,J＝11.0Hz,1H),2.00(s,1H),1.72-1.79(m,10.0Hz,2H).

Example 20(N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperidin-4-yl ] -3- (1H-benzo [ d ] imidazol-2-yl) cyclohexane-1-carboxamide (L-20)

3- (1H-benzo [ d ] imidazol-2-yl) cyclohexane-1-carboxylic acid

1, 3-Cyclohexanedicarboxylic acid (1g, 5.8mmol) and p-phenylenediamine (628mg, 5.8mmol) were dissolved in 10ml of N, N-dimethylformamide, and 2- (7-azobenzotriazol) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (2.43g, 6.34mmol) and N, N-diisopropylethylamine (2.25g, 17.40 mmol) were added. The reaction was stirred at 15 ℃ for 16 h. To the reaction solution was added 50mL of water, and extracted with ethyl acetate (50mL × 3). The aqueous phase was concentrated to give 3g of a black oil which was dissolved in 20ml of acetic acid, concentrated by stirring at 55 ℃ for 4h and purified by column chromatography to give 1.3g of the desired product in 93% yield. LC-MS: M/z (M + H) + -245.0.

Bis (N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperidin-4-yl ] -3- (1H-benzo [ d ] imidazol-2-yl) cyclohexane-1-carboxamide

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝519.0,1H NMR(400MHz,CD3OD)δ8.40(d,J＝7.9Hz,1H),8.13(t,J＝7.8Hz,1H),7.65(dd,J＝7.7,0.9Hz,3H),7.54(d,J＝2.5Hz,2H),7.32(dd,J＝6.1,3.1Hz,2H),7.27–7.16(m,2H),4.62(d,J＝9.1Hz,1H),4.05–3.95(m,1H),3.81(d,J＝13.9Hz,1H),3.50–3.42(m,1H),3.39(s,1H),3.18(dd,J＝15.3,9.6Hz,1H),2.64(s,1H),2.43–2.29(m,1H),2.24–2.04(m,3H),1.94(dd,J＝13.8,10.6Hz,2H),1.74(dd,J＝11.1,5.5Hz,3H),1.66–1.45(m,3H).

Example 21N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperidin-4-yl ] -2- (pyridin-2-ylamino) pyrimidine-4-carboxamide (L-21)

Mono, 2- (pyridin-2-ylamino) pyrimidine-4-carboxylic acid

Pyridin-2-amine (534mg, 5.67mmol) was dissolved in 1ml of N, N-dimethylformamide and 60% NaH (227mg, 5.6768mmol) was added at 20 ℃. The reaction was stirred at 20 ℃ for 1 h. 2-Chloropyrimidine-4-carboxylic acid (300mg, 1.89mmol) was added and the reaction was stirred at 70 ℃ for 18 h. The reaction was allowed to cool to room temperature and 20mL of water was added and the reaction was extracted with dichloromethane (20mL × 2). The aqueous phase was acidified with 1N hydrochloric acid to pH 5 and concentrated. The residue was dissolved in 5mL of N, N-dimethylformamide, stirred for 10 minutes, filtered, and concentrated to give 80mg of a yellow solid with a yield of 19.5%. LC-MS: M/z (M + H) + 217.0.

Bis (N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperidin-4-yl ] -2- (pyridin-2-ylamino) pyrimidine-4-carboxamide

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝520.0,¹H NMR(400MHz,CDCl3)δ8.74(d,J＝4.9Hz,1H),8.50(t,J＝9.1Hz,2H),8.36(s,1H),8.27(d,J＝4.7Hz,1H),8.04(d,J＝8.2Hz,1H),7.95(t,J＝7.8Hz,1H),7.84(t,J＝7.4Hz,1H),7.65(ddd,J＝17.5,9.1,5.3Hz,3H),7.28–7.25(m,1H),7.12–7.01(m,1H),4.68(d,J＝13.3Hz,1H),4.37–4.13(m,1H),3.87(d,J＝13.5Hz,1H),3.28(t,J＝11.8Hz,1H),3.14(t,J＝11.5Hz,1H),2.15(d,J＝11.2Hz,1H),2.01(d,J＝10.6Hz,1H),1.79(dd,J＝21.2,11.4Hz,2H).

Example 22(N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperidin-4-yl ] -2-morpholinopyrimidine-4-carboxamide (L-22)

(N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperidin-4-yl ] -2-morpholinopyrimidine-4-carboxamide)

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝513.0,1H NMR(400MHz,CDCl3)δ8.57(d,J＝4.8Hz,1H),8.52(d,J＝7.8Hz,1H),7.95(t,J＝7.8Hz,1H),7.75(d,J＝8.2Hz,2H),7.63–7.58(m,1H),7.39–7.32(m,3H),4.78(d,J＝13.5Hz,1H),4.26(dt,J＝10.9,9.5Hz,1H),3.92(d,J＝13.9Hz,1H),3.88–3.76(m,8H),3.34(t,J＝11.9Hz,1H),3.12(t,J＝11.6Hz,1H),2.21(d,J＝9.7Hz,1H),2.07(d,J＝11.7Hz,1H),1.81–1.63(m,2H).

Example 23N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) -2- (phenylamino) pyrimidine-4-carboxamide (L-23)

N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) -2- (phenylamino) pyrimidine-4-carboxamide

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝517.0,1H NMR(400MHz,CDCl3)δ8.61–8.52(m,2H),8.48(d,J＝4.9Hz,1H),8.24(d,J＝6.9Hz,1H),7.98(t,J＝7.8Hz,1H),7.63(d,J＝7.7Hz,3H),7.46(s,1H),7.37(t,J＝8.0Hz,2H),7.30(d,J＝3.2Hz,1H),7.09(t,J＝7.4Hz,1H),6.97(d,J＝4.9Hz,1H),4.24(d,J＝12.6Hz,1H),4.08(d,J＝11.7Hz,1H),3.87(dd,J＝11.7,4.4Hz,1H),3.69(dd,J＝12.1,4.5Hz,2H),3.14(dt,J＝11.7,7.3Hz,1H),2.56(d,J＝2.2Hz,1H),1.97(dd,J＝18.6,4.3Hz,2H).

Example 24(5- (6- (1- (1-H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (phenylamino) pyrimidin-4-yl) methanone (L-24)

(5- (6- (1- (1-H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (phenylamino) pyrimidin-4-yl) methanone

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝531.0,1H NMR(400MHz,CDCl3)δ8.60–8.44(m,2H),8.02–7.92(m,1H),7.79(dd,J＝6.3,3.1Hz,2H),7.75–7.62(m,2H),7.51(d,J＝7.7Hz,1H),7.41–7.30(m,3H),7.27–7.16(m,1H),7.09(dd,J＝9.6,6.2Hz,1H),4.05-3.79(m,4H),3.78-3.68(m,4H),3.07(s,2H).

Example 25(N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) -2- (pyridin-2-ylamino) pyrimidine-4-carboxamide (L-25)

(N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) -2- (pyridin-2-ylamino) pyrimidine-4-carboxamide

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝518.0,1H NMR(400MHz,CD3OD)δ8.71(d,J＝4.9Hz,1H),8.41(dd,J＝7.6,1.3Hz,1H),8.31(dd,J＝9.5,4.8Hz,2H),8.21–8.08(m,2H),8.07-7.82(m,1H),7.68(s,2H),7.40–7.28(m,2H),7.17(d,J＝4.9Hz,1H),7.05(ddd,J＝7.2,5.0,0.9Hz,1H),4.24(d,J＝12.5Hz,1H),4.14(d,J＝11.5Hz,1H),3.99(dd,J＝11.5,4.3Hz,1H),3.75(dt,J＝13.2,5.1Hz,1H),2.71(t,J＝2.4Hz,1H),2.17–2.05(m,2H).

Example 26((5- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (pyridin-2-ylamino) pyrimidin-4-yl) methanone (L-26)

((5- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (pyridin-2-ylamino) pyrimidin-4-yl) methanone

2- (2-pyridylamino) pyrimidine-4-carboxylic acid (40mg, 0.18mmol) was dissolved in 2ml of N, N-dimethylformamide, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (145mg, 0.28mmol) and N, N-diisopropylethylamine (72mg,0.56mmol) were added. After the reaction mixture was stirred for 20 minutes, 2,3,3a, 4,6,6 a-hexahydro-1H-pyrrolo [3,4-c ] pyrrol-5-yl- [6- (1H-benzimidazole-add-2-yl) -2-pyridyl ] methanone (62mg, 0.18mmol) was added and the reaction mixture was stirred at 15 ℃ for 16 hours. 10ml of water was added to the reaction solution, and the resulting solid was purified by thin layer chromatography (dichloromethane: methanol 10:1) to obtain 15mg of a white solid with a yield of 15.25%.

LC-MS:m/z:(M+H)+＝532.0,1H NMR(400MHz,CD3OD)δ8.68(dd,J＝26.6,5.0Hz,1H),8.63-8.61(m,1H),8.32–8.22(m,1H),8.19–8.07(m,2H),7.92–7.51(m,4H),7.36–7.26(m,2H),7.20(dd,J＝14.8,5.0Hz,1H),6.84-6.82(m,1H),4.29–3.65(m,8H),3.17–3.03(m,2H).

Example 27(9- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3, 9-diazaspiro [5.5] undecan-3-yl) (2- (phenylamino) pyrimidin-4-yl) methanone (L-27)

(9- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3, 9-diazaspiro [5.5] undecan-3-yl) (2- (phenylamino) pyrimidin-4-yl) methanone

The operation is the same as L-26

LC-MS:m/z:(M+H)+＝573.0,1H NMR(400MHz,DMSO-d6)δ12.96(s,1H),9.82(s,1H),8.59(d,J＝4.9Hz,1H),8.38(dd,J＝7.9,1.0Hz,1H),8.11(t,J＝7.8Hz,1H),7.75–7.72(m,3H),7.62-7.56(m,2H),7.31-7.21(m,4H),6.96(t,J＝7.3Hz,1H),6.88(d,J＝4.9Hz,1H),3.78–3.54(m,4H),3.35(s,4H),1.72–1.31(m,8H).

Example 286- (1H-benzo [ d ] imidazol-2-yl) -N- (1- (2- (phenylamino) pyrimidine-4-carbonyl) pyrrolidin-3-yl) pyridinamide (L-28)

6- (1H-benzo [ d ] imidazol-2-yl) -N- (1- (2- (phenylamino) pyrimidine-4-carbonyl) pyrrolidin-3-yl) pyridinoline amide

The operation is the same as L-26

LC-MS:m/z:(M+H)+＝505.0,1H NMR(400MHz,CD3OD)δ8.62(dd,J＝30.1,4.9Hz,1H),8.41(t,J＝7.9Hz,1H),8.12(q,J＝7.8Hz,1H),7.86(d,J＝7.7Hz,1H),7.75–7.54(m,4H),7.41–7.22(m,5H),6.97(dd,J＝12.5,7.3Hz,1H),4.72–4.52(m,1H),4.34-3.54(m,4H),2.42(dd,J＝12.9,5.7Hz,1H),2.20(d,J＝5.5Hz,1H).

Example 296- (1H-benzo [ d ] imidazol-2-yl) -N- (1- (2- (pyridin-2-ylamino) pyrimidine-4-carbonyl) pyrrolidin-3-yl) pyridinamide (L-29)

6- (1H-benzo [ d ] imidazol-2-yl) -N- (1- (2- (pyridin-2-ylamino) pyrimidine-4-carbonyl) pyrrolidin-3-yl) pyridinoline amide the procedure was as for L-26

LC-MS:m/z:(M+H)+＝506.0,1H NMR(400MHz,CD3OD)δ8.73(dd,J＝33.7,4.9Hz,1H),8.48–8.35(m,1H),8.32–8.00(m,3H),7.87(ddd,J＝7.8,2.1,1.0Hz,1H),7.75-7.73(m,2H),7.61(s,1H),7.46(dd,J＝43.3,4.9Hz,1H),7.36–7.23(m,2H),6.99(dd,J＝7.3,5.0Hz,1H),4.78–4.30(m,2H),4.09-4.01(m,1H),4.02–3.77(m,2H),2.49–2.12(m,2H).

Example 30N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) piperidin-4-yl) -6- (1H-benzo [ d ] imidazol-2-yl) pyridinylamide (L-30)

N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) piperidin-4-yl) -6- (1H-benzo [ d ] imidazol-2-yl) pyridinylamide

The operation is the same as L-5

LC-MS:m/z:(M+H)+＝543.22,¹H NMR(400MHz,CDCl₃)δ8.49(d,J＝7.2Hz,2H),8.07–7.86(m,2H),7.72(s,4H),7.58(dd,J＝7.7,1.0Hz,2H),7.38–7.31(m,4H),4.69(d,J＝13.1Hz,2H),4.55(d,J＝7.8Hz,2H),3.83(d,J＝13.8Hz,4H),3.15(dt,J＝22.4,11.4Hz,4H),2.06(dd,J＝56.4,13.3Hz,4H).

Example 31N- (4- (9-methyl-3, 9-diazaspiro [5.5] undecan-3-yl) phenyl) -1- (2- (phenylamino) pyrimidine-4-carbonyl) pyrrolidine-3-carboxamide (L-31)

N- (4- (9-methyl-3, 9-diazaspiro [5.5] undecan-3-yl) phenyl) -1- (2- (phenylamino) pyrimidine-4-carbonyl) pyrrolidine-3-carboxamide

The operation is the same as L-5

4- (9-methyl-3, 9-diazaspiro [5.5] undecan-3-yl) aniline from Bidi medicine

LC-MS:m/z:(M+H)+＝554.23,¹H NMR(400MHz,MeOD)δ8.50–8.34(m,1H),8.19–8.07(m,1H),7.83(t,J＝13.8Hz,1H),7.69(s,2H),7.49(d,J＝9.0Hz,1H),7.42–7.27(m,2H),6.97(dd,J＝28.4,9.0Hz,2H),4.21–3.87(m,4H),3.77(dt,J＝12.3,7.7Hz,1H),3.19–3.06(m,4H),2.83(s,4H),2.57(d,J＝5.6Hz,3H),2.44–2.26(m,2H).

Example 32N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) pyrrolidin-3-yl) -6- (1H-benzo [ d ] imidazol-2-yl) pyridinylamide (L-32)

N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) pyrrolidin-3-yl) -6- (1H-benzo [ d ] imidazol-2-yl) pyridinylamide

The operation is the same as L-6

LC-MS:m/z:(M+H)+＝529.5,¹H NMR(400MHz,CDCl₃)δ8.70(s,2H),8.57(d,J＝23.6Hz,1H),8.46(d,J＝7.9Hz,1H),8.34(d,J＝6.2Hz,2H),8.16(dd,J＝22.0,7.1Hz,2H),7.86(dd,J＝17.5,9.7Hz,2H),7.80–7.50(m,4H),7.36–7.16(m,4H),4.61(d,J＝5.9Hz,2H),4.41(s,1H),4.03(dd,J＝11.5,6.2Hz,1H),3.78(dd,J＝58.9,16.7Hz,4H),3.53(s,3H),2.18(dd,J＝12.9,6.3Hz,1H),1.93(dd,J＝39.9,18.0Hz,2H),1.74–1.50(m,2H),1.32(dt,J＝14.2,10.8Hz,4H).

Example 33 cyclohexane-1, 4-diylbis ((5- (4-nitrophenyl) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone) (L-33)

Cyclohexane-1, 4-diylbis ((5- (4-nitrophenyl) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone)

The operation is the same as L-8

2- (4-Nitrophenyl) octahydropyrrolo [3,4-c ] pyrrole from Bideu medicine

LC-MS:m/z:(M+H)+＝603.21,¹H NMR(400MHz,CDCl₃)δ8.15(d,J＝8.1Hz,4H),6.50(d,J＝8.6Hz,4H),4.00–3.65(m,8H),3.65–3.27(m,8H),3.15(d,J＝34.2Hz,4H),2.39(s,2H),2.07–1.72(m,4H),1.59(dd,J＝25.9,13.6Hz,4H),1.45–1.20(m,4H).

Example 341, 4-Phenylenebis ((5- (4-Nitrophenyl) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone) (L-34)

1, 4-Phenylenebis ((5- (4-nitrophenyl) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone)

The operation is the same as L-8

LC-MS:m/z:(M+H)+＝597.21,¹H NMR(400MHz,CDCl₃)δ8.15(t,J＝8.8Hz,4H),8.01–7.86(m,4H),6.61–6.43(m,4H),4.28–3.88(m,4H),3.84–3.51(m,8H),3.51–3.38(m,2H),3.38–3.21(m,2H),3.21–2.81(m,4H).

Example 351- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -N- (4- (9-methyl-3, 9-diazaspiro [5.5] undecan-3-yl) phenyl) pyrrolidine-3-carboxamide (L-35)

1- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -N- (4- (9-methyl-3, 9-diazaspiro [5.5] undecan-3-yl) phenyl) pyrrolidine-3-carboxamide

The operation is the same as L-6

LC-MS:m/z:(M+H)+＝578.31,¹H NMR(400MHz,MeOD)δ8.59(d,J＝4.7Hz,1H),7.66(dd,J＝15.3,8.1Hz,2H),7.44(dd,J＝15.0,8.9Hz,2H),7.36–7.25(m,2H),7.04(ddd,J＝30.4,15.7,6.8Hz,4H),4.16–3.76(m,5H),3.70(s,4H),3.27–3.05(m,4H),2.80(s,3H),2.54(s,2H),2.27(d,J＝5.2Hz,2H),1.69(s,5H).

Example 36 piperazine-1, 4-diylbis ((3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone) (L-36)

3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid (0.12g,0.5mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.28g,0.55mmol) and N, N-diisopropylethylamine (0.14g,1.1mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-bath, stirred for 0.5h, added with piperazine (0.04g,0.5mmol), stirred for 0.5h and then returned to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (12mg,22 μmol) with a yield of 4.5%. LC-MS M/z (M + H) + (527).

¹H NMR(400MHz,Chloroform-d)δ8.15(d,2H),8.08–8.00(m,4H),7.91(s,2H),7.65(d,J＝9.1Hz,2H),7.56–7.46(m,2H),7.39(d,J＝7.6Hz,2H),7.21(m,2H),6.82(m,2H),3.73(d,J＝89.9Hz,8H).

Example 376- (1H-benzo [ d ] imidazol-2-yl) -N- (1- (3-nitrobenzyl) pyrrolidin-3-yl) picolinamide (L-37)

In 6mL of N, N-dimethylformamide was dissolved m-nitrobenzoic acid (0.08g,0.48mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.30g,0.58mmol) and N, N-diisopropylethylamine (0.16g,1.3mmol) under ice-cooling, and after stirring for 0.5H, 6- (1H-benzo [ d ] imidazol-2-yl) -N- (pyrrolidin-3-yl) picolinamide (0.15g,0.48mmol) was added, and after stirring for 0.5H, the reaction was returned to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (15mg,32 μmol) with a yield of 6.8%. LC-MS M/z (M + H) + 457.

Example 38: n- (1- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) piperidin-4-yl) -3-nitrobenzamide (L-38)

(6-1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (4-aminopiperidin-1-yl) methanone (0.088g,0.27mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.15g,0.3mmol) and N, N-diisopropylethylamine (0.12g,1.0mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-cooling, and after stirring for 0.5H, m-nitrobenzoic acid (0.04g,0.27mmol) was added, and after stirring for 0.5H, the reaction was returned to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (11mg,32 μmol) with a yield of 8.6%. LC-MS M/z (M + H) + 471.

Example 39: synthesis of (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) pyrrolidin-2-yl) (5- (4-nitrophenyl) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone (L-39)

3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid (0.1g,0.4mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.24g,0.44mmol) and N, N-diisopropylethylamine (0.12g,1.0mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-bath, stirred for 0.5h, then 2- (4-nitrophenyl) -5-prolyl octahydropyrrolo [3,4-c ] pyrrole (0.13g,0.4mmol) was added, and after stirring for 0.5h, the reaction was returned to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (16mg, μmol) with a yield of 7.2%. LC-MS M/z (M + H) + (551).

1H NMR(400MHz,Chloroform-d)δ8.20–7.99(m,5H),7.90(d,J＝9.8Hz,1H),7.64(t,J＝8.8Hz,1H),7.53–7.45(m,2H),7.21(m,1H),6.82(m,1H),6.57–6.38(m,2H),3.81(m,7H),3.62–3.06(m,8H),2.25(m,2H).

Example 40: (9- (3- (1H-benzo [ d ] imidazol-2-yl) benzoyl) -3, 9-diazaspiro [5.5 stripes ] undec-3-yl) (3-nitrophenyl) methanone (L-40)

In 6mL of N, N-dimethylformamide was dissolved m-nitrobenzoic acid (0.041g,0.25mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.14g,0.27mmol) and N, N-diisopropylethylamine (0.12g,1.0mmol) under ice-bath, and after stirring for 0.5H, (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (3, 9-diazaspiro [5.5] undecan-3-yl) methadone (0.093g,0.25mmol) was added, and after stirring for 0.5H, the mixture was returned to room temperature and reacted overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (17mg, μmol) with a yield of 12.9%. LC-MS M/z (M + H) + (525).

¹H NMR(400MHz,Chloroform-d)δ10.74(s,1H),8.48(dd,J＝8.0,1.1Hz,1H),8.34–8.27(m,2H),7.97(t,J＝7.8Hz,1H),7.87(d,J＝6.9Hz,1H),7.77(m,1H),7.64(t,J＝7.9Hz,1H),7.57(m,2H),7.37–7.32(m,2H),3.94–3.74(m,4H),3.52(s,2H),3.42(s,2H),1.59(m,8H).

Example 41: synthesis of (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (3-nitrophenyl) methanone (L-41)

M-nitrobenzoic acid (0.041g,0.25mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.14g,0.27mmol) and N, N-diisopropylethylamine (0.12g,1.0mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-bath, stirred for 0.5H then (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone (0.083g,0.25mmol) was added and stirring was continued for 0.5H and allowed to return to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (17mg, μmol) with a yield of 12.9%. LC-MS M/z (M + H) + 483.

1H NMR(400MHz,Chloroform-d)δ11.58(s,1H),8.52(dd,J＝28.6,7.9Hz,1H),8.38(s,1H),8.30(t,J＝9.1Hz,1H),8.04–7.49(m,6H),7.32(m 2H),4.22(m,1H),4.09–4.00(m,1H),3.91–3.32(m,6H),3.05(m,2H).

Example 42: n- (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) -2- (anilino) pyrimidine-4-carboxamide (L-42)

Synthesis of mono-tert-butyl (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) carbamate

3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid (1g,4.2mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.96g,5mmol), 1-hydroxybenzotriazole (0.66g,5mmol) and N, N-diisopropylethylamine (1.19g,9.2mmol) were dissolved in 20mL of N, N-dimethylformamide under ice-bath, stirred for 0.5h, tert-butylpiperidin-4-ylcarbamate (0.92g,4.6mmol) was added, and after stirring for 0.5h, the reaction was returned to room temperature overnight. The reaction was poured into 80mL of water and extracted with ethyl acetate (80mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (PE: EA ═ 5:1) to give an off-white solid (1.3g,3mmol) with a yield of 73%. LC-MS M/z (M + H) + (421).

Synthesis of di- (4-aminopiperidin-1-yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone

Tert-butyl (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) carbamate (1.3g,3mmol) was dissolved in 20mL of dichloromethane under ice-cooling, a saturated 1, 4-dioxane hydrochloric acid solution (2mL,8mmol) was added, and after 0.5 hour of stirring, the reaction was returned to room temperature overnight. The reaction solution was concentrated under reduced pressure, and the obtained solid was directly used in the next reaction. The yield is more than 90%. LC-MS M/z (M + H) + (321).

Synthesis of tris, N- (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) -2- (anilino) pyrimidine-4-carboxamide

2- (anilino) pyrimidine-4-carboxylic acid (0.060g,0.27mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.14g,0.27mmol) and N, N-diisopropylethylamine (0.12g,1.0mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-bath, stirred for 0.5h and then (4-aminopiperidin-1-yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone (0.089g,0.27mmol) was added and stirred for 0.5h before returning to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (20mg,38 μmol), yield 14.3%. LC-MS M/z (M + H) + (518).

¹H NMR(400MHz,Chloroform-d)δ8.65(d,J＝4.8Hz,1H),8.22(d,J＝6.7Hz,1H),7.97(m,4H),7.65(m,3H),7.52–7.44(m,2H),7.43–7.30(m,5H),7.13(t,J＝7.3Hz,1H),6.92(t,J＝6.7Hz,1H),4.70(s,1H),4.27(s,1H),3.84(s,1H),3.20(m，2H),1.67(s,2H),1.31(m,2H).

Example 43N- (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) -2- (anilino) pyrimidine-4-carboxamide (L-43)

Synthesis of mono-tert-butyl 5- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) hexahydropyrrole-2 (1H) -carboxylate

3- (imidazo [1,2-a ] pyridin-2-yl) benzoic acid (1g,4.2mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.96g,5mmol), 1-hydroxybenzotriazole (0.66g,5mmol) and N, N-diisopropylethylamine (1.19g,9.2mmol) were dissolved in 20mL of N, N-dimethylformamide under ice-bath, stirred for 0.5h, tert-butylpiperidin-4-ylcarbamate (0.98g,4.6mmol) was added, and after stirring for 0.5h, the reaction was returned to room temperature overnight. The reaction was poured into 80mL of water and extracted with ethyl acetate (80mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (PE: EA ═ 5:1) to give an off-white solid (1.26g,2.9mmol) with a yield of 72%. LC-MS M/z (M + H) + (433).

Synthesis of di- (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone

Tert-butyl 5- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) hexahydropyrrole-2 (1H) -carboxylate (1.3g,3mmol) was dissolved in 20mL dichloromethane on ice, saturated 1, 4-dioxane hydrochloric acid solution (2mL,8mmol) was added, stirring was continued for 0.5H and then returned to room temperature overnight. The reaction solution was concentrated under reduced pressure, and the obtained solid was directly used in the next reaction. The yield is more than 90%. LC-MS M/z (M + H) + (333).

2- (anilino) pyrimidine-4-carboxylic acid (0.060g,0.27mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.14g,0.27mmol) and N, N-diisopropylethylamine (0.12g,1.0mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-bath, and after stirring for 0.5H, (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone (0.092g,0.27mmol) was added and stirring was continued for 0.5H and the reaction was returned to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (12mg,22 μmol) with a yield of 8.4%. LC-MS M/z (M + H) + (530).

¹H NMR(400MHz,Chloroform-d)δ8.57(d,J＝13.0Hz,1H),8.12(d,2H),8.03(d,J＝7.0Hz,1H),7.90(d,J＝8.8Hz,1H),7.66–7.36(m,7H),7.27–6.95(m,4H),6.81(t,J＝6.8Hz,1H),4.04–3.40(m,8H),3.01(d,2H).

Example 44N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) -6- (phenylamino) pyridinylamide (L-44)

6- (phenylamino) picolinic acid

Methyl 6-bromopyridine-2-carboxylate (2g,9.26mmol) was dissolved in 50ml dioxane, aniline (826mg,9.26mmol), tris (dibenzylideneacetone) dipalladium (424mg,0.46mmol),4, 5-bis-diphenylphosphino-9, 9-dimethylxanthene (536mg,0.92mmol) and cesium carbonate (7.54g,23.1mmol) were added, and the reaction was stirred at 95 ℃ under nitrogen for 15 hours. The reaction solution was cooled to room temperature, filtered and concentrated to give a yellow solid. The solid was dissolved in 15ml of tetrahydrofuran, 10ml of methanol and 15ml of water, sodium hydroxide (1.2g,29mmol) was added, and the reaction solution was stirred at 20 ℃ for 15 hours. The reaction solution was extracted three times with ethyl acetate (20ml x 3). The aqueous phase was acidified to pH 1 with 2N hydrochloric acid, extracted three times with ethyl acetate (20ml × 3), neutralized with saturated aqueous sodium bicarbonate to pH 1, and the solid was filtered and dried to give 500mg of a white solid with a yield of 25.2%. LC-MS: M/z (M + H) + -215.0.

Bis, N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) -6- (phenylamino) pyridinylamide

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝516.0,1H NMR(400MHz,CD3OD)δ8.47(dd,J＝7.4,1.5Hz,1H),8.26–8.13(m,2H),7.85–7.54(m,5H),7.45–7.23(m,4H),7.08(dd,J＝7.3,0.8Hz,1H),6.99-6.92(m,2H),4.29(d,J＝12.4Hz,1H),4.20(d,J＝11.7Hz,1H),3.97(dd,J＝11.7,4.2Hz,1H),3.75(dd,J＝12.4,4.4Hz,1H),2.74(t,J＝2.4Hz,1H),2.15–2.05(m,2H).

Example 45(9- (6- (1-H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3, 9-diazaspiro [5.5] undecan-3-yl) (6- (phenylamino) pyridin-2-yl) methanone (L-45)

(9- (6- (1-H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3, 9-diazaspiro [5.5] undecan-3-yl) (6- (phenylamino) pyridin-2-yl) methanone

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝572.0,1H NMR(400MHz,CD3OD)δ8.40(dd,J＝8.0,1.0Hz,1H),8.13(t,J＝7.9Hz,1H),7.86–7.53(m,6H),7.33(d,J＝5.1Hz,2H),7.29–7.20(m,2H),6.94(t,J＝7.4Hz,1H),6.91–6.82(m,2H),3.77(dd,J＝28.2,21.3Hz,4H),3.62–3.47(m,4H),1.70(d,J＝37.8Hz,8H).

Example 46(5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (6- (phenylamino) pyridin-2-yl) methanone (L-46)

(5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (6- (phenylamino) pyridin-2-yl) methanone

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝530.0,1H NMR(400MHz,CD3OD)δ8.43(ddd,J＝7.9,5.4,0.9Hz,1H),8.15(dd,J＝15.4,7.7Hz,1H),7.92–7.81(m,1H),7.79–7.27(m,7H),7.23–6.52(m,5H),4.25–3.62(m,8H),3.20–3.03(m,2H).

Example 47N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperidin-4-yl ] -6- (phenylamino) pyridinylamide (L-47)

N- (1- (1- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperidin-4-yl ] -6- (phenylamino) pyridinoline amide

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝518.0,1H NMR(400MHz,CD3OD)δ8.41(dd,J＝8.0,0.9Hz,1H),8.15(t,J＝7.9Hz,1H),7.84–7.57(m,4H),7.56–7.42(m,3H),7.41–7.16(m,4H),7.04–6.91(m,2H),4.54(d,J＝13.7Hz,1H),4.24–4.17(m,1H),3.82(d,J＝13.8Hz,1H),3.50-3.21(m,2H),2.23(d,J＝10.1Hz,1H),2.05(d,J＝10.1Hz,1H),1.75(dt,J＝19.7,10.2Hz,2H).

Example 48N- (6- (5- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) octahydropyrrolo [3,4-c ] pyrrole-2-carbonyl) pyridin-2-yl) acetamide (L-48)

The operation is the same as L-14

6-Acetylaminopyridinecarboxylic acid purchased from Bidao

LC-MS:m/z:(M+H)+＝496.2,¹H NMR(400MHz,MeOD)δ8.43(dd,J＝13.6,7.8Hz,1H),8.15(dd,J＝17.8,8.1Hz,1H),7.96–7.82(m,2H),7.67(dd,J＝41.3,19.9Hz,2H),7.53–7.41(m,1H),7.31(dt,J＝21.6,7.7Hz,3H),4.24–3.83(m,5H),3.80–3.57(m,3H),3.50(s,1H),3.13(d,J＝20.5Hz,2H),2.20(dd,J＝15.6,8.0Hz,2H),2.05(d,J＝15.3Hz,2H),1.63(s,1H).

Example 50N- (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) -2- (anilino) pyridine-4-carboxamide (L-50)

Synthesis of N- (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) -2- (anilino) pyridine-4-carboxamide

2- (anilino) pyridine-4-carboxylic acid (0.060g,0.27mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.14g,0.27mmol) and N, N-diisopropylethylamine (0.12g,1.0mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-bath, stirred for 0.5h and then (4-aminopiperidin-1-yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone (0.089g,0.27mmol) was added and stirred for 0.5h before returning to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (18mg,34 μmol) with a yield of 12.8%. LC-MS M/z (M + H) + (517).

¹H NMR(400MHz,Chloroform-d)δ8.14(m,1H),8.05–7.99(m,2H),7.96(d,J＝8.2Hz,1H),7.89(d,J＝0.7Hz,1H),7.65–7.60(m,3H),7.48(m,1H),7.40–7.34(m,5H),7.19(m,1H),7.14–7.08(m,1H),7.04(s,1H),7.00–6.94(m,1H),6.80(m,1H),4.62(s,1H),4.29–4.14(m,1H),3.82(s,1H),3.31–3.08(m,2H),2.02(m,2H),1.57(d,2H).

Example 51N- (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) -2- (anilino) pyridine-4-carboxamide (L-51)

2- (anilino) pyridine-4-carboxylic acid (0.060g,0.27mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (0.14g,0.27mmol) and N, N-diisopropylethylamine (0.12g,1.0mmol) were dissolved in 6mL of N, N-dimethylformamide under ice-cooling, and after stirring for 0.5H, (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone (0.092g,0.27mmol) was added and stirring was continued for 0.5H and the reaction was returned to room temperature overnight. The reaction was poured into 20mL of water and extracted with ethyl acetate (20mL × 3), washed with saturated brine, the organic phases were combined, dried over anhydrous sodium sulfate, and silica gel column chromatography was concentrated under reduced pressure (DCM: MeOH: 20:1) to give an off-white solid (16mg,30 μmol) with a yield of 11.2%. LC-MS M/z (M + H) + 529.

¹H NMR(400MHz,Chloroform-d)δ8.09(td,J＝20.1,18.0,6.8Hz,3H),7.89(d,J＝14.3Hz,1H),7.54(dt,J＝53.5,7.3Hz,4H),7.36(d,J＝4.4Hz,2H),7.32–7.05(m,5H),6.99–6.85(m,2H),6.83–6.75(m,1H),4.09–3.50(m,8H),3.06–2.85(m,2H).

Example 52N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) -6- (pyridin-2-ylamino) pyridinoline amide (L-52)

Mono, 6- (pyridin-2-ylamino) picolinic acid methyl ester

Methyl 6-bromopyridine-2-carboxylate (2g,9.26mmol) was dissolved in 50ml dioxane, 2-aminopyridine (871mg,9.26mmol), tris (dibenzylideneacetone) dipalladium (424mg,0.46mmol),4, 5-bis-diphenylphosphino-9, 9-dimethylxanthene (536mg,0.92mmol) and cesium carbonate (7.54g,23.1mmol) were added, and the reaction was stirred at 95 ℃ under nitrogen for 15 hours. The reaction solution was cooled to room temperature, filtered and concentrated to give a yellow solid. The solid was dissolved in 15ml of tetrahydrofuran, 10ml of methanol and 15ml of water, sodium hydroxide (0.94g,24mmol) was added, and the reaction solution was stirred at 20 ℃ for 15 hours. The reaction solution was extracted three times with ethyl acetate (20ml x 3). The aqueous phase was acidified to pH 1 with 2N hydrochloric acid, extracted three times with ethyl acetate (20ml x 3), neutralized with saturated aqueous sodium bicarbonate to pH 1, the aqueous phase was concentrated to give a solid, which was added to 50ml N-dimethylformamide, stirred at 20 ℃ for 2 hours, filtered and concentrated to give 460mg of a white solid with a yield of 23.0%. LC-MS M/z (M + H) + (216.0).

Bis, N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) -3-azabicyclo [3.1.0] hexyl-6-yl) -2- (pyridin-2-ylamino) isonicotinamide

The operation is the same as L-51

LC-MS:m/z:(M+H)+＝517.0,1H NMR(400MHz,CD3OD)δ8.45(dd,J＝7.5,1.4Hz,1H),8.27–8.11(m,3H),7.92–7.56(m,6H),7.36(dd,J＝6.1,3.1Hz,2H),7.24(d,J＝7.0Hz,1H),7.02–6.88(m,1H),4.25(dd,J＝21.8,12.0Hz,2H),3.99(dd,J＝11.6,4.4Hz,1H),3.76(dd,J＝12.4,4.5Hz,1H),2.74(t,J＝2.2Hz,1H),2.17–2.06(m,2H).

Example 53(5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (pyridin-2-ylamino) pyridin-4-yl) methanone (L-53)

(5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (pyridin-2-ylamino) pyridin-4-yl) methanone

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝531.0,1H NMR(400MHz,CD3OD)δ8.46–8.35(m,1H),8.27–8.08(m,2H),7.99–6.66(m,11H),4.31–3.53(m,8H),3.13(dt,J＝13.3,7.1Hz,2H).

Example 54(5- (6- (imidazo [1,2-a ] pyridin-2-yl ] pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (pyridin-2-ylamino) pyridin-4-yl) methanone (L-54)

(5- (6- (imidazo [1,2-a ] pyridin-2-yl ] pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (pyridin-2-ylamino) pyridin-4-yl) methanone

The operation is the same as L-14

LC-MS:m/z:(M+H)+＝531.0,1H NMR(400MHz,CD3OD)δ8.43(dd,J＝13.1,6.8Hz,1H),8.25(d,J＝32.8Hz,1H),8.09(d,J＝21.0Hz,2H),7.67–7.47(m,5H),7.40–7.28(m,2H),7.13(dt,J＝8.0,5.8Hz,2H),6.88(ddt,J＝35.3,14.7,7.3Hz,3H),4.11–3.41(m,8H),3.17–2.96(m,2H).

Example 55(5- (6- (1- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone (L-55)

The operation is the same as L-53

(5- (6- (1- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone

LC-MS:m/z:(M+H)+＝554.63,¹H NMR(400MHz,CDCl₃)δ12.67(s,1H),8.13–7.82(m,4H),7.54–7.33(m,4H),7.26(d,J＝7.6Hz,2H),4.54(d,J＝11.9Hz,3H),4.04(t,J＝15.9Hz,3H),1.85(s,1H),1.77(s,1H).

Example 566- (1 h-benzo [ d ] imidazol-2-yl) -n- (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) picolinamide (L-56)

6- (1H-benzo [ d ] imidazol-2-yl) picolinic acid 2(15mg,0.063mmol) was dissolved in N, N-dimethylformamide (5ml), and 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (65mg,0.13mmol) and N, N-diisopropylethylamine (0.02ml) were added to stir at room temperature for 15 minutes. Then, (4-aminopiperidin-1-yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone 1(20mg,0.063mmol) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 16 hours. The reaction solution was concentrated, and the obtained solid was separated twice with a thin layer chromatography plate (dichloromethane: methanol ═ 10:1) to obtain 8mg of a white solid in a yield of 24%.

LC-MS m/z:(M+H)+＝542.0，1H NMR(400MHz,Chloroform-d)δ8.68(dd,J＝7.9,1.1Hz,1H),8.40(d,J＝6.8Hz,1H),8.31(dd,J＝7.7,1.1Hz,1H),8.24(s,2H),8.01(t,J＝7.8Hz,1H),7.93(d,J＝7.8Hz,1H),7.82(d,J＝9.0Hz,1H),7.45(t,J＝7.7Hz,1H),7.39–7.31(m,2H),7.21(s,2H),7.03(t,J＝6.7Hz,1H),4.59(s,1H),4.18(s,1H),3.55(s,1H),2.93–2.55(m,3H).

Example 57(4- (1 h-benzo [ d ] imidazol-2-yl) piperidin-1-yl) (6- (1 h-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone (L-57)

Compounds 1 to 2 were prepared as described in example 42 for the deprotection and compounds 2 to L-57 were prepared as described for L-56

(4- (1 h-benzo [ d ] imidazol-2-yl) piperidin-1-yl) (6- (1 h-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone

LC-MS m/z:(M+H)+＝422.9，1H NMR(400MHz,Methanol-d4)δ8.43(dd,J＝8.0,1.0Hz,1H),8.16(t,J＝7.9Hz,1H),7.72(d,J＝1.1Hz,1H),7.71–7.67(m,2H),7.60–7.53(m,2H),7.34(dd,J＝6.1,3.1Hz,2H),7.27(dd,J＝6.1,3.1Hz,2H),3.96(d,J＝13.7Hz,1H),3.53–3.38(m,2H),3.21(dd,J＝12.8,2.8Hz,1H),2.33(d,J＝12.9Hz,1H),2.26–2.02(m,4H).

Example 58(2, 9-diazaspiro [5.5] undecane-2, 9-diyl) bis (6- (1 h-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone (L-58)

The operation is the same as L-43

2, 9-diazaspiro [5.5] undecane-2-carboxylic acid tert-butyl ester 2 purchased from Bidi medicine

(2, 9-diazaspiro [5.5] undecane-2, 9-diyl) bis (6- (1 h-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone

LC-MS m/z:(M+H)+＝597.1，1H NMR(400MHz,Methanol-d4)δ8.44–8.36(m,2H),8.21–8.14(m,1H),8.12–8.06(m,1H),7.78(q,J＝7.7Hz,1H),7.71–7.68(m,2H),7.64–7.60(m,2H),7.32(dt,J＝6.6,3.1Hz,4H),7.29–7.25(m,1H),4.23–4.11(m,1H),3.95(dd,J＝12.2,6.4Hz,1H),3.83(d,J＝21.5Hz,1H),3.74(dt,J＝13.3,6.7Hz,3H),3.68–3.58(m,2H),3.47(s,2H),1.92–1.83(m,1H),1.80(d,J＝11.9Hz,2H),1.66–1.57(m,2H),1.54(d,J＝4.5Hz,1H).

Example 59(2, 8-diaza [4.5] decane-2, 8-diyl) bis (6- (1 h-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone (L-59)

The operation is the same as L-43

(2, 8-diaza [4.5] decane-2, 8-diyl) bis (6- (1 h-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone

LC-MS m/z:(M+H)+＝583.1，1H NMR(400MHz,Methanol-d4)δ8.45–8.39(m,2H),8.35(dd,J＝7.9,1.1Hz,1H),8.17–8.09(m,2H),8.06(td,J＝8.0,2.6Hz,1H),7.82(ddd,J＝12.1,7.8,1.0Hz,2H),7.70(d,J＝1.1Hz,1H),7.58(dd,J＝7.7,1.0Hz,1H),7.35–7.31(m,3H),7.28(dd,J＝6.1,3.1Hz,1H),3.97(dd,J＝15.2,7.7Hz,2H),3.80(dd,J＝12.5,5.2Hz,3H),3.66–3.58(m,2H),2.08–1.97(m,3H),1.91(dd,J＝7.6,4.9Hz,1H),1.79(t,J＝6.1Hz,2H),1.69(d,J＝5.1Hz,1H).

EXAMPLE 60(7- (6- (1 h-benzo [ d ] imidazol-2-yl) nicotinyl) -2, 7-diazaspiro [4.4] nonan-2-yl) (6- (1 h-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone (L-60)

The operation is the same as L-43

(7- (6- (1 h-benzo [ d ] imidazol-2-yl) nicotinoyl) -2, 7-diazaspiro [4.4] nonan-2-yl) (6- (1 h-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone

LC-MS m/z:(M+H)+＝569.1，1H NMR(400MHz,Methanol-d4)δ8.44(dt,J＝8.0,1.1Hz,1H),8.37(ddd,J＝17.3,7.9,1.0Hz,1H),8.16(t,J＝7.8Hz,1H),8.06(dt,J＝10.2,7.9Hz,1H),7.88(ddd,J＝10.2,7.8,1.0Hz,1H),7.80–7.72(m,2H),7.66(s,2H),7.50(s,1H),7.34(d,J＝6.0Hz,1H),7.30(dq,J＝5.6,3.0,2.3Hz,3H),4.20–3.97(m,2H),3.89(dd,J＝13.2,6.2Hz,2H),3.85–3.76(m,2H),3.78–3.64(m,2H),2.30–2.15(m,2H),2.07(dt,J＝13.7,7.1Hz,2H).

Example 49BT-11

BT-11 was prepared as described in example 2 of CN 107108573A.

EXAMPLE 61(8- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoyl) -2, 8-diazaspiro [4.5] decan-2-yl) (6- (anilino) pyridin-2-yl) methanone (Compound L-61)

The procedure was carried out as in example 82 for the preparation of compound L-82.

LC-MS m/z:(M+H)+＝558.1。

1H NMR(400MHz,Methanol-d4)δ8.40(ddd,J＝11.2,8.0,1.0Hz,1H),8.13(dt,J＝13.7,7.8Hz,1H),7.76–7.62(m,3H),7.60(dd,J＝7.7,1.0Hz,1H),7.58–7.50(m,2H),7.39–7.28(m,2H),7.22(dtd,J＝16.2,7.3,1.9Hz,2H),7.08(ddd,J＝7.0,6.1,0.9Hz,1H),6.97–6.81(m,2H),4.10–3.91(m,1H),3.95–3.78(m,2H),3.73(dt,J＝13.3,8.0Hz,2H),3.64–3.54(m,2H),3.44(dt,J＝11.3,5.5Hz,1H),2.03–1.91(m,2H),1.75(td,J＝12.5,12.1,5.9Hz,2H),1.62(t,J＝5.9Hz,2H).

EXAMPLE 62(8- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoyl) -2, 8-diazaspiro [4.5] decan-2-yl) (2- (anilino) pyrimidin-4-yl) methanone (Compound L-62)

LC-MS m/z:(M+H)+＝559.1。

1H NMR(400MHz,Methanol-d4)δ8.61–8.56(m,1H),8.40(ddd,J＝9.1,7.9,1.0Hz,1H),8.14(dt,J＝10.8,7.9Hz,1H),7.74–7.67(m,2H),7.66(d,J＝1.1Hz,1H),7.65–7.61(m,2H),7.34(tt,J＝7.0,2.8Hz,2H),7.31–7.23(m,2H),7.05–7.02(m,1H),7.01–6.94(m,1H),3.85(dq,J＝10.6,6.2,5.1Hz,2H),3.76–3.70(m,2H),3.61–3.55(m,1H),3.48(d,J＝5.9Hz,1H),2.04–1.96(m,2H),1.76(s,2H),1.67–1.60(m,2H).

EXAMPLE 63(9- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoacyl) -2, 9-diazaspiro [5.5] undecan-2-yl) (6- (anilino) pyridin-2-yl) methanone (Compound L-63)

LC-MS m/z:(M+H)+＝587.7。

1H NMR(400MHz,Chloroform-d)δ8.68(s,1H),8.56(d,J＝8.0Hz,1H),7.98(t,J＝7.8Hz,1H),7.80–7.74(m,2H),7.48–7.40(m,1H),7.31(dd,J＝6.1,3.2Hz,2H),7.28–7.20(m,1H),7.13(dt,J＝7.4,4.5Hz,2H),4.04–3.81(m,2H),3.86–3.72(m,2H),3.74–3.48(m,4H),3.01(s,2H),2.36(s,3H).

EXAMPLE 64(9- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoyl) -2, 9-diazaspiro [5.5] undecan-2-yl) (2- (anilino) pyrimidin-4-yl) methanone (Compound L-64)

LC-MS m/z:(M+H)+＝572.9。

1H NMR(400MHz,Methanol-d4)δ8.58(d,J＝4.9Hz,1H),8.43–8.36(m,1.5H),8.26(d,J＝4.9Hz,0.5H),8.12(td,J＝7.9,1.4Hz,1.5H),7.72–7.68(m,2H),7.64(dd,J＝7.8,1.0Hz,2H),7.58–7.54(m,1.5H),7.33(tq,J＝7.5,2.6Hz,5H),7.19(dd,J＝8.6,7.3Hz,1H),7.04(tt,J＝7.4,1.2Hz,1H),6.91(d,J＝4.9Hz,1H),6.55(d,J＝4.9Hz,0.5H),4.10(dt,J＝13.8,4.9Hz,1H),3.88–3.74(m,3H),3.64(tdd,J＝13.8,9.6,3.8Hz,4H),3.47(d,J＝5.3Hz,2H),3.42(d,J＝1.7Hz,1H),1.80(d,J＝16.3Hz,2H),1.64(dd,J＝9.7,4.8Hz,3H).

EXAMPLE 65(7- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoyl) -2, 7-diazaspiro [4.4] nonan-2-yl) (6- (anilino) pyridin-2-yl) methanone (Compound L-65)

LC-MS m/z:(M+H)+＝554.1。

1H NMR(400MHz,Methanol-d4)δ8.49–8.42(m,1H),8.38(d,J＝7.5Hz,1H),8.32(s,1H),8.21–8.18(m,1H),8.17–8.05(m,2H),7.86(ddd,J＝7.8,5.4,1.1Hz,1H),7.71(dt,J＝7.1,3.5Hz,1H),7.61–7.55(m,2H),7.52–7.48(m,1H),7.40–7.27(m,2H),7.22(dt,J＝6.2,3.6Hz,1H),6.95(dtd,J＝11.7,6.8,1.2Hz,1H),4.18–3.59(m,8H),3.24–3.04(m,2H).

EXAMPLE 66(7- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoyl) -2, 7-diazaspiro [4.4] nonan-2-yl) (4- (anilino) pyrimidin-2-yl) methanone (Compound L-66)

LC-MS m/z:(M+H)+＝544.9。

1H NMR(400MHz,Chloroform-d)δ8.62–8.57(m,1H),8.57–8.53(m,1H),8.01–7.91(m,1H),7.82–7.77(m,1H),7.75-7.68(s,1H),7.71(s,1H),7.68–7.61(m,2H),7.47(ddd,J＝8.5,3.6,1.2Hz,1H),7.36–7.30(m,2H),7.27–7.22(m,1H),7.12–7.08(m,1H),7.05–6.96(m,1H),3.96–3.68(m,6H),3.69–3.53(m,2H),2.02–1.88(m,4H).

Example 67N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoyl) -3-azabicyclo [3.1.0] hex-6-yl) -6-methyl-1H-indole-2-carboxamide (Compound L-67)

LC-MS m/z:(M+H)+＝476.9。

1H NMR(400MHz,DMSO-d6)δ13.20(s,1H),11.43(d,J＝2.1Hz,1H),9.33(d,J＝3.1Hz,1H),8.46(dd,J＝7.7,1.2Hz,1H),8.18(t,J＝7.7Hz,1H),8.11(dd,J＝7.7,1.2Hz,1H),7.77(dd,J＝7.9,1.1Hz,1H),7.73–7.64(m,1H),7.55(d,J＝8.2Hz,1H),7.35(ddd,J＝8.2,7.2,1.2Hz,1H),7.28(ddd,J＝8.3,7.2,1.3Hz,1H),7.25(dd,J＝1.6,0.8Hz,1H),6.96(dd,J＝2.3,0.9Hz,1H),6.90(dd,J＝8.2,1.5Hz,1H),4.17(s,3H),3.74(s,1H),2.62(q,J＝2.7Hz,1H),2.41(s,3H),2.21(s,1H),2.09(s,1H).

Example 68N- (3- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoyl) -3-azabicyclo [3.1.0] hex-6-yl) quinoline-2-carboxamide (Compound L-68)

LC-MS m/z:(M+H)+＝476.1。

1H NMR(400MHz,DMSO)δ13.18(s,1H),9.31(s,1H),8.50(dd,J＝28.7,8.2Hz,1H),8.32–8.01(m,2H),7.98–7.81(m,1H),7.82–7.66(m,2H),7.40–7.22(m,2H),4.16(d,J＝12.5Hz,1H),3.77(d,J＝12.2Hz,1H),3.62(s,1H),3.18(d,J＝5.2Hz,1H),2.10(s,1H).

EXAMPLE 69(5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (quinolin-2-yl) methanone (Compound L-69)

A mixture of (6- (1H-benzo [ d ]]Imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c]Pyrrol-2 (1H) -yl) methanone (33mg, 0.1mmol) and quinoline-2-carboxylic acid (17mg, 0.1mmol) were suspended in N, N-dimethylformamide (3mL), and N, N-diisopropylethylamine (26mg,0.2mmol) and 1-propylphosphoric anhydride (41mg,0.13mmol) were added. The reaction was stirred at 25 ℃ for 16 h. The reaction was concentrated to give a crude product, which was purified by thin layer chromatography (dichloromethane: methanol 15: 1) to give a pale yellow solid (15mg, 31%). LC-MS M/z (M + H)⁺＝488.9；¹H NMR(400MHz,DMSO-d6)δ12.93(d,J＝6.3Hz,1H),8.61–8.34(m,2H),8.14–8.03(m,3H),7.96–7.53(m,6H),7.38–7.17(m,2H),4.21–3.56(m,8H),3.06(s,2H).

Example 70(5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoyl) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (6-methyl-1H-indol-2-yl) methanone (Compound L-70)

LC-MS:m/z:(M+H)+＝491.1；¹H NMR(400MHz,DMSO-d₆)δ12.91(s,1H),11.42(s,1H),8.42(d,J＝7.9Hz,1H),8.13(t,J＝7.8Hz,1H),7.77(dd,J＝27.7,7.7Hz,2H),7.59(d,J＝7.4Hz,1H),7.54–7.38(m,1H),7.35–7.15(m,3H),6.92(t,J＝20.7Hz,2H),4.20–3.56(m,8H),3.09(d,J＝40.8Hz,2H),2.40(s,3H).

Example 71(5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoyl) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2-methyl-1H-indol-3-yl) methanone (Compound L-71)

LC-MS m/z:(M+H)+＝491.1。

1H NMR(400MHz,CDCl3)δ8.68(s,1H),8.56(d,J＝7.7Hz,1H),7.98(t,J＝7.8Hz,1H),7.77(d,J＝7.4Hz,3H),7.51–7.40(m,1H),7.38–7.27(m,4H),7.18–7.06(m,2H),3.96–3.54(m,6H),3.01(s,2H),2.37(s,3H),2.03(d,J＝5.9Hz,1H),1.66(s,1H).

EXAMPLE 72(9- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) -3, 9-diazaspiro [5.5] undecan-3-yl) (6- (anilino) pyridin-2-yl) methanone (Compound L-72)

LC-MS:m/z:(M+H)⁺＝433.2；1H NMR(400MHz,Methanol-d4)δ8.46(d,J＝6.8Hz,1H),8.31(s,1H),8.06(d,J＝7.8Hz,1H),8.00(s,1H),7.66–7.54(m,5H),7.45–7.33(m,2H),7.27(t,J＝7.9Hz,2H),6.96(td,J＝6.8,4.4Hz,2H),6.88(t,J＝7.2Hz,2H),3.79(d,J＝16.7Hz,4H),3.54(s,5H),1.73(s,3H),1.63(s,5H).

Example 73(3, 9-diazospiro [5.5] undecane-3, 9-diyl) bis ((3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone) (Compound L-73)

LC-MS:m/z:(M+H)⁺/2＝298.2；1H NMR(400MHz,Methanol-d4)δ8.45(d,J＝6.8Hz,2H),8.30(s,2H),8.05(d,J＝7.9Hz,2H),8.00(d,J＝1.8Hz,2H),7.66–7.53(m,4H),7.46–7.31(m,4H),6.95(t,J＝6.8Hz,2H),3.83(s,4H),3.52(s,4H),1.69(d,J＝46.5Hz,9H).

Example 74 (Tetrahydropyrrolo [3,4-c ] pyrrole-2, 5(1H, 3H) -diyl) bis ((3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone) (Compound L-74)

LC-MS:m/z:(M+H)⁺＝553.2；1H NMR(400MHz,Methanol-d4)δ8.43(dd,J＝24.7,6.9Hz,2H),8.36–8.22(m,2H),8.10(dd,J＝29.2,20.1Hz,4H),7.57(dd,J＝25.5,8.6Hz,6H),7.34(dt,J＝17.0,8.2Hz,2H),6.94(dt,J＝13.9,6.8Hz,2H),4.05–3.50(m,9H),3.24–3.01(m,2H).

Example 75(4- (2-hydroxyethyl) piperazin-1-yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone (Compound L-75)

LC-MS:m/z:(M+H)⁺＝351.2；1H NMR(400MHz,Methanol-d4)δ8.46(dt,J＝6.9,1.2Hz,1H),8.30(s,1H),8.06(dt,J＝7.9,1.4Hz,1H),8.00(d,J＝1.7Hz,1H),7.64–7.54(m,2H),7.45–7.33(m,2H),6.96(td,J＝6.8,1.2Hz,1H),3.85(s,2H),3.72(t,J＝5.8Hz,2H),3.56(s,2H),2.75–2.51(m,6H).

Example 76(6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (4- (2-hydroxyethyl) piperazin-1-yl) methanone (Compound L-76)

LC-MS:m/z:(M+H)⁺＝352.2；1H NMR(400MHz,Methanol-d4)δ8.40(dd,J＝8.0,0.9Hz,1H),8.14(t,J＝7.9Hz,1H),7.75(s,1H),7.68(dd,J＝7.8,1.0Hz,1H),7.63(d,J＝7.2Hz,1H),7.33(d,J＝6.0Hz,2H),3.89(t,J＝5.2Hz,2H),3.72(t,J＝5.8Hz,2H),3.62(t,J＝5.1Hz,2H),2.71(t,J＝5.2Hz,2H),2.60(dt,J＝12.0,5.5Hz,4H).

Example 776- (1H-benzo [ d ] imidazol-2-yl) -N- (3- (3- (benzo [ d ] thiazol-2-yl) benzoyl) -3-azabicyclo [3.1.0] hex-6-yl) picolinamide (Compound L-77)

3- (benzo [ d ] thiazol-2-yl) benzoic acid methyl ester

2-bromo-1, 3-benzothiazole (1.07g, 5.0mmol), (3-methoxycarbonylphenyl) boronic acid (0.9g, 5.0mmol), K₂CO₃(1.38g, 10.0mmol) and [1,1' -bis (diphenylphosphino) ferrocene]A solution of palladium dichloride (0.1g,0.5 mmol) in dioxane (50mL) and water (10mL) was stirred at 80 ℃ for 4 hours. The reaction was concentrated to dryness and purified by flash chromatography (silica) (petroleum ether: ethyl acetate ═ 3:1) to give methyl 3- (1, 3-benzothiazol-2-yl) benzoate (1.0g, 74.3%) as a white solid.

Bis, 3- (benzo [ d ] thiazol-2-yl) benzoic acid

Methyl 3- (1, 3-benzothiazol-2-yl) benzoate (54mg, 0.2mmol) was added to MeOH (5mL) and water (1mL), LiOH (24mg, 1.0mmol) was added, and the reaction was stirred at 80 ℃ for 1 h. The reaction was concentrated to dryness to give the crude product, which was used directly in the next reaction.

Tris, 6- (1H-benzo [ d ] imidazol-2-yl) -N- (3- (3- (benzo [ d ] thiazol-2-yl) benzoyl) -3-azabicyclo [3.1.0] hex-6-yl) picolinamide

LC-MS:m/z:(M+H)⁺＝557.2；1H NMR(400MHz,DMSO-d6)δ13.18(s,1H),9.29(d,J＝3.1Hz,1H),8.46(dd,J＝7.8,1.2Hz,1H),8.24–8.15(m,4H),8.13–8.08(m,2H),7.83–7.65(m,4H),7.59(td,J＝8.2,7.7,1.3Hz,1H),7.55–7.47(m,1H),7.31(s,2H),4.17(d,J＝12.1Hz,1H),4.00–3.85(m,1H),3.71–3.61(m,2H),2.07(s,2H).

Example 78(3, 9-diazaspiro [5.5] undecane-3, 9-diyl) bis ((2- (phenylamino) pyrimidin-4-yl) methanone) (Compound L-78)

Mono, 9- (2- (2- (phenylamino) pyrimidine-4-carbonyl) -3, 9-diazaspiro [5.5] undecane-3-carboxylic acid tert-butyl ester

Tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate (100mg, 0.39mmol) (compound represented by formula 2) and 2-anilinopyrimidine-4-carboxylic acid (85mg, 0.39mmol) (compound represented by formula 1) were suspended in 3ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (101mg,0.78mmol) and 2- (7-azobenzotriazol) -N, N, N ', N' -tetramethylurea hexafluorophosphate (179mg,0.47mmol) were added. The reaction was stirred at 30 ℃ for 16 h. To the reaction solution was added 10ml of ice water, stirred for five minutes, filtered, and the solid was dried to give 175mg of a crude product as a brown solid with a yield of 98.58%. LC-MS M/z (M + H) + (452.0).

Di- (2- (phenylamino) pyrimidin-4-yl) (3, 9-diazaspiro [5.5] undecan-3-yl) methanones

Tert-butyl 9- (2- (2- (phenylamino) pyrimidine-4-carbonyl) -3, 9-diazaspiro [5.5] undecane-3-carboxylate (175mg, 0.39mmol), a compound represented by formula 3, was dissolved in 3mL of methanol, dioxane hydrochloride solution (3mL,4M,12mmol) was added thereto, the reaction mixture was stirred at 15 ℃ for 2H, the reaction mixture was concentrated, and dried to obtain a crude product of 136mg as a brown solid with a yield of 99.87%. LC-MS: M/z (M + H) + 352.0.

Tris, (3, 9-diazaspiro [5.5] undecane-3, 9-diyl) bis ((2- (phenylamino) pyrimidin-4-yl) methanone)

LC-MS:m/z:(M+H)+＝549.0,1H NMR(400MHz,CD₃OD)δ8.55(d,J＝4.9Hz,2H),7.67(dd,J＝8.6,1.0Hz,4H),7.36–7.26(m,4H),7.03(t,J＝7.4Hz,2H),6.87(d,J＝4.9Hz,2H),3.77(dd,J＝11.7,5.6Hz,4H),3.50(dd,J＝11.1,5.3Hz,4H),1.77–1.57(m,8H).

Example 792- (phenylamino) -N- (1- (2- (2- (phenylamino) pyrimidine-4-carbonyl) piperidin-4-yl) pyrimidine-4-carboxamide (Compound L-79)

Mono (tert-butyl (1- (2- (phenylamino) pyrimidine-4-carbonyl) piperidin-4-yl) carbamate

Tert-butylpiperidin-4-ylcarbamate (100mg, 0.50mmol) (a compound represented by the formula 2) and 2-anilinopyrimidine-4-carboxylic acid (107mg, 0.50mmol) (a compound represented by the formula 1) were suspended in 3ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (129mg,1.0mmol) and 2- (7-azobenzotriazol) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (228mg,0.60mmol) were added. The reaction was stirred at 30 ℃ for 16 h. To the reaction solution was added 10ml of ice water, stirred for five minutes, filtered, and the solid was dried to give 185mg of a crude product as a brown solid with a yield of 93.21%. LC-MS M/z (M + H) + (498.0).

Di- (4-aminopiperidin-1-yl) (2- (phenylamino) pyrimidin-4-yl) methanones

Tert-butyl (1- (2- (phenylamino) pyrimidine-4-carbonyl) piperidin-4-yl) carbamate (185mg, 0.47mmol) (the compound represented by formula 3) was dissolved in 3mL of methanol, and dioxane hydrochloride solution (3mL,4M,12mmol) was added. The reaction was stirred at 15 ℃ for 2 h. The reaction solution was concentrated and dried to obtain a crude product in the form of 138mg of a brown solid with a yield of 99.70%. LC-MS M/z (M + H) + (298.0).

Tris, 2- (phenylamino) -N- (1- (2- (2- (phenylamino) pyrimidine-4-carbonyl) piperidin-4-yl) pyrimidine-4-carboxamide

LC-MS:m/z:(M+H)+＝495.0,1H NMR(400MHz,CD₃OD)δ8.66(d,J＝4.9Hz,1H),8.57(d,J＝4.9Hz,1H),7.74–7.60(m,4H),7.41–7.24(m,5H),7.04(dt,J＝20.0,7.4Hz,2H),6.91(d,J＝4.9Hz,1H),4.56(d,J＝14.7Hz,1H),4.26–4.15(m,1H),3.98–3.89(m,1H),3.41–3.34(m,1H),3.23–3.13(m,1H),2.19–2.08(m,1H),2.02(dd,J＝9.1,4.0Hz,1H),1.79–1.63(m,2H).

Example 80(9- (6- (phenylamino) pyridinyloxy) -3, 9-diazaspiro [5.5] undecan-3-yl) (2- (phenylamino) pyrimidin-4-yl) methanone (compound L-80)

LC-MS:m/z:(M+H)+＝548.0,1H NMR(400MHz,CD3OD)δ(d,J＝4.9Hz,1H),7.64(ddd,J＝11.8,9.4,6.1Hz,5H),7.29(dt,J＝12.4,7.9Hz,4H),6.99(dt,J＝26.9,7.4Hz,2H),6.88(dd,J＝9.5,5.7Hz,3H),3.77(dt,J＝11.6,5.7Hz,4H),3.61–3.44(m,4H),1.83–1.50(m,8H).

Example 816- (phenylamino) -N- (1- (2- (phenylamino) pyrimidine-4-carbonyl) piperidin-4-yl) pyridinoline amide (Compound L-81)

LC-MS:m/z:(M+H)+＝494.0,1H NMR(400MHz,CD3OD)δ8.57(d,J＝4.9Hz,1H),7.69(dd,J＝16.7,8.2Hz,3H),7.49(dd,J＝18.9,7.5Hz,3H),7.31(dt,J＝24.3,7.9Hz,4H),7.07–6.96(m,3H),6.91(d,J＝4.9Hz,1H),4.46(d,J＝13.3Hz,1H),4.19(ddd,J＝14.0,9.9,4.0Hz,1H),3.86(d,J＝13.4Hz,1H),3.43–3.36(m,1H),3.27(dd,J＝13.6,3.0Hz,1H),2.23–2.11(m,1H),2.09–1.97(m,1H),1.76–1.60(m,2H).

Example 82(5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (((4-fluorophenyl) amino) pyrimidin-4-yl) methanone (Compound L-82)

Mono, 2- ((4-fluorophenyl) amino) pyrimidine-4-carboxylic acid

2-Chloropyrimidine-4-carboxylic acid (500mg,3.15mmol) was dissolved in 15ml of dioxane, p-fluoroaniline (881mg,9.46mmol) was added, and the reaction solution was stirred at 70 ℃ for 18 hours. The reaction was cooled to room temperature, 20ml of water and 10ml of 1N sodium hydroxide were added, and the reaction was extracted twice with ethyl acetate (20 ml. times.2). The aqueous phase was acidified with 1N hydrochloric acid to pH 3 and the solid was filtered and dried to give 500mg of a white solid in 67.98% yield. LC-MS M/z (M + H) + (234.0).

Bis, (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (((4-fluorophenyl) amino) pyrimidin-4-yl) methanone

2,3,3a, 4,6,6 a-hexahydro-1H-pyrrolo [3,4-c ] pyrrol-5-yl- [6- (1H-benzimidazol-2-yl) -2-pyridinyl (40mg, 0.12mmol) (the compound represented by formula 4) and 2- ((4-fluorophenyl) amino) pyrimidine-4-carboxylic acid (28mg, 0.12mmol) (the compound represented by formula 3) were suspended in 5ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (62mg,0.48mmol) and 1-propylphosphoric anhydride (115mg,0.18mmol) were added. The reaction was stirred at 15 ℃ for 16 h. The reaction was concentrated to give a crude product, which was purified by thin layer chromatography (dichloromethane: methanol 10:1) to give the desired product as a white solid in 20mg yield of 30.39%.

LC-MS:m/z:(M+H)+＝549.0,1H NMR(400MHz,CDCl3)δ8.48(ddd,J＝39.8,21.6,6.4Hz,2H),8.03–7.54(m,6H),7.49–7.30(m,2H),7.26–6.93(m,3H),4.31–3.67(m,8H),3.12–2.91(m,2H).

Example 83 (Tetrahydropyrrolo [3,4-c ] pyrrole-2, 5(1H, 3H) -diyl) bis ((2- (phenylamino) pyrimidin-4-yl) methanone) (Compound L-83)

5- (2- (phenylamino) pyrimidine-4-carbonyl) hexahydropyrrolo [3,4-c ] pyrrole-2 (1H) -carboxylic acid tert-butyl ester

Tert-

butyl

2,3,3a, 4,6,6 a-hexahydro-1H-pyrrolo [3,4-c ] pyrrole-5-carboxylate (100mg, 0.47mmol) (compound of formula 2) and 2-anilinopyrimidine-4-carboxylic acid (101mg, 0.47mmol) (compound of formula 1) were suspended in 3ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (122mg,0.94mmol) and 1-propylphosphoric anhydride (449mg,0.71mmol) were added. The reaction was stirred at 15 ℃ for 16 h. To the reaction solution was added 10ml of ice water, stirred for five minutes, filtered, and the solid was dried to give a crude product of 180mg of a brown solid with a yield of 93.31%. LC-MS: M/z (M + H) + ═ 410.0.

Di- (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (phenylamino) pyrimidin-4-yl) methanone

Tert-butyl 5- (2- (phenylamino) pyrimidine-4-carbonyl) hexahydropyrrolo [3,4-c ] pyrrole-2 (1H) -carboxylate (180mg, 0.44mmol), a compound of formula 3, was dissolved in 3mL methanol and dioxane hydrochloride solution (3mL,4M,12mmol) was added. The reaction was stirred at 15 ℃ for 2 h. The reaction was concentrated, the solid washed with ethyl acetate (10mL), and dried to give the crude product as 120mg of a brown solid in 88.24% yield. LC-MS M/z (M + H) + (310.0).

Tris, (tetrahydropyrrolo [3,4-c ] pyrrole-2, 5(1H, 3H) -diyl) bis ((2- (phenylamino) pyrimidin-4-yl) methanone)

LC-MS:m/z:(M+H)+＝507.0,1H NMR(400MHz,CDCl3)δ8.56–8.42(m,2H),7.53(dd,J＝19.5,8.3Hz,4H),7.18(dt,J＝30.7,7.3Hz,4H),7.03–6.79(m,4H),3.93–3.46(m,8H),2.94(d,J＝7.4Hz,2H).

Example 84(2- (phenylamino) -N- (3- (2- (2- (phenylamino) pyrimidine-4-carbonyl) -3-azabicyclo [3.1.0] hex-6-yl) pyrimidine-4-carboxamide (Compound L-84)

Mono, ((1R, 5S, 6S) -6- (2- (phenylamino) pyrimidine-4-carboxamido) -3-azabicyclo [3.1.0] hexane-3-carboxylic acid tert-butyl ester

Tert-butyl (1R, 5S, 6S) -6-amino-3-azabicyclo [3.1.0] hexane-3-carboxylate (100mg, 0.50mmol) (compound of formula 2) and 2-anilinopyrimidine-4-carboxylic acid (108mg, 0.51mmol) (compound of formula 1) were suspended in 3ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (130mg,1.0mmol) and 1-propylphosphoric anhydride (480mg,0.75mmol) were added. The reaction was stirred at 15 ℃ for 16 h. 10ml of ice water was added to the reaction solution, stirred for five minutes, filtered, and the solid was dried to obtain a crude product of 180mg of a brown solid with a yield of 90.28%. LC-MS M/z (M + H) + (396.0).

Di, N- ((1R, 5S, 6S) -3-azabicyclo [3.1.0] hex-6-yl) -2- (phenylamino) pyrimidine-4-carboxamide

Tert-butyl ((1R, 5S, 6S) -6- (2- (phenylamino) pyrimidine-4-carboxamide) -3-azabicyclo [3.1.0] hexane-3-carboxylate (180mg, 0.45mmol), a compound of formula 3, was dissolved in 3mL of methanol, dioxane hydrochloride solution (3mL,4M,12mmol) was added, the reaction was stirred at 15 ℃ for 2H, the reaction was concentrated, the solid was washed with ethyl acetate (10mL), and dried to give a crude product as 120mg of a brown solid in 89.27% yield LC-MS: M/z (M + H) + 296.0.

Tris, (2- (phenylamino) -N- (3- (2- (2- (phenylamino) pyrimidine-4-carbonyl) -3-azabicyclo [3.1.0] hex-6-yl) pyrimidine-4-carboxamide

LC-MS:m/z:(M+H)+＝493.0,1H NMR(400MHz,DMSO-d6)δ9.80(d,J＝28.2Hz,1H),8.70-8.62(m,2H),7.76-7.74(m,4H),7.32-7.25(m,4H),7.01-6.97(3,3H),4.04–3.96(m,1H),3.87(d,J＝11.3Hz,1H),3.79(dd,J＝11.4,3.9Hz,1H),3.59(dd,J＝12.3,4.0Hz,1H),2.66(d,J＝2.2Hz,1H),1.98(d,J＝5.9Hz,2H).

Example 85(2- (phenylamino) pyrimidin-4-yl) (piperazin-1-yl) methanone piperazine-1, 4-diylbis ((2- (phenylamino) pyrimidin-4-yl) methanone) (compound L-85)

Mono, 4- (2- (phenylamino) pyrimidine-4-carbonyl) piperazine-1-carboxylic acid tert-butyl ester

1-tert-Butoxycarbonyl-piperazine (100mg, 0.54mmol) (compound of formula 2) and 2-anilinopyrimidine-4-carboxylic acid (115m, 0.54mmol) (compound of formula 1) were suspended in 3ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (139mg,1.07mmol) and 2- (7-azobenzotriazol) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (245mg,0.64mmol) were added. The reaction was stirred at 30 ℃ for 16 h. To the reaction solution was added 10ml of ice water, stirred for five minutes, filtered, and the solid was dried to give 190mg of a crude product as a brown solid in a yield of 92%. LC-MS M/z (M + H) + (384.0).

Bis, ((2- (phenylamino) pyrimidin-4-yl) (piperazin-1-yl) methanone

Tert-butyl 4- (2- (phenylamino) pyrimidine-4-carbonyl) piperazine-1-carboxylate (190mg, 0.49mmol) (the compound represented by formula 3) was dissolved in 3mL of methanol, and dioxane hydrochloride solution (3mL,4M,12mmol) was added. The reaction was stirred at 15 ℃ for 2 h. The reaction solution was concentrated and dried to obtain a crude product of 139mg as a brown solid in a yield of 99.01%. LC-MS M/z (M + H) + (284.0).

Tris, (2- (phenylamino) pyrimidin-4-yl) (piperazin-1-yl) methanone piperazine-1, 4-diylbis ((2- (phenylamino) pyrimidin-4-yl) methanone)

LC-MS:m/z:(M+H)+＝481.0,1H NMR(400MHz,DMSO-d6)δ9.84(d,J＝21.0Hz,2H),8.74–8.51(m,2H),7.71(dd,J＝20.8,7.4Hz,4H),7.50–7.21(m,4H),7.13–6.78(m,4H),3.62(dd,J＝76.7,37.7Hz,8H).

Example 86 piperazine-1, 4-diylbis ((6- (phenylamino) pyridin-2-yl) methanone) (Compound L-86)

4- (6- (phenylamino) pyridinyloxy) piperazine-1-carboxylic acid tert-butyl ester

1-tert-Butoxycarbonyl-piperazine (100mg, 0.54mmol) (compound of formula 2) and 6- (phenylamino) picolinic acid (115mg, 0.54mmol) (compound of formula 1) were suspended in 3ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (139mg,1.07mmol) and 2- (7-azobenzotriazol) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (245mg,0.64mmol) were added. The reaction was stirred at 30 ℃ for 16 h. To the reaction solution was added 10ml of ice water, stirred for five minutes, filtered, and the solid was dried to give 190mg of a crude product as a brown solid in a yield of 92%. LC-MS, M/z (M + H) + -383.0.

Di- (6- (phenylamino) pyridin-2-yl) (piperazin-1-yl) methanone

Tert-butyl 4- (6- (phenylamino) pyridinyloxy) piperazine-1-carboxylate (190mg, 0.49mmol) (the compound represented by the formula 3) was dissolved in 3mL of methanol, and dioxane hydrochloride solution (3mL,4M,12mmol) was added. The reaction was stirred at 15 ℃ for 2 h. The reaction solution was concentrated and dried to obtain a crude product of 139mg as a brown solid in a yield of 99.12%. LC-MS, M/z (M + H) + (283.0).

Tris, piperazine-1, 4-diylbis ((6- (phenylamino) pyridin-2-yl) methanone)

LC-MS:m/z:(M+H)+＝479.0,1H NMR(400MHz,DMSO-d6)δ9.21(d,J＝26.7Hz,2H),7.81–7.50(m,6H),7.26(dt,J＝44.9,7.5Hz,4H),7.03–6.70(m,6H),3.83–3.44(m,8H).

Example 87(2, 6-diazospiro [3.3] heptane-2, 6-diyl) bis ((6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) methanone) (Compound L-87)

LC-MS m/z:(M+H)+＝542.2。

1H NMR(400MHz,DMSO-d6)δ8.45(dd,J＝7.9,1.1Hz,2H),8.16(t,J＝7.8Hz,2H),8.00(dd,J＝7.8,1.1Hz,2H),7.70(s,4H),7.28(d,J＝6.5Hz,4H),5.10(d,J＝10.7Hz,2H),5.01(d,J＝10.8Hz,2H),4.46–4.39(m,4H).

Example 883- (imidazo [1,2-a ] pyridin-2-yl) -N- (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) benzamide (Compound L-88)

LC-MS m/z:(M+H)+＝542.2。

1H NMR(400MHz,Chloroform-d)δ8.53(s,1H),8.20(t,J＝7.8Hz,2H),8.03(dd,J＝12.9,7.2Hz,4H),7.97(s,1H),7.90(d,J＝7.7Hz,1H),7.74(d,J＝9.0Hz,1H),7.68(d,J＝9.1Hz,1H),7.51(q,J＝8.0Hz,2H),7.39(d,J＝7.6Hz,1H),7.35–7.30(m,1H),7.22(dd,J＝9.1,6.7Hz,1H),6.99(d,J＝7.8Hz,1H),6.92(t,J＝6.8Hz,1H),6.83(t,J＝6.7Hz,1H),4.74(d,J＝28.3Hz,1H),4.33(d,J＝10.0Hz,1H),3.89(s,1H),3.23(s,1H),3.05(s,1H),2.66(s,3H),2.23(t,J＝7.7Hz,1H).

Example 893- (imidazo [1,2-a ] pyridin-2-yl) -N- ((1R, 5S, 6S) -3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) -3-azabicyclo [3.1.0] hex-6-yl) benzamide (Compound L-89)

LC-MS m/z:(M+H)+＝539.2。

1H NMR(400MHz,Chloroform-d)δ8.36(d,J＝1.8Hz,1H),8.14(ddd,J＝7.8,6.7,3.3Hz,2H),8.06–8.01(m,2H),8.02–7.98(m,2H),7.81(dt,J＝7.8,1.5Hz,1H),7.63(t,J＝9.2Hz,2H),7.47(t,J＝7.7Hz,2H),7.39(dt,J＝7.7,1.5Hz,1H),7.20(tdd,J＝9.3,7.4,1.3Hz,2H),7.06(d,J＝2.7Hz,1H),6.84–6.78(m,2H),4.32(d,J＝12.4Hz,1H),3.83–3.75(m,2H),3.64(dd,J＝12.4,4.3Hz,1H),2.70(q,J＝2.5Hz,1H),1.91(d,J＝29.8Hz,2H).

Example 903- (imidazo [1,2-a ] pyridin-2-yl) -N- (((1R, 5S, 6S) -3- (6- (phenylamino) pyridinyloxy) -3-azabicyclo [3.1.0] hex-6-yl) benzamide (Compound L-90)

LC-MS m/z:(M+H)+＝515.2。

1H NMR(400MHz,Chloroform-d)δ8.42(s,1H),8.17(d,J＝6.8Hz,1H),8.01(d,J＝7.7Hz,1H),7.94(s,1H),7.85(d,J＝7.8Hz,1H),7.69(d,J＝9.1Hz,1H),7.58(t,J＝7.9Hz,1H),7.51(t,J＝7.8Hz,1H),7.37(s,2H),7.26(s,1H),7.20(d,J＝7.4Hz,1H),7.10(q,J＝5.1,4.3Hz,1H),6.90(dt,J＝15.0,7.7Hz,3H),6.78(s,1H),4.29(d,J＝12.4Hz,1H),4.20(d,J＝11.8Hz,1H),3.94(dd,J＝11.8,4.1Hz,1H),3.77–3.65(m,2H),2.71(d,J＝2.7Hz,1H),2.03(s,1H).

Example 916- (1H-benzo [ d ] imidazol-2-yl) -N- (3- ((1, 4-dioxy-1, 4-dihydronaphthalen-2-yl) amino) -4-methylbenzoyl) -3-azabicyclo [3.1.0] hex-en-6-yl) picolinamide (Compound L-91)

First, 3-amino-4-methyl-benzoic acid (1.5g, 9.9mmol), naphthalene-1, 4-dione (1.6g, 9.9mmol) and copper acetate (0.2g, 0.99mmol) were dissolved in AcOH (50mL) and stirred at 60 ℃ for 16 h. The reaction was concentrated to dryness and recrystallized from EtOH (10mL) and dried to give 3- [ (1, 4-dioxy-2-naphthyl) amino ] -4-methyl-benzoic acid (2g, 66%) as a red solid.

Second, the procedure was the same as in example 82 for the preparation of Compound L-82.

LC-MS:m/z:(M+H)⁺＝609.3；1H NMR(400MHz,Methanol-d4)δ8.45(dd,J＝7.2,1.7Hz,1H),8.25–8.13(m,3H),8.04(dd,J＝7.6,1.3Hz,1H),7.79(dtd,J＝25.1,7.4,1.4Hz,3H),7.63(d,J＝7.4Hz,1H),7.54–7.44(m,3H),7.36(s,2H),5.60(s,1H),4.31(d,J＝12.3Hz,1H),3.99–3.82(m,2H),3.71(dd,J＝12.3,4.5Hz,1H),2.72(t,J＝2.5Hz,1H),2.36(s,3H),2.19–2.12(m,1H),2.07(d,J＝9.9Hz,1H).

EXAMPLE 92(9- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) -3, 9-diazaspiro [5.5] undecan-3-yl) (3- (4-methyl-1H-imidazol-1-yl) phenyl) methanone (Compound L-92)

LC-MS:m/z:(M+H)⁺/2＝280.2；1H NMR(400MHz,Methanol-d4)δ8.46(dt,J＝6.8,1.2Hz,1H),8.30(d,J＝0.7Hz,1H),8.11(d,J＝1.4Hz,1H),8.05(dt,J＝7.9,1.3Hz,1H),8.00(t,J＝1.6Hz,1H),7.72–7.54(m,5H),7.46–7.30(m,4H),6.96(td,J＝6.8,1.2Hz,1H),3.82(s,4H),3.50(d,J＝1.6Hz,4H),2.27(d,J＝1.1Hz,3H),1.68(d,J＝48.3Hz,8H).

Example 936- (1H-benzo [ d ] imidazol-2-yl) -N- (3- (3- (4-methyl-1H-imidazol-1-yl) benzoyl) -3-azabicyclo [3.1.0] hex-6-yl) picolinamide (Compound L-93)

First, (3-methoxycarbonylphenyl) boronic acid (1.8g, 10mmol), 4-methyl-1H-imidazole (0.82g, 10mmol), pyridine (0.81mL, 10mmol) and copper acetate (0.4g, 2.0mmol) were dissolved in DCM (50mL) and the reaction was stirred at room temperature for 16 hours. The reaction was concentrated to dryness and purified by flash chromatography (silica) (petroleum ether: ethyl acetate ═ 2:1) to give methyl 3- (4-methylimidazol-1-yl) benzoate (1g, 46%) as a white solid.

Secondly, methyl 3- (4-methylimidazol-1-yl) benzoate (43mg, 0.2mmol) was dissolved in THF (5mL) and water (1mL), and after LiOH (24mg, 1.0mmol) was added to the reaction mixture, the mixture was stirred at 80 ℃ for 2 hours. The reaction was concentrated to dryness and used directly for the next reaction.

Thirdly, the procedure is the same as in the preparation of Compound L-82 of example 82.

LC-MS:m/z:(M+H)⁺＝504.2；1H NMR(400MHz,Methanol-d4)δ8.46(dd,J＝7.3,1.6Hz,1H),8.26–8.12(m,3H),7.81–7.62(m,5H),7.53(dt,J＝7.5,1.4Hz,1H),7.45–7.32(m,3H),4.32(d,J＝12.3Hz,1H),3.90(dd,J＝11.0,4.5Hz,1H),3.82(d,J＝10.9Hz,1H),3.75(dd,J＝12.4,4.7Hz,1H),2.76(t,J＝2.4Hz,1H),2.29(d,J＝1.0Hz,3H),2.18(d,J＝4.6Hz,1H),2.08(d,J＝12.6Hz,1H).

EXAMPLE 94(9- (3- (benzo [ d ] thiazol-2-yl) benzoyl) -3, 9-diazaspiro [5.5] undecan-3-yl) (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) methanone (Compound L-94)

LC-MS:m/z:(M+H)⁺＝612.3；1H NMR(400MHz,Methanol-d4)δ8.46(dt,J＝6.9,1.2Hz,1H),8.30(d,J＝0.7Hz,1H),8.21(dt,J＝7.8,1.4Hz,1H),8.19–8.16(m,1H),8.06(ddt,J＝6.8,5.2,1.0Hz,3H),8.02–7.99(m,1H),7.73–7.64(m,1H),7.64–7.54(m,4H),7.48(ddd,J＝8.3,7.2,1.2Hz,1H),7.44–7.33(m,2H),6.96(td,J＝6.8,1.2Hz,1H),3.84(s,4H),3.52(s,4H),1.70(d,J＝48.3Hz,8H).

Example 952- ((5- (9- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) -3, 9-diazaspiro [5.5] undec-3-carbonyl) -2-methylphenyl) amino) naphthalene-1, 4-dione (Compound L-95)

LC-MS:m/z:(M+H)⁺＝664.3；1H NMR(400MHz,Chloroform-d)δ8.14(ddd,J＝15.6,7.3,2.1Hz,3H),8.04(d,J＝7.9Hz,1H),7.99(d,J＝1.8Hz,1H),7.91(s,1H),7.79(td,J＝7.6,1.4Hz,1H),7.74–7.62(m,2H),7.50(t,J＝7.7Hz,1H),7.43–7.33(m,4H),7.28–7.18(m,2H),6.83(t,J＝6.7Hz,1H),5.98(s,1H),3.79(s,4H),3.50(s,4H),2.34(s,3H),1.61(d,J＝57.2Hz,8H).

Example 963- (4- (9- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) -3, 9-diazaspiro [5.5] undec-3-carbonyl) benzamido) thiophene-2-carboxamide (Compound L-96)

First, 3-aminothiophene-2-carboxamide (1.4g, 9.8mmol) and N, N-diisopropylethylamine (2.5g, 20mmol) were dissolved in tetrahydrofuran (200mL), methyl 3-chlorocarbonyl benzoate (2.0g, 9.8mmol) was added, and the mixture was stirred at 25 ℃ for 16 h. The reaction was concentrated to dryness and purified by flash chromatography (silica) (petroleum ether: ethyl acetate 50: 50) to afford methyl 3- [ (2-carbamoyl-3-thienyl) carbamoyl ] benzoate (1g, 33%) as a yellow solid.

Secondly, methyl 3- [ (2-carbamoyl-3-thienyl) carbamoyl ] benzoate (180mg, 0.6mmol) was dissolved in MeOH (5mL) and water (1mL), and NaOH (71mg, 3.0mmol) was added thereto, followed by stirring at 100 ℃ for 5 days. The reaction was concentrated to dryness and water (5mL) was added to the crude product, the PH was adjusted to 5 with 1N dilute hydrochloric acid and filtered to give 3- [ (2-carbamoyl-3-thienyl) carbamoyl ] benzoic acid as a yellow solid (90mg, 52%).

LC-MS:m/z:(M+H)⁺＝647.3；1H NMR(400MHz,Methanol-d4)δ8.47(dd,J＝6.8,1.3Hz,1H),8.31(d,J＝1.4Hz,1H),8.12–8.08(m,2H),8.07–8.03(m,1H),8.00(d,J＝1.7Hz,1H),7.66–7.56(m,4H),7.44–7.34(m,3H),7.03–6.93(m,2H),3.82(s,4H),3.48(d,J＝30.4Hz,4H),1.68(d,J＝50.0Hz,8H).

Example 97((2- (phenylamino) pyrimidin-4-yl) (9- (2- (pyridin-2-ylamino) pyrimidine-4-carbonyl) -3, 9-diazaspiro [5.5] undecan-3-yl) methanone (Compound L-97)

LC-MS:m/z:(M+H)+＝482.0,1H NMR(400MHz,DMSO-d6)δ10.08(d,J＝26.4Hz,1H),9.86(d,J＝20.0Hz,1H),8.66(ddd,J＝20.0,14.7,4.9Hz,2H),8.23(ddd,J＝29.4,21.0,6.0Hz,2H),7.86–7.63(m,3H),7.29(dt,J＝21.7,8.0Hz,2H),7.18–6.88(m,4H),3.79–3.46(m,8H).

EXAMPLE 98((2- (phenylamino) pyrimidin-4-yl) (9- (2- (pyridin-2-ylamino) pyrimidine-4-carbonyl) -3, 9-diazaspiro [5.5] undecan-3-yl) methanone (compound L-98)

LC-MS:m/z:(M+H)+＝550.0,1H NMR(400MHz,CDCl₃)δ8.66(d,J＝4.9Hz,1H),8.57(d,J＝4.9Hz,1H),8.39(d,J＝8.5Hz,2H),7.72(t,J＝8.5Hz,1H),7.62(d,J＝8.1Hz,2H),7.56(s,1H),7.35(t,J＝7.8Hz,2H),7.08(t,J＝7.3Hz,1H),7.00(dd,J＝13.2,5.9Hz,2H),6.92(d,J＝4.9Hz,1H),3.86–3.67(m,4H),3.50(d,J＝4.0Hz,4H),1.73–1.52(m,8H).

Example 99(N- (1- (2- (phenylamino) pyrimidine-4-carbonyl) piperidin-4-yl) -2- (pyridin-2-ylamino) pyrimidine-4-carboxamide (E100124-081) (Compound L-99)

LC-MS:m/z:(M+H)+＝495.2,1H NMR(400MHz,CDCl₃)δ9.31(s,1H),8.76(d,J＝4.9Hz,1H),8.59(d,J＝4.9Hz,1H),8.41(d,J＝4.8Hz,1H),8.33(d,J＝8.4Hz,1H),8.09(s,1H),7.86(d,J＝8.2Hz,1H),7.79–7.72(m,1H),7.62(dd,J＝14.3,6.4Hz,3H),7.34(t,J＝7.8Hz,2H),7.10–7.00(m,2H),6.95(d,J＝4.9Hz,1H),4.63(d,J＝13.5Hz,1H),4.32–4.18(m,1H),3.98(d,J＝13.8Hz,1H),3.27(t,J＝11.4Hz,1H),3.11–3.03(m,1H),2.09(dd,J＝38.8,10.9Hz,2H),1.69–1.56(m,2H).

Example 100 (Tetrahydropyrrolo [3,4-c ] pyrrole-2, 5(1H, 3H) -diyl) bis ((6- (phenylamino) pyridin-2-yl) methanone) (Compound L-100)

5- (6- (phenylamino) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrole-2 (1H) -carboxylic acid tert-butyl ester

Tert-butyl hexahydropyrrolo [3,4-c ] pyrrole-2 (1H) -carboxylate (100mg, 0.47mmol), a compound of formula 2, and 6- (phenylamino) picolinic acid (101mg, 0.47mmol), a compound of formula 1, were suspended in 3ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (122mg,0.94mmol) and 1-propylphosphoric anhydride (449mg,0.71mmol) were added. The reaction was stirred at 30 ℃ for 16 h. To the reaction solution was added 10ml of ice water, stirred for five minutes, filtered, and the solid was dried to obtain 190mg of a crude product as a brown solid with a yield of 98.96%. LC-MS M/z (M + H) + (409.0).

Bis (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (6- (phenylamino) pyridin-2-yl) methanone

Tert-butyl 5- (6- (phenylamino) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrole-2 (1H) -carboxylate (190mg, 0.47mmol) (the compound represented by the formula 3) was dissolved in 3mL of methanol, and dioxane hydrochloride solution (3mL,4M,12mmol) was added. The reaction was stirred at 15 ℃ for 2 h. The reaction was concentrated and dried to give a crude product as a brown solid in a yield of 150mg, 94.38%. LC-MS M/z (M + H) + (309.0).

Tris, (tetrahydropyrrolo [3,4-c ] pyrrole-2, 5(1H, 3H) -diyl) bis ((6- (phenylamino) pyridin-2-yl) methanone)

LC-MS:m/z:(M+H)+＝505.0,1H NMR(400MHz,CDCl3)δ7.62(td,J＝8.1,3.4Hz,2H),7.41–7.30(m,8H),7.08(ddd,J＝12.8,9.9,5.5Hz,2H),6.97–6.73(m,4H),4.05(ddd,J＝13.8,9.7,4.8Hz,3H),3.91–3.65(m,5H),2.98(s,2H).

EXAMPLE 1016- (phenylamino) -N- (((1R, 5S, 6S) -3- (6- (phenylamino) pyridinyloxy) -3-azabicyclo [3.1.0] hex-6-yl) pyridinoline amide (Compound L-101)

Mono (1R, 5S, 6S) -6- (6- (phenylamino) pyridinecarboxamido) -3-azabicyclo [3.1.0] hexane-3-carboxylic acid tert-butyl ester (E100124-067)

Tert-butyl (1R, 5S, 6S) -6-amino-3-azabicyclo [3.1.0] hexane-3-carboxylate (100mg, 0.50mmol) (compound of formula 2) and 6- (phenylamino) picolinic acid (108mg, 0.50mmol) (compound of formula 1) were suspended in 3ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (130mg,1.01mmol) and 1-propylphosphoric anhydride (481mg,0.76mmol) were added. The reaction was stirred at 30 ℃ for 16 h. To the reaction solution was added 10ml of ice water, stirred for five minutes, filtered, and the solid was dried to give 198mg of a crude product as a brown solid with a yield of 99.6%. LC-MS: M/z (M + H) + 395.0.

Di, N- (((1R, 5S, 6S) -3-azabicyclo [3.1.0] hex-6-yl) -6- (phenylamino) pyridinoline amide

Tert-butyl (1R, 5S, 6S) -6- (6- (phenylamino) pyridinecarboxamido) -3-azabicyclo [3.1.0] hexane-3-carboxylate (198mg, 0.50mmol), a compound of formula 3, was dissolved in 3mL of methanol, and dioxane hydrochloride solution (3mL,4M,12mmol) was added. The reaction was stirred at 15 ℃ for 2 h. The reaction solution was concentrated and dried to obtain a crude product of 148mg as a brown solid in a yield of 99.1%. LC-MS M/z (M + H) + (295.0).

Tris, 6- (phenylamino) -N- (((1R, 5S, 6S) -3- (6- (phenylamino) pyridininyl) -3-azabicyclo [3.1.0] hex-6-yl) pyridinoline amide

LC-MS:m/z:(M+H)+＝491.0,1H NMR(400MHz,CDCl₃)δ7.98(s,1H),7.68–7.57(m,3H),7.45–7.30(m,8H),7.21–7.08(m,3H),7.03–6.89(m,3H),6.70(s,1H),4.30(d,J＝12.5Hz,1H),4.18(d,J＝11.6Hz,1H),3.98(d,J＝11.6Hz,1H),3.76–3.68(m,1H),2.69(d,J＝2.0Hz,1H),1.91(s,2H).

Example 102(5- (6- (phenylamino) pyridyl) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2- (phenylamino) pyrimidin-4-yl) methanone (compound L-102)

LC-MS:m/z:(M+H)+＝506.0,1H NMR(400MHz,CD3OD)δ8.57(dd,J＝12.9,4.9Hz,1H),7.70–7.61(m,2H),7.59–7.42(m,3H),7.36–6.71(m,9H),4.01–3.46(m,8H),3.11–2.92(m,2H).

Example 103(2- (phenylamino) -N- (((1R, 5S, 6S) -3- (6- (phenylamino) pyridyl) -3-azabicyclo [3.1.0] hex-6-yl) pyrimidine-4-carboxamide (Compound L-103)

LC-MS:m/z:(M+H)+＝492.0,1H NMR(400MHz,CD3OD)δ8.61(d,J＝4.9Hz,1H),7.69–7.54(m,5H),7.32(dt,J＝16.2,4.8Hz,5H),7.08–6.86(m,4H),4.20(d,J＝12.5Hz,1H),4.12(d,J＝11.7Hz,1H),3.88(dd,J＝11.8,4.3Hz,1H),3.72–3.63(m,1H),2.60(t,J＝2.3Hz,1H),2.01–1.89(m,2H).

Example 104N- ((1R, 5S, 6S) -3- (3- (1H-pyrrol-1-yl) thiophene-2-carbonyl) -3-azabicyclo [3.1.0] hex-6-yl) -3- (imidazo [1,2-a ] pyridin-2-yl) benzamide (Compound L-104)

LC-MS:m/z:(M+H)+＝494.2。

1H NMR(400MHz,Chloroform-d)δ8.38(s,1H),8.18(d,J＝6.7Hz,1H),7.99(d,J＝7.8Hz,1H),7.

94(s,1H),7.82(d,J＝7.8Hz,1H),7.68(d,J＝9.1Hz,1H),7.50(t,J＝7.7Hz,1H),7.44(d,J＝5.3Hz,1H),7.27(s,1H),7.06(d,J＝5.3Hz,1H),6.90–6.85(m,1H),6.74(s,1H),6.33(t,J＝2.2Hz,2H),4.25(d,J＝12.5Hz,1H),3.53(d,J＝13.3Hz,1H),3.32(d,J＝11.0Hz,1H),2.70–2.61(m,1H),2.45(t,J＝2.5Hz,1H),1.86(s,1H).

Example 1053- (imidazo [1,2-a ] pyridin-2-yl) -N- ((1R, 5S, 6S) -3- (2-phenoxynicotinamido) -3-azabicyclo [3.1.0] hex-6-yl) benzamide (Compound L-105)

LC-MS:m/z:(M+H)+＝516.2。

1H NMR(400MHz,Chloroform-d)δ8.47(s,1H),8.21(dt,J＝5.1,2.4Hz,2H),8.00(d,J＝7.7Hz,1H),7.87(d,J＝7.7Hz,1H),7.77–7.68(m,2H),7.53(t,J＝7.7Hz,1H),7.44(t,J＝7.8Hz,2H),7.37–7.30(m,1H),7.26–7.18(m,3H),7.08(dd,J＝7.4,4.9Hz,1H),6.93(t,J＝7.2Hz,2H),4.31(d,J＝12.4Hz,1H),3.88–3.80(m,1H),3.76(d,J＝10.8Hz,1H),3.69(dd,J＝12.4,4.5Hz,1H),2.76(d,J＝2.6Hz,1H),2.03(d,J＝7.6Hz,1H),1.97(d,J＝4.1Hz,1H).

Example 106N- ((1R, 5S, 6S) -3- (1H-indazole-3-carbonyl) -3-azabicyclo [3.1.0] hex-6-yl) -3- (imidazo [1,2-a ] pyridin-2-yl) benzamide (compound L-106)

LC-MS:m/z:(M+H)+＝463.1。

1H NMR(400MHz,DMSO-d6)δ13.60(s,1H),8.73(d,J＝3.9Hz,1H),8.57(d,J＝6.7Hz,1H),8.47(s,1H),8.42(d,J＝1.9Hz,1H),8.16(d,J＝8.2Hz,1H),8.11(dd,J＝7.7,1.7Hz,1H),7.80–7.75(m,1H),7.65–7.58(m,2H),7.54(t,J＝7.8Hz,1H),7.45–7.41(m,1H),7.29(s,1H),7.24(t,J＝7.5Hz,1H),6.94(s,1H),4.49(d,J＝11.7Hz,1H),4.10(d,J＝12.3Hz,1H),4.04–4.00(m,1H),3.70–3.62(m,2H),2.04(s,1H),1.97(s,1H).

Example 1074-butoxy-N- (1- (3- (imidazo [1,2-a ] pyridin-2-yl) benzoyl) piperidin-4-yl) benzamide (compound L-107)

LC-MS:m/z:(M+H)+＝497.3。

1H NMR(400MHz,Chloroform-d)δ8.17(d,J＝6.8Hz,1H),8.04–7.98(m,2H),7.91(s,1H),7.79–7.73(m,2H),7.70(d,J＝9.1Hz,1H),7.49(t,J＝7.6Hz,1H),7.37(d,J＝7.6Hz,1H),7.25(t,J＝8.0Hz,1H),6.94–6.89(m,2H),6.85(t,J＝6.7Hz,1H),6.30(d,J＝7.9Hz,1H),4.75(s,1H),4.28(d,J＝6.9Hz,1H),3.86(s,1H),3.22(s,1H),3.02(s,1H),2.29(s,2H),2.03(s,1H),1.79(p,J＝6.8Hz,2H),1.50(hept,J＝6.8,6.2Hz,4H),1.02–0.95(m,3H).

Example 108(4- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperazin-1-yl) (quinolin-3-yl) methanone (Compound L-108)

LC-MS:m/z:(M+H)+＝463.0,1H NMR(400MHz,CDCl₃)δ9.01(s,1H),8.63(s,1H),8.32(s,1H),8.17(d,J＝8.1Hz,1H),8.02(t,J＝7.6Hz,1H),7.95–7.80(m,2H),7.79–7.63(m,3H),7.38(dd,J＝6.0,3.0Hz,2H),3.85(d,J＝72.4Hz,8H).

Example 109(4- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperazin-1-yl) (4-methylpyridin-3-yl) methanone (Compound L-109)

LC-MS:m/z:(M+H)+＝427.0,1H NMR(400MHz,CDCl₃)δ8.78–8.43(m,3H),8.04(d,J＝7.4Hz,1H),7.74(d,J＝22.5Hz,3H),7.39(s,2H),7.21(s,1H),4.01–3.29(m,8H),2.40(s,3H).

Example 110(4- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) piperazin-1-yl) (1H-indazol-3-yl) methanone (Compound L-110)

LC-MS:m/z:(M+H)+＝452.0,1H NMR(400MHz,CDCl₃)δ11.00(d,J＝117.6Hz,2H),8.52(s,1H),8.11(s,1H),7.97(t,J＝7.8Hz,1H),7.69(d,J＝6.8Hz,3H),7.49(d,J＝8.4Hz,1H),7.45–7.30(m,3H),7.22(s,1H),4.44–3.58(m,8H).

Example 1116- (4- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) piperazine-1-carbonyl) -4, 5-dihydropyridazin-3 (2H) -one (Compound L-111)

LC-MS:m/z:(M+H)+＝432.0,1H NMR(400MHz,CDCl₃)δ8.91(s,1H),8.57(s,1H),7.99(t,J＝7.8Hz,1H),7.86–7.60(m,3H),7.41–7.32(m,2H),4.00–3.61(m,8H),2.91(s,2H),2.62(s,2H).

Example 112(4- (6- (1H-benzo [ d ] imidazol-2-yl ] pyridinyloxy) piperazin-1-yl) (thiophen-2-yl) methanone (Compound L-112)

LC-MS:m/z:(M+H)+＝418.0,1H NMR(400MHz,CDCl₃)δ8.57(d,J＝7.8Hz,1H),8.01(dd,J＝15.8,8.0Hz,1H),7.71(t,J＝8.5Hz,3H),7.50(d,J＝5.0Hz,1H),7.41–7.32(m,3H),7.11–7.05(m,1H),4.09–3.67(m,8H).

Example 113(3, 9-diazaspiro [5.5] undecane-3, 9-diyl) bis ((6- (phenylamino) pyridin-2-yl) methanone) (Compound L-113)

Mono, 9- (6- (6- (phenylamino) pyridinyloxy) -3, 9-diazaspiro [5.5] undecane-3-carboxylic acid tert-butyl ester

Tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate (187mg, 0.74mmol) (the compound represented by the formula 2) and 6- (phenylamino) picolinic acid (150mg, 0.70mmol) (the compound represented by the formula 1) were suspended in 3ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (181mg,1.40mmol) and 1-propylphosphoric anhydride (668mg,1.05mmol) were added. The reaction was stirred at 15 ℃ for 16 h. To the reaction solution was added 10ml of ice water, stirred for five minutes, filtered, and the solid was dried to give a crude product of 220mg as a brown solid with a yield of 69.73%. LC-MS M/z (M + H) + (451.0).

Di- (6- (phenylamino) pyridin-2-yl) (3, 9-diazaspiro [5.5] undecan-3-yl) methanone

Tert-butyl 9- (6- (6- (phenylamino) pyridinyloxy) -3, 9-diazaspiro [5.5] undecane-3-carboxylate (175mg, 0.33mmol) (compound of formula 3) was dissolved in 5mL of methanol, dioxane hydrochloride solution (5mL,4M,20mmol) was added and the reaction was stirred at 15 ℃ for 2H, the reaction was concentrated and dried to give a crude product of 115mg as a brown solid with a yield of 98.56% LC-MS: M/z (M + H) + 351.0.

Tris, (3, 9-diazaspiro [5.5] undecane-3, 9-diyl) bis ((6- (phenylamino) pyridin-2-yl) methanone)

LC-MS:m/z:(M+H)+＝547.0,1H NMR(400MHz,CDCl₃)δ8.04(s,1H),7.64–7.56(m,2H),7.39–7.33(m,7H),7.11(dt,J＝8.5,3.5Hz,2H),6.99(d,J＝7.2Hz,2H),6.91(d,J＝8.4Hz,3H),3.67(d,J＝96.1Hz,8H),1.75–1.51(m,8H).

Example 1146- (phenylamino) -N- (1- (6- (6- (phenylamino) pyridinyloxy) piperidin-4-yl) pyridinylamide (compound L-114)

Mono (tert-butyl (1- (6- (phenylamino) pyridinyloxy) piperidin-4-yl) carbamate

Tert-butylpiperidin-4-ylcarbamate (147mg, 0.74mmol) (the compound represented by the formula 2) and 6- (phenylamino) picolinic acid (150mg, 0.70mmol) (the compound represented by the formula 1) were suspended in 3ml of N, N-dimethylformamide, and N, N-diisopropylethylamine (181mg,1.4mmol) and 1-propylphosphoric anhydride (668mg,1.05mmol) were added. The reaction was stirred at 30 ℃ for 16 h. To the reaction solution was added 10ml of ice water, stirred for five minutes, filtered, and the solid was dried to obtain a crude product as 230mg of a brown solid in a yield of 82.34%. LC-MS: M/z (M + H) + 397.0.

Di- (4-aminopiperidin-1-yl) (6- (phenylamino) pyridin-2-yl) methanone

Tert-butyl (1- (2- (phenylamino) pyrimidine-4-carbonyl) piperidin-4-yl) carbamate (150mg, 0.38mmol) (the compound represented by the formula 3) was dissolved in 5mL of methanol, and dioxane hydrochloride solution (5mL,4M,20mmol) was added. The reaction was stirred at 15 ℃ for 2 h. The reaction was concentrated and dried to give the crude product as a brown solid in 110mg yield of 98.10%. LC-MS M/z (M + H) + (297.0).

Tris, 6- (phenylamino) -N- (1- (6- (6- (phenylamino) pyridinyloxy) piperidin-4-yl) pyridinylamide

LC-MS:m/z:(M+H)+＝493.0,1H NMR(400MHz,CDCl₃)δ8.06–7.99(m,1H),7.72–7.61(m,3H),7.38(dt,J＝13.4,8.0Hz,8H),7.15(t,J＝7.1Hz,2H),6.98(dd,J＝21.4,7.9Hz,3H),4.61(s,1H),4.28(d,J＝8.2Hz,1H),3.96(s,1H),3.37–3.14(m,2H),2.12(d,J＝28.1Hz,2H),1.73(d,J＝10.2Hz,2H).

Example 1153- (4- (4- (6- (1H-benzo [ d ] imidazol-2-yl) pyridyl) piperazine-1-carbonyl) benzamido) thiophene-2-carboxamide (Compound L-115)

LC-MS:m/z:(M+H)⁺＝579.8；1H NMR(400MHz,Methanol-d4)δ8.41(s,1H),8.14(s,3H),7.81–7.61(m,5H),7.36(d,J＝16.9Hz,3H),6.98(s,1H),3.95(d,J＝36.7Hz,4H),3.67(t,J＝29.0Hz,4H).

Example 1162- ((5- (4- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) piperazine-1-carbonyl) -2-methylphenyl) amino) naphthalene-1, 4-dione (Compound L-116)

LC-MS:m/z:(M+H)⁺＝596.8；1H NMR(400MHz,Chloroform-d)δ8.58(s,1H),8.40–7.92(m,3H),7.72(s,5H),7.55–7.19(m,7H),6.03(s,1H),3.85(d,J＝36.6Hz,8H),2.34(s,3H).

Example 117(4- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) piperazin-1-yl) (3- (4-methyl-1H-imidazol-1-yl) phenyl) methanone (Compound L-117)

LC-MS:m/z:(M+H)⁺＝419.9；1H NMR(400MHz,Methanol-d4)δ8.41(s,1H),8.14(d,J＝8.1Hz,2H),7.89–7.54(m,6H),7.48(s,1H),7.34(s,3H),4.19–3.48(m,8H),2.27(s,3H).

Example 1184- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinoyl) -N- (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) piperazine-1-carboxamide (Compound L-118)

3-imidazo [1,2-a ] pyridin-2-ylaniline (42mg, 0.2mmol) was dissolved in anhydrous dichloromethane (5mL), triphosgene (20mg, 0.067mmol) was added, and the mixture was stirred at 25 ℃ for 16 h. The reaction was concentrated to dryness and used directly in the next reaction.

[6- (1H-Benzimidazol-2-yl) -2-pyridyl ] -piperazin-1-yl-methanone (63mg, 0.2mmol) and N, N-diisopropylethylamine (79mg, 0.6mmol) were dissolved in N, N-dimethylformamide (1mL), 2- (3-isocyanatophenyl) imidazo [1,2-a ] pyridine (48mg, 0.2mmol) was added, and the reaction was stirred at 25 ℃ for 2 hours. The reaction was concentrated to dryness and purified by flash chromatography (silica) (dichloromethane: methanol ═ 20:1) to give 4- [6- (1H-benzimidazol-2-yl) pyridine-2-carbonyl ] -N- (3-imidazo [1,2-a ] pyridin-2-ylphenyl) piperazine-1-carboxamide as a yellow solid (35mg, 32%).

LC-MS:m/z:(M+H)⁺/2＝272.0；1H NMR(400MHz,Methanol-d4)δ8.47–8.40(m,2H),8.20–8.12(m,2H),7.91(t,J＝1.8Hz,1H),7.75(dd,J＝7.8,1.0Hz,2H),7.62(dt,J＝7.4,1.5Hz,2H),7.56(d,J＝9.1Hz,1H),7.46–7.29(m,5H),6.93(td,J＝6.8,1.2Hz,1H),3.95(t,J＝5.2Hz,2H),3.81(d,J＝5.5Hz,2H),3.71(s,4H).

Example 1191, 3-bis (3- (imidazo [1,2-a ] pyridin-2-yl) phenyl) urea (Compound L-119)

The procedure was carried out in the same manner as in the preparation of compound L-118 in example 118.

LC-MS:m/z:(M+H)⁺/2＝223.0；1H NMR(400MHz,Methanol-d4)δ8.27(dt,J＝6.8,1.2Hz,1H),8.04(s,1H),7.92(t,J＝1.9Hz,1H),7.64–7.51(m,3H),7.38(t,J＝7.9Hz,1H),7.30(ddd,J＝9.1,6.8,1.2Hz,1H),6.90(td,J＝6.8,1.1Hz,1H).

Example 120 Synthesis of (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (1H-indazol-3-yl) methanone (Compound L-120)

Synthesis of (6- (1H benzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone hydrochloride

The operation is as follows: 540mg of tert-butyl 5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrole-2 (1H) -carboxylate as a starting material was put into a reaction flask, 40ml of methanol was added thereto, 20ml of a 4M/L hydrochloric acid/1, 4-dioxane solution was added thereto with stirring, and the mixture was stirred at room temperature overnight. The next day, LC-MS showed the reaction was complete. Directly concentrating under reduced pressure to remove solvent. Yield of 500 mg: 100 percent

LC-MS:m/z:(M+H)+＝369.9。

Synthesis of bis (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (1H-indazol-3-yl) methanone.

The operation is as follows: 60mg (1eq) of the starting material (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone hydrochloride was put into a reaction flask, 2ml of anhydrous DMF was added, 26.25mg (1eq) of the starting material 1H-indazole-3-carboxylic acid was added, and then, t3p103.2mg (50% EA solution, 1.5eq) and DIPEA83.7mg (3eq) were added with stirring, and the mixture was stirred at 30 ℃ overnight, the next day and LC-MS reaction was completed. And (3) post-treatment: the reaction solution was poured into 20ml of ice water and stirred, 50ml of dichloromethane was added for 3 times of extraction, and organic layers were combined, extracted with saturated brine and dried over anhydrous sodium sulfate. Filtration and concentration to dryness gave a residue which was subjected to column chromatography (DCM: MEOH ═ 0 to-5%) to give the product which was then separated on a thick plate chromatography (DCM: MEOH ═ 95: 5) to give 32.5mg of pure product. Yield: 41.9 percent.

LC-MS:m/z:(M+H)+＝478.2。

¹H NMR(400MHz,Methanol-d₄)δ8.46–8.37(m,1H),8.20(d,J＝8.2Hz,1H),8.12(dt,J＝10.1,7.9Hz,1H),7.88–7.81(m,1H),7.77–7.52(m,3H),7.48–7.39(m,1H),7.37–7.19(m,3H),4.49–3.67(m,8H),3.17(ttd,J＝15.6,7.3,3.4Hz,2H).

Example Synthesis of 1216- (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) octahydropyrrolo [3,4-c ] pyrrole-2-carbonyl) -4, 5-dihydropyridazin-3 (2H) -one (Compound L-121)

The operation is as follows: 60mg (1eq) of the starting material (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone hydrochloride was put into a reaction flask, 2ml of anhydrous DMF was added, 23.04mg (1eq) of the starting material 6-oxo-1, 4,5, 6-tetrahydropyridazine-3-carboxylic acid was added, T3P103.2mg (50% EA solution, 1.5eq), DIPEA83.7mg (3eq) were added with stirring, and the mixture was stirred at 30 ℃ overnight, the next day, and LC-MS reaction was completed. And (3) post-treatment: the reaction solution was poured into 20ml of ice water and stirred, 50ml of dichloromethane was added for 3 times of extraction, and organic layers were combined, extracted with saturated brine and dried over anhydrous sodium sulfate. Filtration and concentration to dryness gave a residue which was subjected to column chromatography (DCM: MEOH ═ 0 to-5%) to give the product which was then separated by thick chromatography plates (DCM: MEOH ═ 95: 5) to give 19.6mg of pure product. Yield: 26.4 percent.

LC-MS:m/z:(M+H)+＝458.2。

¹H NMR(400MHz,Methanol-d₄)δ8.42(ddd,J＝7.9,4.6,0.9Hz,1H),8.14(td,J＝7.9,1.0Hz,1H),7.88–7.82(m,1H),7.69(d,J＝40.9Hz,2H),7.34(d,J＝4.9Hz,2H),4.24–3.52(m,8H),3.12(dddd,J＝14.9,12.4,4.0,2.1Hz,2H),2.91–2.79(m,2H),2.61–2.45(m,2H).

EXAMPLE 122 Synthesis of (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (quinolin-3-yl) methanone (Compound L-122)

The operation is as follows: 60mg (1eq) of the starting material (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone hydrochloride was charged into a reaction flask, 2ml of anhydrous DMF was added, 28.08mg (1eq) of the starting material quinoline-3-carboxylic acid was added, T3P103.2mg (50% EA solution, 1.5eq), DIPEA83.7mg (3eq) were added with stirring, and the mixture was stirred overnight at 30 ℃ the next day until LC-MS reaction was completed. And (3) post-treatment: the reaction solution was poured into 20ml of ice water and stirred, 50ml of dichloromethane was added for 3 times of extraction, and organic layers were combined, extracted with saturated brine and dried over anhydrous sodium sulfate. Filtration and concentration to dryness gave a residue which was subjected to column chromatography (DCM: MEOH ═ 0 to-5%) to give the product which was then separated on a thick plate chromatography (DCM: MEOH ═ 95: 5) to give 41.8mg of pure product. Yield: 52.8 percent.

LC-MS:m/z:(M+H)+＝489.2。

¹H NMR(400MHz,Methanol-d₄)δ9.04(d,J＝17.9Hz,1H),8.59(d,J＝27.0Hz,1H),8.41(dd,J＝22.3,7.9Hz,1H),8.18–7.82(m,5H),7.69(dt,J＝32.4,7.4Hz,3H),7.33(s,2H),4.28–4.04(m,2H),3.96(tt,J＝13.6,8.3Hz,2H),3.88–3.56(m,4H),3.29–3.05(m,2H).

Example 123 Synthesis of (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (4-methylpyridin-3-yl) methanone (Compound L-123)

The operation is as follows: 60mg (1eq) of the starting material (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone hydrochloride was charged to a reaction flask, 2ml of anhydrous DMF was added, 22.2mg (1eq) of the starting material 4-methylnicotinic acid was added, and then, t3p103.2mg (50% EA solution, 1.5eq) and dipea83.7mg (3eq) were added with stirring, and then, the mixture was stirred overnight at 30 ℃ until LC-MS reaction was completed. And (3) post-treatment: the reaction solution was poured into 20ml of ice water and stirred, 50ml of dichloromethane was added for 3 times of extraction, and organic layers were combined, extracted with saturated brine and dried over anhydrous sodium sulfate. Filtration and concentration to dryness gave a residue which was subjected to column chromatography (DCM: MEOH ═ 0 to-5%) to give the product which was then separated on a thick plate chromatography (DCM: MEOH ═ 95: 5) to give 49.1mg of pure product. Yield: 67%.

LC-MS:m/z:(M+H)+＝453.2。

¹H NMR(400MHz,Methanol-d₄)δ8.50(d,J＝5.5Hz,1H),8.47–8.37(m,2H),8.14(dt,J＝10.7,7.8Hz,1H),7.90–7.81(m,1H),7.72(s,2H),7.46–7.29(m,3H),4.25–3.85(m,4H),3.81–3.49(m,4H),3.20–3.06(m,2H),2.38(d,J＝29.1Hz,3H).

EXAMPLE 124 Synthesis of (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (3-chloro-4-fluorophenyl) methanone (Compound L-124)

The operation is as follows: 80mg (1eq) of the raw material (6- (1H benzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone hydrochloride was put into a reaction flask, 2ml of anhydrous DMF was added, 37.76mg (1eq) of the raw material 3-chloro-4-fluorobenzoic acid was added, T3P137.6mg (50% EA solution, 1.5eq), DIPEA111.6mg (3eq) were added with stirring, and the mixture was stirred at 30 ℃ overnight, the next day and LC-MS reaction was completed. And (3) post-treatment: the reaction solution was poured into 20ml of ice water and stirred, 50ml of dichloromethane was added for 3 times of extraction, and organic layers were combined, extracted with saturated brine and dried over anhydrous sodium sulfate. Filtration and concentration to dryness gave a residue which was subjected to column chromatography (DCM: MEOH 0 to 5%) to give the product which was then separated by thick chromatography plates (DCM: MEOH 95 to 5) to give 55mg of pure product. Yield: 51.88 percent.

LC-MS:m/z:(M+H)+＝489.8。

¹H NMR(400MHz,DMSO-d₆)δ12.92(s,1H),8.41(t,J＝7.6Hz,1H),8.13(q,J＝7.5Hz,1H),7.83–7.77(m,2H),7.73(t,J＝6.9Hz,1H),7.59(q,J＝7.5,6.9Hz,2H),7.48(dt,J＝32.4,8.9Hz,1H),7.26(dq,J＝14.6,7.7,7.2Hz,2H),4.18–3.35(m,8H),3.11–2.90(m,2H).

EXAMPLE 125 Synthesis of (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (2-methylquinolin-6-yl) methanone (Compound L-125)

The operation is as follows: 80mg (1eq) of the starting material (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone hydrochloride was put into a reaction flask, 2ml of anhydrous DMF was added, 40.48mg (1eq) of the starting material 2-methylquinoline-6-carboxylic acid was added, T3P137.6mg (50% EA solution, 1.5eq), DIPEA111.6mg (3eq) were added with stirring, and the mixture was stirred at 30 ℃ overnight, the next day, and LC-MS reaction was completed. And (3) post-treatment: the reaction solution was poured into 20ml of ice water and stirred, 50ml of dichloromethane was added for 3 times of extraction, and organic layers were combined, extracted with saturated brine and dried over anhydrous sodium sulfate. Filtration and concentration to dryness gave a residue which was subjected to column chromatography (DCM: MEOH 0 to 5%) to give the product which was then isolated by thick plate chromatography (DCM: MEOH 95 to 5) to give 70mg of pure product. Yield: and (4) 64.5%.

LC-MS:m/z:(M+H)+＝502.9。

¹H NMR(400MHz,DMSO-d₆)δ12.93(s,1H),8.46–8.24(m,2H),8.20–8.07(m,2H),7.94(dd,J＝29.9,8.9Hz,1H),7.86(d,J＝8.6Hz,1H),7.80(d,J＝7.6Hz,1H),7.73(dd,J＝11.9,7.9Hz,1H),7.61(dd,J＝16.2,7.9Hz,1H),7.48(dd,J＝26.5,8.6Hz,1H),7.26(dq,J＝14.1,7.1Hz,2H),4.19–3.47(m,8H),3.12–2.91(m,2H),2.72–2.62(m,3H).

EXAMPLE 126 Synthesis of (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) (4- (4-chlorophenyl) cyclohexyl) methanone (Compound L-126)

The operation is as follows: 80mg (1eq) of the starting material (6- (1 Hbenzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone hydrochloride was put into a reaction flask, 2ml of anhydrous DMF was added, 51.6mg (1eq) of the starting material 4- (4-chlorophenyl) cyclohexane-1-carboxylic acid was added, T3P137.6mg (50% EA solution, 1.5eq), DIPEA111.6mg (3eq) were added with stirring, and the mixture was stirred at 30 ℃ overnight, the next day, and LC-MS reaction was completed. And (3) post-treatment: the reaction solution was poured into 20ml of ice water and stirred, 50ml of dichloromethane was added for 3 times of extraction, and organic layers were combined, extracted with saturated brine and dried over anhydrous sodium sulfate. Filtration and concentration to dryness gave a residue which was subjected to column chromatography (DCM: MEOH ═ 0 to-5%) to give the product which was then separated on a thick plate chromatography (DCM: MEOH ═ 95: 5) to give 53mg of pure product. Yield: 44.2 percent.

LC-MS:m/z:(M+H)+＝553.8。

¹H NMR(400MHz,DMSO-d₆)δ12.93(d,J＝22.3Hz,1H),8.41(d,J＝7.9Hz,1H),8.17–8.08(m,1H),7.82–7.69(m,2H),7.59(t,J＝6.7Hz,1H),7.28(ddd,J＝30.5,16.0,7.3Hz,6H),4.16–3.33(m,8H),3.11–2.87(m,2H),2.43(t,J＝10.0Hz,2H),1.94–1.70(m,4H),1.61–1.39(m,4H).

EXAMPLE 127 Synthesis of (5- (6- (1H-benzo [ d ] imidazol-2-yl) pyridinyloxy) hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) ([1,1' -biphenyl ] -4-yl) methanone (Compound L-127)

The operation is as follows: 80mg (1eq) of the starting material (6- (1H-benzo [ d ] imidazol-2-yl) pyridin-2-yl) (hexahydropyrrolo [3,4-c ] pyrrol-2 (1H) -yl) methanone hydrochloride was put into a reaction flask, 2ml of anhydrous DMF was added, 43mg (1eq) of the starting material [1,1' -biphenyl ] -4-carboxylic acid was added, T3P137.6mg (50% EA solution, 1.5eq), DIPEA111.6mg (3eq) were added with stirring, and stirring was carried out overnight at 30 ℃ the next day until LC-MS reaction was completed. And (3) post-treatment: the reaction solution was poured into 20ml of ice water and stirred, 50ml of dichloromethane was added for 3 times of extraction, and organic layers were combined, extracted with saturated brine and dried over anhydrous sodium sulfate. Filtration and concentration to dryness gave a residue which was subjected to column chromatography (DCM: MEOH 0 to 5%) to give the product which was then isolated by thick plate chromatography (DCM: MEOH 95 to 5) to give 32mg of pure product. Yield: 28.8 percent.

LC-MS:m/z:(M+H)+＝513.9。

¹H NMR(400MHz,DMSO-d₆)δ12.94(s,1H),8.41(dd,J＝13.3,8.0Hz,1H),8.13(q,J＝7.9Hz,1H),7.83–7.70(m,4H),7.70–7.57(m,5H),7.46(ddt,J＝25.7,13.0,6.6Hz,3H),7.27(dt,J＝13.4,6.5Hz,2H),4.14–3.36(m,8H),3.13–2.91(m,2H).

Examples of receptor binding LANCL2 binding examples

1. Experimental Material

1.1 reagent Material

Ligand: lancl2

Running buffer: 20mM MES,150mM NaCl, 0.05% P20, pH 6.5, 1% DMSO

1.2 instrumentation

The instrument name: biacore S200

Chip type: CM5(29-1496-03)

2. Experimental methods

2.1 ligand coupling

The LANCL2 protein was immobilized and the protein was diluted to 50. mu.g/ml with sodium acetate solution at pH 4.0.

Sample introduction conditions are as follows: the surface of the CM5 chip was activated with a mixture of EDC/NHS at a flow rate of 10. mu.l/min for a sample injection time: 420 s; subsequently, the sample injection of LANCL2 was carried out at a flow rate of 5. mu.l/min for the following sample injection times: 2000s, single ligand coupling amount of about 1800 RU; finally, ethanolamine is used for sealing the surface of the chip, the ethanolamine sampling flow rate is 10 mul/min, and the sampling time is as follows: 420 s.

Coupling buffer: 20mM MES,150mM NaCl, 0.05% P20, pH 6.5.

2.2 Experimental conditions

An analyte: all small molecule compound sample analytes were diluted 2-fold from 50 μ M concentration to 0.78 μ M concentration, and compound solutions were finally prepared containing 1% DMSO.

Sample introduction conditions of small molecule compounds: the flow rate was 30. mu.l/min, the binding time 60s, and the dissociation time 300 s.

Running buffer: 20mM MES,150mM NaCl, 0.05% P20, pH 6.5, 1% DMSO.

Temperature of the sample chamber: 25 ℃; analysis temperature: at 25 ℃.

Method

Lancl 2-kinetic determination of small molecule interactions. BIACORE S200 was used to determine kinetic parameters of binding of small molecules BT-11 and L-1-60 (analytes) to LANCL2 (ligands). Data were generated in triplicate in a dose-dependent (5-8 titration points) fashion and analyzed to determine binding models (Langmuir, conformational shifts, etc.), real-time association and dissociation constants, and equilibrium dissociation constants. SPR technology allows to validate specific LANCL 2-phytochemical component interactions and to increase the gold standard for the binding mechanism and rate for profound understanding. Experiments were performed on carboxymethyl polyglucose (CM5) sensor chips by covalent attachment of LANCL2 by amine coupling. Data were analyzed with BIACORE S200T200 evaluation software (version 1) to determine the affinity binding constant (KD) using the 1:1 binding model.

Results

The compounds of the invention bind strongly to LANCL 2. To confirm binding of the compound to the LANCL2 protein, we performed SPR analysis in the BIACORE S200 instrument. Optical technique SPR for detecting molecular interactions was used to measure the binding affinity between LANCL2 and its ligands (test compounds). We immobilized purified recombinant LANCL2 protein on BIACORE sensor chip and injected small molecules onto the protein surface using instrumental microfluidics. The change in total mass on the chip surface was measured, which corresponds to small binding to proteins. By injecting a series of small molecule concentrations, we were able to calculate the binding signal of the test compound to LANCL2, the dissociation signal, the steady state binding affinity of the compound and the binding signal curve of the compound at different concentrations (some of the compounds in this patent do not calculate affinity and the binding signal curve at different concentrations was placed in this patent as evidence that the compound had binding activity). The binding sensorgram shows typical small molecule protein interactions with extremely fast association and fast dissociation rates. These rapid interactions are beyond the technical capabilities of the instrument. Therefore, the reliable association rate constant (ka) and dissociation rate constant (kd) were not determined. Equilibrium dissociation constants (Kd) are commonly used to describe the affinity between a ligand and a protein, such as how tightly the ligand binds to a particular protein. Ligand-protein affinity is affected by non-covalent intermolecular interactions between two molecules, such as hydrogen bonding, electrostatic interactions, hydrophobic forces, and van der waals forces. By plotting the equilibrium binding levels against the compound concentration, we were able to measure the steady state affinity (Kd) of each interaction. The compound of the invention has good binding property with the LANCL2 protein, even partial compounds of the invention such as (L-2, L-9, L-11, L-15, L-25, L-40, L-52, L-77, L-89, L-95, L-96 and L-106) have better binding activity than the positive reference compound BT-ll.

Specific data are shown in the following table.

KD (M) denotes binding capacity (in mol); rmax (ru) represents maximum binding force; N/A represents no binding activity; "/" indicates that the assay results are inconvenient for calculating KD, and this fraction will exhibit its binding activity in the form of a binding curve showing the binding signal intensity of the compound at different concentrations; a represents poor solubility. Binding curves for some of the compounds are shown in FIGS. 1 to 12.

Research on relieving effect of compound on TNBS-induced enteritis of mice

1. Background of the study

IBD belongs to a class of autoimmune diseases, which can be classified as crohn's disease and ulcerative colitis. The project utilizes a mouse colitis model induced by TNBS to simulate the Crohn's disease, and evaluates the curative effect of corresponding compounds, so as to develop the drug for treating the Crohn's disease.

2. Purpose of study

This project is directed to testing the palliative effect of representative compounds on TNBS-induced colitis in mice.

3. Reagent

Reagents	Vendor	Cat
			DPBS	Corning	21-031-CVR
TNBS	Beijing coupled technologies Ltd	2508-19-2
			Anhydrous ethanol	Aladdin (Aladdin)	64-17-5
Mesalazine (finished medicine)	Losan Pharma GmbH	NA
			Sodium chloride injection	SHANDONG KELUN PHARMACEUTICAL Co.,Ltd.	NA
1.25% Avermectin	NANJING AIBI BIOTECH Co.,Ltd.	M2910

4. Instrument for measuring the position of a moving object

Equipment	Vendor	Model
			Electronic balance	Hezhou balance	YH-2000
Electronic analytical balance	Mettle Toledo	585310

5. Experimental methods

5.1 dissolution and preservation of Compounds

Preparation method of L56: an appropriate amount of the compound L56 was weighed into a brown sample bottle, added with a volume of solvent 95% (20% HP- β -CD) + 5% (10% sodium benzoate), vortexed for 1 minute, and sonicated to facilitate dissolution. The compounds were formulated once daily.

Preparation method of L30: an appropriate amount of the compound L30 was weighed into a brown sample bottle, added with a volume of solvent 95% (20% HP- β -CD) + 5% (10% sodium benzoate), vortexed for 1 minute, and sonicated to facilitate dissolution. The compounds were formulated once daily.

The preparation method of Mesa (Mesalamine) comprises the following steps: weighing a proper amount of melaxazine (Selleck) compound into a brown sample bottle, adding a certain volume of solvent 0.5% CMC-Na, vortexing for 1 minute, and ultrasonically promoting dissolution. The compounds were formulated once daily.

5.2 route and frequency of administration of Compounds

56 female Balb/c mice, weighing about 18g, were 8-10 weeks old, and were randomly divided into 7 groups, 6 model groups, and 1 Sham control group. The compounds were formulated once daily from the beginning of Day-1 administration to the end of Day7, with the specific routes and frequencies of administration detailed in table 1 and the compound formulations and volumes administered in table 2.

TABLE 1 animal grouping and dosing regimens

Group of	Animal number (only)	Administration dose (mg/kg)	Route of administration	Frequency of administration	Administration cycle
						Sham group	5	-	-	-	-
Solvent control group	5	-	PO	BID	9days
						L56 group	5	50mpk	PO	BID	9days
L30 group	6	50mpk	PO	BID	9days
						Mesa	5	100mpk	PO	QD	9days

Note: the positive medicine is Mesalamine (Mesa)

TABLE 2 dosing volumes and final drug concentrations

Group of	Dosage to be administered	Volume of administration (mL)	Final drug concentration (mg/mL)	Frequency of administration
					Solvent control group	---	0.2	0	BID
L56 group	50mpk	0.2	5	BID
					L30 group	50mpk	0.2	5	BID
Mesa	100mpk	0.2	10	QD

Note: the mice were weighed and the above table shows the administration volume calculated for 20 g of mice.

5.3 TNBS-induced enteritis model construction in mice

Day0, Balb/c mice weighing about 18-20 g were anesthetized with 0.25 ml of 1.25% avermectin. Model group mice were rectally perfused with 150 microliters of 1% TNBS solution (final concentration 50% ethanol). Sham control mice Day0 were rectally perfused with 50% ethanol.

5.4 fixation of Colon tissue in mice

The colons of the mice were photographed, measured for length, weighed after removal of the contents, and then each mouse was longitudinally cut at 1/2, curled in a uniform direction by the method of Swiss roll (Swiss-roll) and fixed in neutral paraformaldehyde.

5.5DAI scoring criteria

The DAI score consisted of 3 parts, and was scored by weight change, stool and stool blood mix, with specific DAI scoring criteria as shown in Table 3. In the whole experimental process, the DAI scoring of all mice is completed by the same person, and the consistency of scoring scale is ensured.

TABLE 3DAI scoring criteria

5.6 Colon histopathology scoring criteria

The colon histopathology score of the mouse consists of 5 parts, and the specific scoring criteria are shown in table 4. The pathology scoring is performed by a pathologist in the clinical pathology platform profession by a double-blind method.

TABLE 4 Colon histopathology scoring criteria

5.7 statistical analysis

The experimental data were statistically analyzed by ANOVA method, positive drugs Mesalamine (PO,100mpk, QD) group, L56(PO,50mpk, BID) group, L30(PO,50mpk, BID) group, <0.05, <0.01, <0.005, <0.0001

6. Results and analysis

6.1 mouse weight Change and DAI score

Weight data were collected for 10 days (Day-1 to Day8) for each group of mice and corresponding DAI scores were analyzed using Two way ANOVA. As shown in the data of fig. 13A, the body weight loss was significantly reduced in mice of the Mesalamine (PO,100mpk, QD) group compared to the Vehicle group, the L56(PO,50mpk, BID) group, while the body weight loss was significantly reduced in mice of the L30(PO,50mpk, BID) group compared to the Vehicle group at Day5 to Day 8. The DAI score data as shown in fig. 13B also shows that the DAI score was significantly lower in mice of the Vehicle, L30(PO,50mpk, BID), L56(PO,50mpk, BID), and Mesalamine (PO,100mpk, QD) groups than in mice of the Vehicle group. Combining the body weight change and the DAI score, we found that L30(PO,50mpk, BID), L56(PO,50mpk, BID), was effective in alleviating the weight loss in mice caused by TNBS-induced colitis.

Note: in figure 13, statistical analysis of body weight change and disease activity indices of mice in the model group and other groups used the two way ANOVA method, compared to the model group, to simulate the model group, <0.05 × p <0.01 × p <0.005 × p < 0.0001; mesalazine group, wherein # p is less than 0.05# # p is less than 0.01# # # p is less than 0.005# # # p is less than 0.0001; l5650 mg/kg group ^ p <0.05^ p <0.01^ p <0.005^ p < 0.0001; l3050mg/kg group: p <0.05$ $ p <0.01$ $ p <0.005$ $ p <0.0001.two way-ANOVA A Dunnett's method was used for multiple group comparisons.

6.2 Colon weight to Length ratio changes in mice

Generally, inflammation causes a shortening of the colon and an increase in colon weight. As shown by the data in fig. 14A, the colon weight to length ratio was significantly lower and statistically significantly different for the mice in the vehicle group, L30(PO,50mpk, BID), L56(PO,50mpk, BID), and Mesalamine (PO,100mpk, QD) groups, as compared to the vehicle group. As the data in fig. 14B show, the colon was significantly longer in the Mesalamine (PO,100mpk, QD) group compared to the vehicle group, L56(PO,50mpk, BID) group. As shown by the data in fig. 14C, the colon was lower in the L30(PO,50mpk, BID), L56(PO,50mpk, BID), and Mesalamine (PO,100mpk, QD) mice compared to the vehicle group mice, which was similar in weight to the colon of the Sham group mice. These data further demonstrate that L30(PO,50mpk, BID), L56(PO,50mpk, BID) are capable of numerous remissions for TNBS-induced colitis in mice.

Note: in fig. 14, statistical analysis of the colon weight to length ratios of mice from the model group to the other groups was performed by one way ANOVA method, compared to the model group, p <0.05 p <0.01 p <0.005 p <0.0001, and one way ANOVA was performed by Dunnett's method for multiple comparisons.

6.3 mouse Colon tissue HE staining and pathological Scoring

We then performed HE staining of colon tissue from 7 groups of mice and scored by the pathologist. Compared with the mice in the Vehicle group, the colon tissues of the mice in the L56(PO,50mpk, BID) group and Mesalamine (PO,100mpk, QD) group had lower pathological scores and were statistically significantly different. Further illustrates that L56(PO,50mpk, BID) can effectively relieve the enteritis of the TNBS model mice.

Conclusion

Combining the data of In-life experiment and pathological analysis, it can be known that L56(PO,50mpk, BID) can well slow down TNBS-induced enteritis In mice.

The intestinal morphology is shown in FIG. 15(Sham & Vehicle, Mesalamine (PO,100mpk, QD) & L56(PO,50mpk, BID) and L30(PO,50mpk, BID).

Research on relieving effect of compound on TNBS-induced enteritis of mice (II)

1. Background of the study

2. Purpose of study

3. Reagent

Reagents	Vendor	Cat
			DPBS	Corning	21-031-CVR
TNBS	Beijing coupled technologies Ltd	2508-19-2
			Anhydrous ethanol	Aladdin (Aladdin)	64-17-5
Mesalazine (finished medicine)	Losan Pharma GmbH	NA
			Sodium chloride injection	Shandong Kelun medicineCompany of industry Ltd	NA
1.25% Avermectin	NANJING AIBI BIOTECH Co.,Ltd.	M2910

4. Instrument for measuring the position of a moving object

5. Experimental methods

5.1 dissolution and preservation of Compounds

The preparation method of BT-11 comprises the following steps: an appropriate amount of the BT11 compound was weighed into a brown sample vial, a volume of vehicle 0.5% CMC-Na was added, vortexed for 1 minute, and sonicated to facilitate dissolution. The compounds were formulated once daily.

Preparation method of L11: weighing appropriate amount of L11 compound into brown sample bottle, adding a certain volume of solvent 0.5% CMC-Na, vortexing for 1 min, and ultrasonically promoting dissolution. The compounds were formulated once daily.

Preparation method of L25: weighing appropriate amount of L25 compound into brown sample bottle, adding a certain volume of solvent 0.5% CMC-Na, vortexing for 1 min, and ultrasonically promoting dissolution. The compounds were formulated once daily.

Preparation method of L84: weighing appropriate amount of L84 compound into brown sample bottle, adding a certain volume of solvent 0.5% CMC-Na, vortexing for 1 min, and ultrasonically promoting dissolution. The compounds were formulated once daily.

Preparation method of L77: weighing appropriate amount of L77 compound into brown sample bottle, adding a certain volume of solvent 0.5% CMC-Na, vortexing for 1 min, and ultrasonically promoting dissolution. The compounds were formulated once daily.

Preparation method of L101: an appropriate amount of the L101 compound was weighed into a brown sample bottle, a volume of sodium chloride injection (saline) was added, vortexed for 1 minute, and sonicated to facilitate dissolution. The compounds were formulated once daily.

Preparation method of L10: weighing appropriate amount of L10 compound into brown sample bottle, adding a certain volume of solvent 0.5% CMC-Na, vortexing for 1 min, and ultrasonically promoting dissolution. The compounds were formulated once daily.

Preparation method of L23: weighing appropriate amount of L23 compound into brown sample bottle, adding a certain volume of solvent 0.5% CMC-Na, vortexing for 1 min, and ultrasonically promoting dissolution. The compounds were formulated once daily.

5.2 route and frequency of administration of Compounds

Female Balb/c mice 60, weighing about 18g, 8-10 weeks old, were randomly divided into 12 groups, 11 model groups and 1 Sham control group. The compounds were formulated once daily from the beginning of Day-1 administration to the end of Day7, with the specific routes and frequencies of administration detailed in table 1 and the compound formulations and volumes administered in table 2.

TABLE 1 animal grouping and dosing regimens

TABLE 2 dosing volumes and final drug concentrations

Group of	Dosage to be administered	Volume of administration (mL)	Final drug concentration (mg/mL)	Frequency of administration
					Model control group	---	0.2	0	BID
Mesalazine group	100mpk	0.2	10	QD
					L11 group	50mpk	0.2	5	BID
L25 group	50mpk	0.2	5	BID
					L84 group	50mpk	0.2	5	BID
L77 group	50mpk	0.2	5	BID
					L101 group	50mpk	0.2	5	BID
L10 group	50mpk	0.2	5	BID
					L23 group	50mpk	0.2	5	BID
BT-11 group	50mpk	0.2	5	BID

Note: the mice were weighed and the above table shows the administration volume calculated for 20 g of mice. The solvent group is the model control group.

5.3 TNBS-induced enteritis model construction in mice

5.4 fixation of Colon tissue in mice

5.5 Collection of fresh tissue from the Colon of mice

The remaining 1/2 colon tissue was then cut longitudinally at 1/2 and split into two tubes, snap frozen in liquid nitrogen, stored at-80 ℃ and transported on dry ice for subsequent experiments.

5.6 Collection of mesenteric lymph nodes from mice

Collecting mesenteric lymph nodes of the mice, storing at 4 ℃, and immediately transferring to a client for flow analysis after all samples are collected.

5.7DAI scoring criteria

TABLE 3DAI scoring criteria

5.8 statistical analysis

Experimental data were statistically analyzed by ANOVA and other groups were subjected to Dunnett's test with Vehicle (PO, QD) group data to compare the groups, p <0.05, p <0.01, p <0.0001

6. Results and analysis

6.1 mouse weight Change and DAI score

Weight data were collected for 10 days (Day-1 to Day8) for each group of mice and corresponding DAI scores were analyzed using Two way ANOVA. As shown by the data in fig. 16A, the body weight loss was significantly reduced in the L11(PO,50mpk, BID) and L10(PO,50mpk, BID) groups of the 9 test compound group mice compared to the Vehicle group. Except that the mice in the L84(PO,50mpk, BID) and BT11(PO,50mpk, BID) groups showed no significant decrease in body weight loss compared with the mice in the Vehicle group. The other 5 test compounds all had significant effects in alleviating weight loss in mice, but not as significantly as L11 and L10. Also, it can be seen in the DAI score data as shown in fig. 16B that the DAI scores of the L11(PO,50mpk, BID) and L10(PO,50mpk, BID) group mice were significantly lower in the 9 test compound group mice than in the Vehicle group. The other 7 test compounds all had significant effects in improving DAI scores, but not as significant as L11 and L10 effects. Combining the weight change and DAI score, we found that L11(PO,50mpk, BID) and L10(PO,50mpk, BID) were effective in alleviating the weight loss in mice caused by TNBS-induced colitis. More interestingly, L10(PO,50mpk, BID) is equivalent in potency to the positive drug Mesalamine (PO,100mpk, QD).

6.2 mice diarrhea and hematochezia score

Also, separate diarrhoea and hematochezia scores were analysed using the method of Two way ANOVA. As shown in fig. 17A, the diarrhea was significantly slowed in mice of the L11(PO,50mpk, BID) and L10(PO,50mpk, BID) groups among the 9 test compound groups compared to the Vehicle group. The other 7 test compounds all had significant effects in ameliorating diarrhea in enteritis mice, but not as significant as the L11 and L10 effects. As shown in fig. 17B, the fecal blood was significantly reduced in the L11(PO,50mpk, BID) and L10(PO,50mpk, BID) mice in the 9 test compound groups compared to the Vehicle group. The other 7 test compounds all had significant effects in improving hematochezia in enteritis mice, but not as significant as L11 and L10. Therefore, L11(PO,50mpk, BID) and L10(PO,50mpk, BID) were found to be very effective in alleviating the symptoms of diarrhea and hematochezia in TNBS model mice.

6.3 Colon weight to Length ratio changes in mice

Generally, inflammation causes a shortening of the colon and an increase in colon weight. At the end of the sampling, mice in the L10(PO,50mpk, BID) group, L25(PO,50mpk, BID) group and L11(PO,50mpk, BID) group with significant efficacy were selected for colonic photography, length measurement and weighing. As shown by the data in fig. 18C, the colon weight to length ratio was significantly lower and statistically significantly different for mice in the L10(PO,50mpk, BID), L25(PO,50mpk, BID), L11(PO,50mpk, BID) and Mesalazine (PO,100mpk, QD) groups compared to the vehicle group. As the data in fig. 18A indicate, the colon was significantly longer in mice of the L10(PO,50mpk, BID), L25(PO,50mpk, BID), L11(PO,50mpk, BID) groups compared to the vehicle group. As the data in fig. 18B indicate, the colon was lower in the L10(PO,50mpk, BID) group, L25(PO,50mpk, BID) group, L11(PO,50mpk, BID) group, and Mesalazine (PO,100mpk, QD) group mice compared to the vehicle group mice. These data further demonstrate that L11(PO,50mpk, BID) and L10(PO,50mpk, BID) are able to alleviate inflammation in TNBS enteritis mice.

7. Conclusion

Combining the data from the In-life experiment, it was found that L11(PO,50mpk, BID) and L10(PO,50mpk, BID) were able to slow down TNBS-induced enteritis In mice well.

The intestinal morphology is shown in figure 19.

Claims

1. A carbonyl heterocyclic compound shown as a formula II or pharmaceutically acceptable salt thereof;

wherein A is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond or-NH-;

q is

or-NH-;

L¹-Z¹and Z²-L²Independently is

And not simultaneously being

The B terminal is connected with a carbonyl or B';

b' is a connecting bond,

-C (═ O) - (5-7 membered cycloalkyl) -, -C (═ O) - (6-10 membered fused heterocycloalkyl) -, -C (═ O) - (oxo 5-7 membered heterocycloalkenyl) -, -C (═ O) - (oxo,

or-C (═ O) - (7-10 membered fused heteroaryl) -; the 6-to 10-membered fused heterocycloalkyl group contains 1 to 3N atoms; c (═ O) - (oxo 5-7 membered heterocycloalkenyl) -contains 1 to 3N atoms; the-C (═ O) - (7-10 membered fused heteroaryl) -group contains 1 to 3N atoms;

Z³-L³、Z^3a-L^3ais a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

Y^3aand Y^4aIndependently is CH orN；

R³Is C_1-6Alkyl groups of (a);

a' is

NO₂、-O-C_1-6Alkyl of (C)_1-6Alkyl group of (A) or (B),

Or H;

Y⁵is CH or N;

when Q is

A is

When A and A' are different.

2. Carbonyl heterocycles or pharmaceutically acceptable salts thereof as claimed in claim 1 of formula II,

is composed of

End a represents the position of connection with A;

and/or, Q²In, Z¹And Z²At ortho, meta or para position;

and/or when Q²When the alkyl is 5-7 membered cycloalkyl, the 5-7 membered cycloalkyl is cyclopentyl, cyclohexyl or cycloheptyl; e.g. cyclohexyl, and

and/or when Q²When the heterocyclic group is a 5-7 membered monocyclic heterocyclic alkyl group, the 5-7 membered monocyclic heterocyclic alkyl group is an N-heterocyclic pentyl group or an N-heterocyclic hexyl group; for example

And/or, when B' is

When the temperature of the water is higher than the set temperature,

is composed of

For example

The a 'end is connected with A';

and/or, when B' is-C (═ O) - (5-7 membered cycloalkyl) -said 5-7 membered cycloalkyl is cyclopentyl, cyclohexyl or cycloheptyl; such as cyclohexyl;

and/or, when B 'is-C (═ O) - (5-7 membered cycloalkyl) -, -C (═ O) -is located in the ortho, meta or para position, e.g. meta, of a';

and/or, when B' is-C (═ O) - (6-10 membered fused heterocycloalkyl) -said 6-10 membered fused heterocycloalkyl is 8-10 membered fused heterocycloalkyl in which N atoms are 1 or 2 and one N atom is attached to-C (═ O) -; for example-C (═ O) - (6-to 10-membered fused heterocycloalkyl) -is

And/or, when B' is-C (═ O) - (oxo 5-7 membered heterocycloalkenyl), said 5-7 membered heterocycloalkenyl is heterocyclohexenyl containing 2N atoms, e.g.

And/or, when B' is-C (═ O) - (7-10 membered fused-ring heteroaryl) -said-C (═ O) - (7-10 membered fused-ring heteroaryl) -is 6-membered heteroarylacene or 5-membered heteroarylacene, and may also be quinolinyl;

and/or when R³Is C_1-6When there is an alkyl group, said C_1-6Alkyl of (a) is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl;

and/or, when B' is

When the temperature of the water is higher than the set temperature,

is composed of

For example

And/or, when A' is

When the temperature of the water is higher than the set temperature,

is composed of

3. Carbonyl heterocycles or pharmaceutically acceptable salts thereof as claimed in claim 1 of formula II,

when Q is²In the case of a 5-to 7-membered cycloalkyl group, L¹-Z¹And Z²-L²Independently is

And/or when Q²In the case of 5-to 7-membered monocyclic heterocycloalkyl, L¹-Z¹And Z²-L²One of them is

The other is

And/or, when B 'is a connecting bond, A' is

And/or, when B' is

When A' is

NO₂、-O-C_1-6Alkyl of (C)_1-6Alkyl group of (A) or (B),

Or H, can also be

Or NO₂；

And/or, when B 'is-C (═ O) - (5-7 membered cycloalkyl) -, a' is

And/or, when B 'is-C (═ O) - (6-to 10-membered fused heterocycloalkyl) -, a' is

And/or, when B 'is-C (═ O) - (oxo 5-7 membered heterocycloalkenyl) -a' is H;

and/or, when B' is

When A' is

And/or, when B' is

When, A' is H;

and/or, when B 'is-C (═ O) - (7-10 membered fused heteroaryl) -, a' is H;

and/or, A is the same as A';

and/or the presence of a gas in the gas,

same as B'.

4. Carbonyl heterocycles or pharmaceutically acceptable salts thereof as claimed in claim 1 of formula II,

is composed of

And/or Q is

or-NH-;

and/or B '-A' is

Can also be made of

5. The carbonyl heterocyclic compound of formula II, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein the carbonyl heterocyclic compound of formula II is any one of the following schemes:

scheme 1:

a is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond or-NH-;

q is

or-NH-;

L¹-Z¹and Z²-L²Independent of each otherThe ground is

And not simultaneously being

b' is

-C (═ O) - (oxo 5-7 membered heterocycloalkenyl) -, -O,

or-C (═ O) - (7-10 membered fused heteroaryl) -;

Z³-L³、Z^3a-L^3ais a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

Y^3aand Y^4aIndependently CH or N;

R³is C_1-6Alkyl groups of (a);

a' is

-O-C_1-6Alkyl of (C)_1-6Alkyl group of (A) or (B),

Or H;

Y⁵is CH or N;

when Q is

A is

When A and A' are different;

scheme 2:

a is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond or-NH-;

q is

or-NH-;

L¹-Z¹and Z²-L²Independently is

And not simultaneously being

b' is a connecting bond,

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

a' is

NO₂or-O-C_1-6Alkyl groups of (a);

Y⁵is CH or N;

scheme 3:

a is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond or-NH-;

q is

or-NH-;

L¹-Z¹and Z²-L²Independently is

And not simultaneously being

b' is a connecting bond,

Z³-L³is a bond, -C (═ O) -or-C (═ O))-NH-；

Y³And Y⁴Independently CH or N;

a' is

NO₂or-O-C_1-6Alkyl groups of (a);

Y⁵is CH or N;

scheme 4:

a is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond;

q is

B' is a connecting bond,

-C (═ O) - (oxo 5-7 membered heterocycloalkenyl) -, -O,

or-C (═ O) - (7-10 membered fused heteroaryl) -;

Z³-L³、Z^3a-L^3ais a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

Y^3aand Y^4aIndependently CH or N;

R³is C_1-6Alkyl groups of (a);

a' is

C_1-6Alkyl group of (A) or (B),

Or H;

Y⁵is CH or N;

when Q is

A is

When A and A' are different;

scheme 5:

a is

T is a connecting bond;

q is

B '-A' is the following structure:

scheme 6:

a is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond;

q is

L¹-Z¹And Z²-L²Independently is

And not simultaneously being

Ring Q²Is 5-7 membered monocyclic heterocycloalkyl;

b' is a connecting bond,

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

a' is

NO₂、

or-O-C_1-6Alkyl groups of (a);

Y⁵is CH or N;

scheme 7:

a is

Or NR¹R²；

R¹And R²Independently is H or C_6-18Aryl of (a);

Y¹and Y²Independently CH or N;

t is a connecting bond;

q is

L¹-Z¹And Z²-L²Independently is

And not simultaneously being

Ring Q²Is 5-7 membered monocyclic heterocycloalkyl;

b' is

or-C (═ O) - (5-7 membered cycloalkyl) -;

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

a' is

or-O-C_1-6Alkyl groups of (a);

Y⁵is CH or N;

scheme 8:

the carbonyl heterocyclic compound shown in the formula II is shown in the formula II-a:

wherein A is

Y¹And Y²Independently CH or N;

q is

L¹-Z¹And Z²-L²Independently is

And not simultaneously being

The B terminal is connected with a carbonyl or B';

b' is a connecting bond,

-C (═ O) - (5-7 membered cycloalkyl) -or-C (═ O) - (6-10 membered fused heterocycloalkyl) -; the 6-to 10-membered fused heterocycloalkyl group contains 1 to 3N atoms;

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

a' is

Or NO₂；

Y⁵Is CH or N;

scheme 9:

a is

Y¹And Y²Independently CH or N;

q is

L¹-Z¹And Z²-L²Independently is

And not simultaneously being

Q²Is a 5-7 membered cycloalkyl or a 5-7 membered monocyclic heterocycloalkyl; 5-7 membered monocyclic heterocycloalkyl containing 1 to 3N atoms;

b' is a connecting bond,

Z³-L³is a connecting bond, -C (═ O) -or-C (═ O) -NH-;

Y³and Y⁴Independently CH or N;

a' is

Or NO₂；

Y⁵Is CH or N;

scheme 10:

a is

Y¹And Y²Independently CH or N;

q is

B' is

Z³-L³is-C (═ O) -;

Y³and Y⁴Independently CH or N;

a' is

Scheme 11:

a is

Is composed of

Q is

B' is a connecting bond,

A' is

Or NO₂；

Y⁵Is CH or N.

6. The carbonyl heterocycle compound of formula II, or the pharmaceutically acceptable salt thereof, of claim 1, wherein said carbonyl heterocycle compound of formula II is selected from the group consisting of:

7. a pharmaceutical composition comprising a carbonyl heterocyclic compound of formula II as set forth in any one of claims 1-6 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

8. Use of a carbonyl heterocyclic compound of formula II as defined in any one of claims 1-6, a pharmaceutically acceptable salt thereof or a composition as defined in claim 7 for the preparation of a lanthionine C-like protein 2 agonist.

9. Use of a carbonyl heterocyclic compound of formula II as defined in any one of claims 1-6, a pharmaceutically acceptable salt thereof or a composition as defined in claim 7 for the manufacture of a medicament; the drug may be a drug for preventing and/or treating a disease associated with lanthionine C-like protein 2, and/or the drug may be a drug for preventing and/or treating an autoimmune, chronic inflammatory, chronic metabolic or infectious disease.

10. The use according to claim 9,

the diseases related to the lanthionine C-like protein 2 are one or more of autoimmune, chronic inflammatory, chronic metabolic and infectious diseases;

and/or, the autoimmune disorder is inflammatory bowel disease, systemic lupus, rheumatoid arthritis, type 1 diabetes, psoriasis, multiple sclerosis;

and/or, the chronic metabolic disease is metabolic syndrome, obesity, prediabetes, cardiovascular disease and type 2 diabetes;

and/or, the infectious disease is a viral disease.